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Approximately 90% of all therapeutic targets in the human proteome operate solely inside 
the cell, making them unavailable for recognition by antibodies which instead bind 
antigens presented on the exterior of the cell surface. To target the 90%, the human 
immune system utilises a class of binding proteins known as T-cell receptors (TCRs). 
These TCRs recognise peptide fragments sourced from proteins produced inside the cell 
that have subsequently been degraded and transported to the cell surface by the human 
leukocyte antigen (HLA, pHLA with peptide bound). TCRs are membrane bound and 
attached to T-cells and use their six complementarity-determining region (CDR) loops to 
bind antigenic pHLA molecules (i.e. peptides that come from protein antigens). TCR 
binding to pHLA molecules induces an immune response from the T-cell, which 
ultimately leads to the antigen presenting cells death. The capability of TCRs to identify 
antigens which are not naturally expressed on the cell surface (unlike antibodies) has 
helped drive the development of a new class of therapeutics that consist of a soluble, 
bispecific TCR engineered to bind a specific antigenic pHLA for the treatment of various 
diseases (such as cancers and viral infections). Natural TCRs bind with characteristically 
poor affinities (~µM) and half-lives (~seconds), which are undesirable properties for a 
therapeutic. The CDR loops on TCRs are therefore normally subjected to affinity 
maturation to produce TCRs with affinities in ~pM range for their target pHLA. This does 
however carry a significant risk in terms of safety, as the very large majority of peptides 
presented by HLA molecules are sourced from endogenous (i.e. healthy) proteins and 
must not be bound by the TCR in order to avoid the production of an autoimmune response 
on the healthy cells.  
These requirements for a highly specific TCR that binds with high affinity to its target 
pHLA is the primary motivation for this thesis, as herein, fundamental engineering 
principles for generating TCRs with these properties are determined and protocols to 
evaluate these properties are developed and demonstrated. This insight is obtained 
through combinations of structural analysis, molecular dynamics simulations and free 
energy calculations, providing an atomistic description of how this has occurred for 
several TCRs. Furthermore, we characterise how different peptide cargo can tune the 
molecular flexibility of the entire pHLA molecule, including regions distal from the HLA 
binding site. These findings suggest peptide dependant tuning of the HLA molecule may 
play a role in regulating the functional outcome of an immune response.  
Ultimately, this work and the principles identified herein will aid in the rational design of 





Chapter 1:  
Introduction and Background  
 
The main thrust of this thesis focusses on using engineered T-cell Receptors (TCRs) as 
therapeutics, with a focus towards both gaining key insights into design principles for 
affinity and specificity, as well as characterising the allosteric regulation of the TCRs 
therapeutic target, the peptide-human leukocyte antigen (pHLA). As each results chapter 
in this thesis contains its own introduction, this section will provide a broader overview 
of the topics covered. Herein, I will first describe TCRs and pHLAs in their natural context 
(as vital parts of the immune system) before moving on to discuss the application of TCRs 
as therapeutics and the challenges associated with this. 
1.1 The Human Immune System  
 
All organisms contain an immune system which acts to protect the host against disease. 
In humans, the immune system is highly complex, with many mechanisms in place to 
protect against pathogens.1 This system can be broken down into multiple “layers” of 
protection, the first of which can be described as simple physical barriers that prevent 
entry into the host such as the skin. Other examples of this layer include coating the 
airways with mucus to catch microorganisms as they are inhaled, or stomach acid, which 
provides a hostile environment (low pH) for most microorganisms. The next layer is the 
“innate immune system” which is found in all plants and animals, as well as most 
bacteria.2 The innate immune response is fast acting and non-specific (in the sense that 
the response to different pathogens is the same).  
The final layer of the immune system is the “adaptive (or acquired) immune system”.3 
The adaptive immune system is significantly slower acting than the innate immune 
response, but highly specific towards the given pathogen (or pathogen infected cells). The 
adaptive immune system recognizes “non-self” (i.e. not natively produced) molecules 
such as proteins or lipids which are referred to as antigens. A key benefit of the adaptive 
immune system is in the generation of “memory cells”, which are produced during the 
first exposure to a given antigen. These memory cells can lie dormant in the body for 
several years unless they re-identify their target antigen from the host becoming re-
infected. Upon exposure to the given antigen these memory cells can trigger an effective 
adaptive immune response significantly more rapidly when compared to the first exposure 
event. Interestingly, this “training” of the adaptive immune system to recognize and then 






1.2 Antigen Binding by The Adaptive Immune system  
 
Two related classes of proteins are used by the adaptive immune system to identify and 
target antigens.3 The first are antibodies (also known as immunoglobulins), which are 
produced by B-cells as either membrane bound (protruding out of a given B-cell and into 
the extracellular surface) or as soluble proteins. Human antibodies adopt a “Y” shaped 
quaternary structure (see Figure 1), whereby there are two antigen binding domains 
located on the ends of the forks of the Y (known as the antigen-binding fragment regions, 
Fab regions), whilst the bottom of the Y (known as the fragment crystallizable region, Fc 
region) is used to communicate with other parts of the immune system. Antibodies bind 
antigens through six specialised loops, known as complementarity-determining regions 
(CDRs). These CDR loops are “hypervariable” in sequence composition which is 
essential for providing coverage against the wide variety of possible epitopes (antigen 
binding sites).3 The second class of targeting protein used by the adaptive immune system 
is the T-cell receptor (TCR), which are produced by T-cells as membrane bound proteins 
(see Figure 1). These proteins share common structural features with the Fab region of 
an antibody, including in the use of six CDR loops to bind their target antigens. TCRs 
consist of two different chains (α and β or a less common variant made of γ and δ chains) 
which both contribute equally to forming the antigen binding site by providing three CDR 
loops per chain to bind the epitope.  
Figure 1: Diagrams of the structural configurations of antibodies and TCRs. The 
transmembrane region is indicted as optional in antibodies as they can be expressed as 





A key difference between TCRs and antibodies is in the nature of the epitopes they target. 
Whilst antibodies can target a range of different molecular surfaces found on proteins (or 
other molecules like lipids and sugars), TCRs bind only a small fragment of an antigen. 
These small fragments are presented to the TCR by a multi-domain protein complex 
known as the major histocompatibility complex (MHC), with the TCR binding to both the 
antigen fragment and the MHC.5 The following subsection will now describe the 
mechanism by which MHC molecules present antigens for TCR recognition.  
 
1.3 Antigen Presentation to T-Cell Receptors 
 
As discussed briefly above, TCRs differ from antibodies in that they target only small 
fragments of antigens presented on the cell surface. These antigens (which are most often 
peptides, but can also be lipids or metabolites6) are displayed on the cell surface by 
binding to the major histocompatibility complex (MHC). Please note that the MHC is a 
general term used to describe this molecule which is found in all vertebrates.4 The human 
leukocyte antigen (HLA) is the human form of the MHC and the term “HLA” will now 
be used throughout to avoid any confusion.  
HLA molecules bind peptides available inside the cell to form the peptide-HLA (pHLA) 
complex. Once a pHLA complex is produced, it is transported to the cell surface and 
presented facing outwards into the extracellular milieu, allowing for TCR recognition.7 It 
should be noted at this point that HLA molecules bind to and present both endogenous 
(self-produced and therefore “healthy”) and antigenic peptides. It is primarily the role of 
the TCR to bind (and therefore trigger an immune response) to only antigenic peptides 
and not the self-peptide-HLA (self-pHLA) molecules which are also presented on the 
surface of the cell (discussed further in Section 1.5).  
There are two major classes of HLA molecules (Class I and II) and both perform different 
roles in the immune system. HLA class I molecules present peptide fragments on the 
surface of their cells, with these peptides sourced from proteins produced inside the cell 
(see Figure 2). This process occurs in all nucleated cells (cells with a nucleus), with the 
first step being the degradation of proteins into small peptides via the proteasome.8 The 
peptide fragments which bind to the HLA strongly enough are then transported and 
presented onto the cell surface for TCR recognition. Unlike Class I, HLA Class II 
molecules source peptides for presentation from outside the cell.9 Proteins outside the cell 
surface are internalised and degraded into peptides. The peptides produced that can bind 
HLA Class II are then transported to the cell surface for TCR recognition. HLA Class II 
expression and presentation is performed only by certain immune cells, which include 
dendritic and B-cells.9 This is due to the different roles the two HLA Classes have in the 
immune system. HLA Class I molecules are recognised by TCRs located on cytotoxic T-





Class I molecule.8 HLA Class II molecules are instead recognised by TCRs present on T-
helper cells.9 Unlike in Class I, antigen recognition (in this case by the T-helper cells) 
does not kill the HLA Class II presenting cell. T-helper cells are instead responsible for 
up/down regulating the local immune response. To ensure the correct T-cell type binds 
the correct HLA Class, a co-receptor present on the T-cell must also bind the pHLA in 
order to trigger an immune response.4 Cytotoxic T-cells contain a CD8 co-receptor 
molecule which can only bind to HLA Class I molecules8, whereas T-helper cells contain 
a CD4 co-receptor molecule which can only bind to HLA Class II molecules.9 These co-
receptors are both located far away from the TCR/peptide binding site. 
 
1.4 Structural Characterisation of the pHLA Complex 
 
HLA Class I and II molecules are composed of two different protein subunits (Figure 
3A).9 In HLA Class I, a single protein chain forms both the peptide binding groove and 
the connection to the interior of the cell (via a transmembrane helix). This protein chain 
is in complex with a small (100 residue) β2-microglobulin (β2m) domain, which binds 
well away from the peptide binding site. In contrast, HLA Class II consists of two protein 
subunits of approximately equal size, with both domains connected to the interior of the 
cell (again via a transmembrane helix). In HLA Class II, both domains also play a roughly 
equal role in forming the peptide binding groove (Figure 3A). In both HLAs, the binding 
groove consists of a β-sheet base with a flanking α-helix either side to form the cavity. As 
Figure 2: Schematic representation of antigen processing, presentation and T-cell 
binding pathways for HLA Class I and II. In the HLA Class I pathway, the antigen is 
first degraded in the proteasome (1), then bound to a HLA molecule (if it can bind) to 
form a pHLA complex (2), before being presented on the cell surface for both TCR and 
CD8 co-receptor recognition (3). In HLA Class II, antigens from the extracellular milieu 
are internalised (1), degraded by the proteasome (2), then peptides which are able to bind 
to a HLA Class II molecule (3) are presented on the cell surface for both TCR and CD4 




the results chapters of this thesis focus on HLA Class I molecules (due to their increased 
relevance as therapeutic targets, see Section 1.3), the remainder of this section will focus 
on characterising the structural features of HLA Class I in more detail.  
HLA Class I Molecules tend to bind peptides of sequence lengths between 8–12, primarily 
through interactions between the HLA and the first and last few residues of the peptide.10 
The regions of the HLA responsible for binding the N and C-terminal residues of the 
peptide are referred to as the A and F-pockets respectively (See Figure 3B+C). This 
“anchoring” effect of the N and C-terminal portions of the peptide often results in these 
residues playing a less significant role in TCR recognition, as they are relatively buried 
into the HLA’s peptide binding pockets. The central portion of the peptide however tends 
to “bulge out” of the binding pocket, making these residues primarily responsible for 
regulating TCR affinity to the pHLA.  
There are 177 isoforms of HLA Class I molecules1, and the combination of A and F-
pockets and peptide N and C-terminal residues will largely control whether a particular 
peptide will bind to a given HLA isoform, and therefore can be presented to a TCR. 
Extensive studies have been performed to characterise the peptide sequence space that 
individual HLA isoforms are capable of binding.11–13 A commonality identified is the 
occurrence of peptide “anchors”, which are peptide residues that have to be one of very 
few amino acids in order to enable binding to the HLA isoform. Generally, HLA Class I 
molecules possess two “primary” and two “secondary” anchors (a primary anchor has a 
stronger effect than a secondary anchor), with one of each located in both the N and C-
terminal residues.8      
Figure 3: (A) Schematic diagrams of the HLA Class I and II complexes. All domains 
which make up both complexes are labelled, with domains that are part of the same 
protein coloured the same. The black dotted lines represent the location of the membrane. 
(B) Representative structure of HLA Class I molecule with peptide bound. (C) Top down 
view of the peptide binding site of HLA Class I. Residues which make up the A-pocket 
(peptide N-terminal binding site) and F-pocket (peptide C-terminal binding site) are 
coloured in green and orange respectively. The α-helices which form the groove are 






1.5 How do Naturally Occurring TCRs Achieve Specificity? 
 
Given only the 20 standard amino acids, there are theoretically ~1x1013 (2010) possible 
different peptide sequences for a peptide of length 10 amino acids long. Furthermore, the 
very large majority of peptides that will be presented by the HLA will be from endogenous 
(native and healthy) proteins (and therefore should not be recognized by a TCR). This 
provides the ~2x107 mature TCRs produced by the average human host with a seemingly 
impossible challenge.14 That is, they must be both highly cross reactive (to ensure 
coverage of the vast sequence space possible for antigenic peptides) whilst simultaneously 
being non-cross reactive to the vast number of self-pHLA complexes that will also be 
presented on healthy cells, to ensure an autoimmune response does not occur. Prior studies 
have shown that individual mature TCRs are indeed able to bind (at least) somewhere 
between the high thousands to millions of non-native pHLAs.15,16 
To overcome the aforementioned challenge, the immune system utilises a process known 
as “thymic selection”, in which a naive pool of ~1011 T-Cells (each with different TCRs) 
are selected against several criteria to produce the ~2x107 mature T-cells.14,17 The first 
step of thymic selection (see Figure 4) is “positive selection”, in which naive T-cells are 
tested for their ability to bind self-pHLA molecules.6 T-cells that are unable to bind self-
pHLA are subjected to apoptosis (cell death). This step is important to remove TCRs that 
would likely be of limited value as they would not be able to recognise any pHLA. The 
T-cells that survive positive selection then undergo “negative selection”, in which T-cells 
that bind too strongly to self pHLA are subjected to apoptosis (to remove TCRs that could 
cause autoimmune problems by inducing an immune response towards healthy cells).6  
One consequence of thymic selection is that the TCRs produced tend to bind their targets 
with relatively weak affinities (KD normally ~µM).
18 These relatively weak affinities and 
subsequently weak half-lives (normally in the seconds18) mean multiple TCRs on a single 
T-cell need to bind multiple pHLA on a single (diseased) cell in order to generate a strong 
enough signal for an immune response to be generated.19 This requirement for multiple 
TCRs to bind a diseased cell provides an unfortunate “escape mechanism” often used by 
diseased cells to avoid destruction. That is, the diseased cells down regulate the production 
of pHLA on the cell surface (previous studies have observed as few as 10 antigen specific 
pHLA presented per cell for several different cancers), making it very challenging for the 
“critical mass” of simultaneous TCR binding events to occur that would allow for the 






1.6 Structural Features of the TCR-pHLA Complex 
 
TCRs bind pHLA through their six hypervariable loops (see Figure 5), with both the 
peptide and the two alpha helices of the HLA (α1 and α2) that form the peptide binding 
groove responsible for interactions with the TCR. TCRs tend to dock diagonally over the 
pHLA complex such that the CDR3 loops make contacts primarily with the peptide (as 
well as some HLA residues) and the CDR1+2 loops primarily engage the HLA residues 
on the alpha helices (see Figure 5B+C). The orientation at which the TCR docks can be 
characterised by determining the “docking angle” of the TCR with respect to the pHLA.5 
This measurement determines the angle between the major axis of the peptide and the 
vector between the (conserved) interface cysteine residues on the variable domains, with 
the canonical range of docking angles observed for (crystallised) TCRs between 40 to 
85°.5  
An approach first used to characterise the orientation of the two antibody variable domains 
with respect to one another,20 has been modified for use with TCRs21 (known as 
“Abangle” for antibodies and “TRangle” for TCRs). This approach gives six 
Figure 4: Positive and negative thymic selection of T-cells by the Thymus. Naive T-
cells are produced in the thymus and their affinity towards self-peptides is evaluated. If 
a peptide binds too strongly (scenario 1) or too weakly (scenario 3) the T-cell is 
subjected by apoptosis (cell death). Only in scenario 2 is the T-cell (and its 





measurements (five angles and one distance) to describe the differences in variable 
domain orientations.  Interestingly, clustering of the available structures of antibodies and 
TCRs based on their Abangle/TRangle parameters results in them being clustered into 
separate groups. Furthermore, by computationally modifying TCRs to adopt standard 
antibody variable domain orientations, it was shown that the TCR could no longer bind 
the pHLA with a canonical (i.e. TCR-like) docking angle.21 This may therefore suggest 
that engineering antibodies for the application of pHLA recognition could be more 
challenging than engineering TCRs, as the TCR scaffold has arguably evolved to bind 
with an orientation optimal for peptide discrimination.21  
In Section 1.5, the biological mechanism for thymic selection was described, in which the 
TCRs produced are simultaneously cross-reactive, yet “specific” in the sense that they do 
not bind endogenous pHLA molecules presented on healthy cells. This does not explain 
however the physical chemical mechanism of how TCRs are able to do this. Whilst still 
not fully understood, arguments have been proposed in the literature to rationalise these 
observations. The major argument is that TCRs have “hotspot” peptide and HLA residues 
which are primarily responsible for driving binding affinity, meaning if all or most of 
these residues are present, the TCR is likely to bind.22 Recent work has identified a single 
TCR that can bind over a million different peptide sequences presented on the same HLA 
isoform.16 Several peptide sequence motifs were identified from this, with the most 
populated being: xOxGPDxxxO”, whereby “O” is a hydrophobic amino acid and “x” can 
be any amino acid.16 A follow-up study in which eight of the identified peptides in the 
above described motif were crystallised identified the importance of the central “GPD” 
residues in binding the TCR.23 In all eight cases, between 41-50% of all X-ray contacts 
formed between the TCR and pHLA were from just these three residues.23 
Recent work by Riley et al. demonstrated that a single TCR was able to bind two 
distinctive classes of peptide sequences by adopting essentially the same TCR 
conformation for the two different peptides.24 In this study, yeast display of many pHLA 
complexes was used to identify 53 different peptide sequences that could bind the same 
TCR (to form the TCR-pHLA complex). Analysis of the peptides sequences showed two 
distinct classes of peptide that could be differentiated by the presence of either a “DRG” 
or “GIG” motif in the center of the peptide, with each of these motifs “bulging” out of the 
HLA binding groove to engage the TCR. Several of the above identified peptides were 
crystallised, which interestingly showed that the TCR used essentially the same 
orientation to bind both types of motifs (all atom RMSD difference in the CDR loops for 
the TCR was < 1 Å for all examples). In contrast, the two classes of peptides adopted 
vastly different conformations, (with backbone RMSD differences of 3.5 Å).24 This 
demonstrates that not only can the CDR loops of the TCR make use of conformational 
flexibility to enable binding of different pHLA surfaces (not seen in this case but seen in 
others25), but that different peptides can adopt different conformations in the HLA groove 





1.7 The Application of T-cells and TCRs as Therapeutics.  
 
This section provides an overview of the different types of therapeutics either available 
today or currently under investigation that utilise TCRs or T-cells to combat disease. 
These therapeutics can be broken down into four major categories (see Figure 6), by 
partitioning based on the receptor molecule used to recognise the antigen and on the 
solubility of the drug.  
The first category in Figure 6 are so called IMMTACs (Immune mobilising monoclonal 
T-cell receptors Against Cancer), which are soluble, bispecific (can bind two different 
epitopes) and affinity enhanced (KD for target pHLA ~pM) TCRs.
26 As these TCRs are 
Figure 5: (A) Exemplar structure of the TCR-pHLA complex, with the six CDR loops and 
different portions of the overall scaffold coloured differently for clarity. (B+C) Zoom in on 
the TCR-pHLA binding site from two different orientations (same colouring as in A). 






engineered to be soluble (and therefore are not attached to a T-cell) they contain a co-
receptor which binds with picomolar affinity to CD3 receptors on T-cells.26 This enables 
them to recruit T-cells to destroy the antigen presenting cell.  
The second category in Figure 6 are tumour-infiltrating lymphocytes (TILs), which can 
be used in an approach known as adoptive cell therapy (ACT). In ACT, cells from the 
immune system are given to a patient to kill diseased (often cancerous) cells. In TIL 
therapy, T-cells located near tumours are taken from the patient and then multiplied in a 
lab before reinjecting the T-cells back into the patient.27 The basic idea behind this process 
is that the hosts immune system is too weak to fight the tumour but has already produced 
the necessary T-cells to do so. Therefore, supplementing with additional anti-tumour T-
cells can artificially “increase the strength of the immune system” and ultimately assist in 
fighting the disease. TIL therapy is similar to category 1 in that a TCR is used for pHLA 
recognition, however in this case the TCR used is membrane bound and (normally) of low 
affinity (~µM). A major challenge associated with TIL therapy is the risks of toxicity tend 
to be far greater than for soluble therapeutics due to the significantly longer long-half lives 
of T-cells in the body (compared to soluble proteins like TCRs).28 Whilst one could 
engineer the TCRs in TILs to be of high affinity, this is not commonly performed because 
of the increased risk of toxicity.  
The third category in Figure 6 are chimeric antigen receptor T-cells (CAR T-cells).29 
CAR T-cells are T-cells produced by either the patient or a donor which are then 
engineered to produce specific antigen receptors (normally an antibody or antibody 
fragment) to bind a given antigen. The major differences between this category and 
category 2 is in the use of targeting protein (not a TCR) and the nature of the target antigen 
(pHLA for category 2 compared to a whole protein bound to the exterior of the cell surface 
for category 3).29   
Finally, category 4 in Figure 6 refers to the many types of soluble antibody therapeutics 
(or other engineered protein scaffolds that could be used in its place).30 As with category 
1, soluble therapeutics need a way to destroy the antigen presenting cell (and not just bind 
to it). Two commonly used strategies are to (1) add a co-receptor binding site that can 
recruit another part of the immune system to kill the cell (e.g. a T-cell as seen in Figure 
6) or (2) attach a drug molecule to the antibody via a partially chemically labile linker that 
will be released at the site of the diseased cell to kill it (commonly known as antibody-















Figure 6: Schematic diagram of the various types of therapeutics available that utilise 
T-cells to kill diseased/cancerous cells. The dotted lines indicate binding between 
different molecules. In examples 1+2 the antigen presented is a peptide from a pHLA 
molecule, whilst in 3+4 it is a protein expressed on the surface of the cell. A description 
of each of the therapy type is provided in the text. This figure was adapted from one 






1.7.1 The Advantages and Challenges Associated with Soluble, High Affinity TCRs 
as Therapeutics  
 
Chapters 4 and 5 in this thesis focus on gaining insight into fundamental design principles 
for achieving high specificity and high affinity in TCR based therapeutics. These chapters 
are performed in collaboration with scientists from Immunocore, a company that develops 
IMMTACs (category 1 in Figure 6). This subsection will therefore focus on the 
advantages and challenges associated with the use of IMMTAC style therapeutics.  
Targeting pHLA molecules (instead of surface expressed proteins like antibodies or most 
engineered protein scaffolds do) provides access to the internal proteome and a greater 
number of potential targets. It is estimated that ~90% of all potential disease targets are 
located inside the cell (and these targets can be presented by HLA Class I molecules to 
TCRs) as opposed to the ~10% available to drugs that can only recognise antigens on the 
cell surface.32  
The use of a WT-TCR (sourced from either the patients or a donor) with ~µM affinity has 
arguably a reduced risk of toxicity in comparison to an affinity matured nM-pM TCR (as 
the affinity maturation process may have had the unintended consequence of producing a 
TCR with reasonable affinity for an self-pHLA molecule). As discussed in Section 1.5 
however, the low affinity of WT-TCRs can provide diseased cells the opportunity to 
escape TCR recognition by down regulating the expression of antigenic pHLA. Previous 
studies have shown soluble TCRs with picomolar affinity (and subsequently much longer 
half-lives) can kill cells with as low as 5-10 copies of the pHLA target present on an 
individual cell.33 If one can therefore produce affinity matured TCRs that have a large 
enough therapeutic window, then one would expect them to work more effectively than a 
WT-TCR as a therapeutic. A further point to consider is the reduction in the dose required, 
which is likely to be approximately inversely proportional to the affinity for the antigenic 
pHLA.  
Whilst questions have been raised about the fundamental structural/orientational 
differences between TCRs and antibodies21 (see Section 1.6) and whether these 
differences make TCRs better suited than antibodies (or other proteins scaffolds) for 
specific pHLA recognition, there is no reason to think one could not use an antibody 
instead, and indeed several examples exist in the literature of generating antibodies to do 
exactly that.34–36  
Evaluating the specificity of a high affinity TCR (or any engineered protein) as a potential 
therapeutic often requires a large number of cell-based assays, which are both time 
consuming and expensive. This bottleneck could of course be elevated in the future by an 
improved understanding of what makes a specific TCR, and better computational 





1.8 The Application of Computation to Understand and Engineer 
TCRs.  
 
The following section aims to provide insight into how computation has been used to 
study and, in some cases, engineer TCRs. Please note that the theoretical aspects of the 
computational methods used in this thesis are covered in detail in Chapter 2.  
 
1.8.1 Methods to Calculate Protein-Protein Binding Free Energies.  
 
The large number of methods available to calculate protein-protein (or protein-ligand) 
binding free energies can be separated out into “pathway” and “end-state” calculation 
approaches. Common pathway methods include free energy perturbation or 
thermodynamic integration and work based on the principle of defining a reaction 
coordinate (or multiple reaction coordinates) that describe the transition from one state to 
another, in order to calculate the free energy difference between the states. These 
approaches can utilise alchemical (unphysical) pathways to describe the change in free 
energy and thermodynamic cycles can be constructed to produce either absolute or 
relative binding free energies (i.e. ∆𝐺 or ∆∆𝐺 respectively).37  
End-state free energy methods instead calculate the free energy of the two desired states 
separately (i.e. bound and unbound) and then directly subtract their free energies from one 
another. Although in this case one explicitly obtains a ∆𝐺 value, the approximations and 
errors associated with end-state methods mean they are commonly used to predict ∆∆𝐺 
values or to rank a group of similar ligands instead. End-state approaches can be 
performed on a single or multiple conformation(s), with ranking of the protein-ligand 
complexes normally performed using empirical “scoring functions”. Scoring functions 
are based around countering the number and strength of various types of interactions (e.g. 
hydrophobic, hydrogen bonds etc…) between the receptor and ligand to determine the 
strength of the overall interaction.38 The coefficients used for each interaction term are 
normally determined by non-linear regression. An alternative to using a scoring function 
is to use a MMFF to calculate the electrostatic and vdWs interactions between the receptor 
and ligand and then model the solvation effects with an implicit solvent model such as the 
Generalized Born (GB) or Poisson-Boltzmann (PB) equation. This approach is known as 
the MMPB/GBSA (Molecular Mechanics Generalized Born/ Poisson-Boltzmann Surface 
Area) method (described in detail in Section 2.5).39 One could also consider describing 
some or all of the atoms with a quantum mechanical (QM) model, potentially offering 
increased accuracy. Considering the overall size of the TCR-pHLA complex (not only in 
terms of total numbers of atoms, but also that the binding interface is very large), 
approaches that use QM are unlikely to be worth the additional computational cost (most 
QM methods computing times scale significantly greater than linearly with an increasing 





to use a QM method to describe a TCR-pHLA interface, the amount of sampling possible 
(both in terms of number of conformations per complex and number of mutations tested) 
would be significantly reduced as compared to an MMFF method.  
A completely different way to calculate the binding free energy could be to utilise 
machine learning (ML) approaches. ML methods normally require a large amount of 
(reliable) experimental data to generate models that are predictive. ML approaches have 
had reasonable success in predicting which peptide sequences can bind a given HLA 
isoform.40 This is arguably because as long as the HLA A and F-pocket residues are 
compatible with the peptide N and C-terminal residues, binding is reasonably likely to 
occur (see Section 1.4).  
 
1.8.2 Prior Attempts to Perform Rational TCR Engineering 
 
In comparison to the available literature and software programmes/protocols available for 
antibody modelling and design (for example RosettaAntibody41 and the MOE antibody 
modeler suite42), TCRs have been subjected to a relatively limited amount of study. 
Further, most publications that have generated high affinity TCRs appear to have done so 
through high throughput (semi-)random mutagenesis protocols.26,43–45 Two examples do 
exist in the literature however in which molecular docking was used to generate higher 
affinity TCRs.46,47 In the first of these two publications, single point mutations were 
predicted for the TCR α-chain towards binding the Tax peptide/HLA-A2 complex, with 
four point mutations combined to obtain a mutant with an ~100-fold increased affinity 
towards the pHLA.46 In this approach Rosetta was first used to identify potential 
beneficial mutations from the starting crystal structure of the WT-TCR-pHLA. Following 
experimental testing a scoring function named “ZAFFI” (Zlab AFFInity enhancement) 
was developed by taking terms from both the ZRANK48 and Rosetta49 scoring functions 
and parameterising these terms to improve the fitting to the obtained experimental data. 
In the second publication, ZAFFI was used to predict single point mutations this time on 
the melanoma-associated Melan-A/MART-1 peptide bound to HLA-A2.47 Combination 
of two single point mutations resulted in a 400-fold increase in affinity relative to the WT. 
These results demonstrate the potential of docking and computational chemistry towards 
rationally designing TCRs.  
If the TCR-pHLA complex structure is not known docking will be required to obtain a 
starting model from which to design mutations. Even with structures of the apo TCR and 
pHLA, accurate predicition of the complex structure can be challenging. This is in part 
due to the conformational flexibility available to both the CDR loops and the peptide, as 
major conformational changes have previously been observed upon going from the 
unbound to the bound state for both the TCR and peptide.24,50 This means rigid body 




docking approach specifically designed for TCR-pHLA docking known as 
TCRFlexDock52 has also been developed. In this approach, iterative rigid-body moves 
and side chain re-packing is combined with CDR loop and peptide backbone translations, 
in order to sample a large amount of conformational space to obtain a predicted docking 
pose(s).52    
 
1.9 Aims and Objectives  
 
Chapters 3-5 of this thesis explore some of the fundamental aspects of TCR-pHLA 
recognition and pHLA immunology. The research objectives for each chapter are 
presented below:   
 
1.9.1 Objective 1: The role of Peptide Cargo in Allosterically Regulating the HLA 
In Chapter 3, we aimed to determine how different peptide cargo can tune the molecular 
flexibility of the HLA. We explored this using both experiment (pressure and temperature 
(p/T) perturbation) and computation (MD simulations). Our p/T perturbation experiments 
demonstrated significant changes in the conformational dynamics of the pHLA, 
dependant on the peptide cargo. We applied MD simulations to rationalise how different 
peptide cargo could modulate the molecular flexibility of the rest of the HLA molecule. 
Our MD simulations identified several regions across the HLA which had their flexibility 
tuned by the peptide cargo. This includes many regions distal from the peptide binding 
site. We then analysed how different peptides were able to modulate the regions distal 
from the peptide binding site, and the pathways used to do so.  
 
1.9.2 Objective 2: Engineering Principles for TCR-pHLA Specificity  
In Chapter 4, we wished to determine fundamental design principles towards developing 
high specificity TCR-pHLA therapeutics. This was done through a combination of 
experimental (biochemical and structural) and computational (MD simulations and free 
energy calculations) approaches. We demonstrated that our MD simulations and free 
energy calculations were able to rationalise the observed specificity differences seen for 
the case studies considered, demonstrating the approaches used could have future 
applicability in rational design efforts. Our analyses suggested that an increased number 
of contacts between the TCR and peptide (in particular the side chains of the peptide) 
combined with binding with a broad energetic footprint (i.e. no hotspots/many favourable 






1.9.3 Objective 3: Engineering Principles for TCR-pHLA Affinity  
Following on from the results obtained in Chapter 4, in Chapter 5 we wished to gain 
insight into what drives affinity enhancement in engineered TCRs. We performed 
structural analysis, MD simulations and free energy calculations on several case studies 
of affinity maturation, with the aim to understand at the atomic level how affinity was 
enhanced. Analysis of the contacts formed between the TCR and pHLA either from the 
crystal structures or from MD simulations were unable to rationalise the differences in 
affinity. Analysis of changes in flexibility showed some instances of increased rigidity for 
the affinity matured apo TCR (which would be entropically favourable for binding). Our 
free energy calculations were able to reproduce the experimental affinity relationships. 
The decomposition of these results to the per-residue level allowed for the identification 
of several approaches used by TCRs to enhance affinity. Finally, we also demonstrated 
that the energetic footprint between the TCR and pHLA was by and large preserved over 
the course of the affinity maturation process, an important consideration when attempting 





Chapter 2:  
Theory of Methodology 
 
Physical methods to describe atoms and molecules can be broken down into two major 
classes, differentiated by the application of either quantum or classical physics to describe 
them. In quantum mechanical (QM) descriptions, atoms are described as wave-like, with 
a wave function used to provide information about the probability of finding a given 
particle at a particular position, as well as said particles momentum. Further, QM methods 
describe energy in a “quantised” manner, meaning only certain energies (energy levels) 
are allowed to be adopted by the system. In comparison, classical physics based methods 
describe energy as continuous and treat atoms as point particles. Generally, QM methods 
offer a much greater deal of accuracy, yet tend to be significantly slower than classical 
physics based approaches. As Chapters 3-5 of this thesis deal with the describing the 
dynamical properties of large protein complexes, a classical physics based approach 
(through the use of a molecular mechanics force field) is used as it provides a good balance 
between accuracy and speed.  
The following chapter aims to provide the reader with the theoretical background behind 
the simulation approaches used throughout this thesis.  
 
2.1. A Molecular Mechanics Force Field  
 
A molecular mechanics force field (MMFF) is an empirically derived model that describes 
the physical behaviour of atoms and molecules.53 This is achieved by describing atoms 
(or in some cases groups of atoms) as individual particles and using several empirically 
derived equations to describe the interactions between particles. Whilst many different 
MMFFs exist, most take the general form depicted in Figure 8. These terms can be broken 
down into “bonding” (𝐸𝑏𝑜𝑛𝑑, 𝐸𝑎𝑛𝑔, 𝐸𝑑𝑖ℎ and 𝐸𝑖𝑚𝑝) and “non-bonding” (𝐸𝑣𝑑𝑤 and 𝐸𝑒𝑙𝑒𝑐) 
terms, which sum together to give the total potential energy of the system. Bonding 
interactions are normally described by making the “harmonic approximation” (i.e. a 
harmonic potential is used to describe the relationship between the potential energy and 
the distance between atoms). Whilst the harmonic approximation is accurate for 
describing near-equilibrium bond length potential energies and can be solved rapidly with 
a computer, it is important to consider one of its major limitations. Bond breaking is an 
anharmonic process in which once the bond has “broken” the energetic penalty does not 
change (significantly). A harmonic model would therefore be highly inappropriate for 
describing chemical reactions, as bond breaking would be over-penalised. To more 
appropriately describe chemical reactions, one could modify the reacting atoms MMFF 
to describe their 𝐸𝑏𝑜𝑛𝑑 terms with an anharmonic model, as is done in the case of empirical 
valence bond simulations.54 Alternatively, one could turn to quantum mechanical methods 






MMFFs are usually parametrised through some combination of experimental and 
computational calculations, with the quality of the MMFF tested/validated by assessing 
its ability to reproduce certain experimental observations.53 For example, the TIP3P water 
model is commonly used in biological simulations to provide a reasonable description of 
the behaviour of water at physiologically relevant temperatures (298 to 310 K) and 
Figure 7: The common terms used in a molecular mechanics force field (MMFF). All terms 
are summed together to give the total (potential) energy of the system. For the first four terms 
𝑘𝑟, 𝑘𝜃, 𝑘𝜑, and 𝑘𝜔 are force constants dependant on the distance (𝑟), angle (𝜃), dihedral (𝜑) 
and torsion angle (𝜔) respectively. For the van der Waals (vdW) term, 𝜖𝑖𝑗 is the well depth 
(minimum potential energy value possible), 𝜎𝑖𝑗 is the distance between atoms 𝑖 and 𝑗 at which 
the potential energy is 0, and 𝑟𝑖𝑗 is the distance between atoms 𝑖 and 𝑗 respectively. For the 




pressures (1 atm).56 A further benefit is that several biological MMFFs are co-developed 
to work with the TIP3P water model (for example several CHARMM MMFFs57). TIP3P 
is however known to be a poor choice for high or low temperature/pressure simulations 
due to its inability to describe the phase diagram of water (for example, TIP3P has a 
melting temperature of 146 K58). In this case a different water model such as TIP4P/2005 
would be better suited to reproduce the phase behaviour of water.59 The above example 
demonstrates the importance of choosing an appropriate MMFF that is able to well 
describe the properties one wishes to gain insight into. Further, MMFFs are often 
produced to describe one class of molecules at a time (i.e. amino acids/proteins - Amber 
FF14SB60, CHARMM36M61; lipids - Lipid1462; sugars - GLYCAM0663; and small 
organic molecules - GAFF64, CGenFF65). This is arguably because molecules in the same 
class are likely to have similar characteristics and trying to make a MMFF too general is 
likely to lead to an MMFF that is inaccurate.  
 
2.2 Geometry Optimisation  
 
A MMFF allows us to evaluate the potential energy (PE) of a system for a given set of 
atomic coordinates. A complete evaluation of all possible arrangements for a given system 
would therefore provide us with a complete description of the potential energy surface 
(PES), including the location of global and local minima(s) as well as the location of 
saddle points (i.e. transition states). Evaluating the PE of all possible configurations would 
be extremely expensive even for relatively small systems and highly inefficient (as many 
of the configurations evaluated would be of extremely high PE, for instance due to atom 
overlap). Thankfully, several algorithms exist that allow one to identify local minima or 
saddle points and even compute the minimum energy pathway between them.53 
Energy minisation is the process by which a given set of coordinates are “optimised” to 
the nearest local minimum by minimising the potential energy of the system until it cannot 
be further reduced. Fast geometry optimisation procedures such as the steepest descent 
(SD) algorithm work by calculating the first partial derivative for an initial set of 
coordinates.38 The coordinates are then moved a short distance (often referred to as the 
“step size”) in the direction of the negative gradient. This procedure is iterated until the 
gradient obtained for the current configuration is smaller than a given threshold, at which 
point the current geometry is considered to be at the local minimum. Whilst this procedure 
is rapid it often struggles to converge in systems with a large number of dimensions as it 
does not “remember” anything about the shape of the PES between steps.  
Geometry optimisation is highly similar to energy minimisation (in that both aim to 
minimise the energy of the system), however geometry optimisation procedures rely on 
calculating or estimating the second partial derivative of the potential energy (commonly 
known as the Hessian), increasing the accuracy of the process.38 The Hessian is a matrix 
of size 3n x 3n, where n is the total number of atoms in the system. In the conjugate 
gradient (CG) approach the Hessian is estimated and used to improve the quality of the 
prediction of the direction in which to move the coordinates in for a given step.38 The CG 





meaning it does not have to move in the direction of the smallest gradient. For systems 
with a large number of degrees of freedom, this tends to result in a reduction in the number 
of steps required to optimise the geometry.38  
In this thesis, energy minimisation is used to relax the system prior to MD simulations. 
Energy minimisation is first performed using the SD algorithm followed by the CG 
algorithm. This takes advantage of the high speed of SD to efficiently remove any “kinks” 
in the structure and/or relax highly energetically unfavourable conformations. Then the 
CG algorithm can be used to efficiently converge towards the local minimum.  
 
2.3 Molecular Dynamics Simulations  
 
The first derivative of the potential energy (PE) as a function of the atomic coordinates 
(𝑟) is equal to the negative of the force (𝐹).66 With knowledge of the force “felt” by each 
atom alongside each atoms mass (𝑚) we can make use of Newton’s second law of motion 
(Eq 1) to calculate the acceleration (𝑎) of each atom.   






 (Eq 1) 
 
As can be seen above, the second partial derivative of the forces provides the displacement 
(𝑟) of the atomic coordinates with respect to time (𝑡). In a molecular dynamics (MD) 
simulation, we assume constant acceleration over a short period of time (referred to as the 
time-step, ∆𝑡). This enables us to calculate the new positions of the atomic coordinates 
after time ∆𝑡 has passed. We then recalculate the forces on the atoms of the newly updated 
coordinates to predict the coordinates after a further time step (i.e. 2∆𝑡 from the starting 
time). The iteration of this procedure therefore allows us to simulate the dynamics of a 
system over time. In order to calculate the position of the atomic coordinates after the first 











  (Eq 2) 
 
The above equation can then be rearranged to give the displacement of the coordinates 
after the first time-step (i.e. 𝑟(𝑡 + ∆𝑡), see (Eq 3).  
 𝑟(𝑡 + ∆𝑡) = 2𝑟(𝑡) − 𝑟(𝑡 − ∆𝑡) + 
∆𝑡2𝐹(𝑡)
𝑚





To deal with the issue that at 𝑡 = 0 we do not know/have the coordinates of 𝑟(𝑡 − ∆𝑡), 
velocities are randomly assigned to each atom, making sure that the total kinetic energy 
of the system is consistent with simulation temperature (see Section 2.3.2 for further 
details).53    
Whilst the assumption of constant acceleration is incorrect because the forces felt by each 
atom are positionally dependent, a larger timestep would increase the efficiency of an MD 
simulation. The major limitation placed on the maximum time-step possible for a MD 
simulation is the requirement to well describe the fastest motions of the system (bond 
vibrations and rotations).38 For example, a C-H stretch has a frequency of ~3000 cm−1, 
which corresponds to a bond oscillation time of ~11 fs. Therefore, time steps close to or 
higher than the bond oscillation time could result in unrealistic conformations obtained 
over the course of the simulation. As the oscillation time is inversely proportional to the 
square root of the reduced mass of the two atoms in the bond, bonds containing hydrogen 
tend to have the shortest oscillation times. A commonly used procedure in MD 
simulations is to constrain the bond length for any bond that contains a hydrogen atom, 
which tends to allow one to increase the timestep used from 1 fs to 2 fs, effectively 
doubling the simulation speed.66 In this thesis, the SHAKE algorithm67 is used to achieve 
this for all MD simulations run. Coarse-grained simulations (in which small groups of 
atoms are merged into “super atoms”) will simulate particles which have a significantly 
larger reduced mass, allowing for much larger time steps to be used. For example, for 
MARTINI, a coarse-grained MMFF for biomolecules, using a timestep of between 20–
40 fs is recommended for MD simulations.68  
The following subsections will now provide detail on some key considerations for running 
an MD simulation (particularly focussed on simulations of biomolecules in explicit 
solvent as performed in this thesis).  
 
2.3.1 Periodic Boundary Conditions  
 
Most MD simulations aim to recapitulate experiment, in which a protein would be 
surrounded by a large amount of bulk water. Simulating a protein surrounded by a droplet 
of water would give rise to “surface effects”, meaning water molecules at the exterior of 
the droplet would not be solvated by water (as they should be in bulk solution).53 This 
could result in water molecules evaporating off into empty space or overcompensating for 
the limited number of interactions surrounding them to form highly ordered water 
molecules. To alleviate this issue, MD simulations often use periodic boundary conditions 
(PBCs). In a PBC simulation, the solute(s) are solvated in a rectangular (other shapes are 
also possible) box of solvent and this box is replicated in all x, y, and z directions.66 These 
additional boxes are called “images” and are identical to the central box. On a practical 
level, PBCs mean any atom that passes through the box boundary will re-enter the box 





example). Furthermore, non-covalent interactions can be “felt” through the box walls, 
meaning that all solvent molecules are completely solvated, giving a closer representation 
to the behaviour of bulk water.  
 
2.3.2 Pressure and Temperature Regulation 
 
MD simulations are often run using one of three different ensembles, whereby for each 
ensemble, the terms provided are kept constant. These ensembles are: NVE, NVT and 
NPT, where N is the number of particles, V is the volume, E is the energy, T is the 
temperature and P is the pressure.  NVE simulations are the fastest, followed by NVT and 
then NPT simulations. This is because an NVT simulation requires a thermostat whilst an 
NPT simulation requires both a thermostat and barostat (pressure regulator), and an NVE 
simulations requires neither.  
The temperature of an MD simulation is usually measured by its relationship to the kinetic 
energy (𝐾𝐸), see (Eq 4).    
 










〉 (Eq 4) 
 
Where 𝑁 is the number of atoms, 𝑘𝑏 is the Boltzmann constant and 𝑚𝑖 and 𝑣𝑖 are the mass 
and velocity of atom 𝑖 respectively. It is important to note that the average temperature is 
proportional to the kinetic energy, and that on the microscopic scale the kinetic energy 
should fluctuate around this average value (following a Gaussian distribution).53 An NVE 
simulation (in which no thermostat is present) would follow a constant energy scheme, 
not representative of this microscopic variation. Thermostats enable the representation of 
this natural variation, through modifying the velocities of the atoms in the system. In this 
thesis, a Langevin thermostat69 is used to regulate the temperature. Langevin thermostats 
work by implicitly modelling the effects of viscosity and random collisions with the 
surroundings on the system, resulting in both the addition and removal of kinetic energy 
around the target temperature.   
The pressure (𝑃) of an MD simulation is measured using the Virial theorem70, which 
relates the forces applied to the simulation box to the pressure (see (Eq 5).  
 
𝑃 =  
1
3𝑉
〈3𝑁𝑘𝑏𝑇 + ∑ 𝑓𝑖𝑟𝑖
𝑁
𝑖=1
〉 (Eq 5) 
 
Where 𝑉 is the volume and 𝑓 and 𝑟 are the forces and positions of atom 𝑖. Alike 




fluctuate around the average pressure.53 Most barostats work by either modifying the size 
of the simulation box (whilst scaling the coordinates appropriately so the pressure change 
is felt throughout the system and not just at boundary) or by modifying the velocities (and 
therefore forces) to give constant pressure. In this thesis, a Berendsen barostat71 is used to 
regulate the pressure. This is achieved by coupling the system to a weakly interacting 
pressure bath, which scales the volume of the periodic box at set intervals, producing 
fluctuations in the pressure around the target pressure.  
 
2.3.3 Dealing with Long Range Electrostatics Interactions 
 
As discussed in Section 2.1, non-bonded interactions in MMFFs are described by both 
van der Waals (vdWs) and electrostatic interactions. Calculation of non-bonded 
interactions tends to be the slowest part of an MD simulation timestep (as there would be 
𝑛2 pairwise distances to evaluate, where 𝑛 is the number of atoms). The vdWs repulsive 
and attractive terms scale by 𝑟−12 to the 𝑟−6 respectively, meaning after a short distance 
their strength is negligible (see Figure 9). To reduce simulation cost, a distance cut-off 
for vdWs interactions is normally applied such that only interactions within the cut-off 
are considered (this is typically between 8–12 Å).53 Electrostatic interactions however 
scale by 𝑟−1, which would mean ignoring their interactions after short distance cut-off 
would be inappropriate. In implicit solvent simulations, electrostatic interactions normally 
do not have a cut-off (or at least a very large cut-off is used). In explicit solvent 
simulations, electrostatic interactions are treated explicitly if within a certain cut-off 
distance (normally selected to be the same size as the vdW cut-off). Longer range 
interactions are treated by grid-based Ewald summation approaches like the particle mesh 
Ewald (PME) method.72 In these approaches, explicit charges (from all atoms) are spread 
onto a grid covering the entire periodic box and used to define the long range electrostatic 
interactions felt by each atom in all directions.  
It is important to consider non-bonding interactions when deciding on an appropriate box 
size. That is, one does not want to select a periodic box size that is small enough to allow 
the solute to directly interact with itself. Furthermore, the solute can indirectly interact 
with itself by perturbing the solvent. It is therefore important to consider that the box size 








2.3.4 A General MD Simulation Protocol  
 
The setup and running of an MD simulation can be broken down into five general stages 
which are: preparation of the system, geometry optimisation, heating, equilibration and 
production. The following subsection provides details on the key parts of each of these 
steps.  
System preparation involves generating a complete atomic model of the system one wants 
to study alongside the parameters needed to describe the system. The structure of the 
solute can be obtained from X-ray crystal, NMR solution or cryo-EM structures. 
Alternatively, if the structure of the biomolecule is not known, it could be predicted with 
homology modelling or ab initio structure prediction (or some combination of the two).73 
Missing residues (from an experimentally determined structure) should be modelled back 
in where appropriate. Simulations of protein complexes where the structure of the 
complex is not known can be performed by manually docking the receptor and ligand or 
using one of the many different docking algorithms available.74 An important 
Figure 9: Exemplar Leonard-Jones Potential describing the strength of a vdWs 
interactions between two interacting particles. The locations of σ (distance at which the 
intermolecular potential energy is 0, i.e. the vdWs radius) and ϵ (well depth) are indicated 
on the figure. As can be seen from the graph, after a short distance of ~6 Å, the potential 
energy is already near 0. For the equation used to calculate the Leonard-Jones potential, 




consideration for structures solved by crystallography is that the resolution is not normally 
<1 Å. This means the tautomerisation and/or protonation states of histidine residues and 
the position of the side chain amine or carbonyl groups of asparagine and glutamine 
residues cannot be resolved by experiment. Several programs exist to solve this problem 
by identifying the most likely states based on the criteria of optimising the hydrogen bond 
network.75 It is recommended to validate the obtained results by eye to ensure the 
outputted results make sense. The protonation states of titratable residues (or other 
titratable species) should be considered based on the desired simulation pH. Several 
empirical methods exist to rapidly predict the pKa of titratable residues which should 
normally suffice.76 Once the solute has been prepared, one needs to solvate the structure 
in a box of water in order to perform PBC simulations. Finally, the system needs to be 
parameterised and one should take care not only to select MMFF(s) that well describe the 
properties one is interested in obtaining, but also that the MMFFs selected are compatible 
with one another.53 
For the energy minisation step, one should ensure a sufficient number of steps are 
performed such that the structure is close to the local minimum. If not, instabilities can 
arise in the subsequent heating step (as the forces projected onto atoms in high energy 
states can be very large). The heating step is the first point at which velocities (and 
therefore kinetic energy) is assigned to the system. It is generally recommended to start 
from a low temperature (to avoid the introduction of large velocities) and relatively slowly 
heat the system to the desired target temperature.53 In the simulations of TCRs or pHLAs 
performed here, following an initial energy minisation of only the solvent molecules or 
hydrogen atoms, the solvent is heated to the target temperature (using restraints on all 
solute heavy atoms throughout) to allow it to relax around the solute structure(s). Then, 
the entire system is energy minimised again and then heated to the target temperature (this 
time with only gentle restraints on the Cα of any protein atoms).  
Heating is normally performed in the NVT ensemble. It is important to consider that the 
solvent box added will be purposefully too large for the size of the system. This is done 
to allow water molecules adequate room to adjust upon heating, so systems are less likely 
to become trapped in high energy states. As the box size is kept constant during an NVT 
simulation, NPT equilibration simulations should be performed so that an appropriate box 
size can be obtained for the target pressure and temperature. If one plans to later swap 
back to NVT or NVE simulations after NPT equilibration, one should calculate the 
average box size (as this property will fluctuate over the course of the NPT simulations) 
after the box is equilibrated and use this for NVT or NVE simulations. Before moving 
onto production MD simulations (the point at which trajectory information is used for 
analysis) one should validate that the biomolecule itself has stabilised. One way to asses 
this would be to calculate the root-mean-square deviation (RMSD) of the protein over the 
course of equilibration procedure (only beginning production MD simulations once this 






2.4 Allosteric Analysis of MD Simulations  
 
In Chapter 3, some less commonly used simulation analysis techniques are performed in 
order to probe for allosteric communication between different parts of the protein 
complex. Herein, a short description is provided on the two approaches used.   
 
2.4.1 Dynamic Cross Correlation Matrices (DCCM) 
 
The identification of correlated motion between atoms over the course of a simulation(s) 
can help to identify regions distal from one another that appear to be dynamically linked 
to one another. The amount of cross correlation (𝐶𝑖,𝑗) between atoms 𝑖 and 𝑗 can be 
calculated using (Eq 6).77  
 𝐶𝑖,𝑗 =  〈∆𝑟𝑖. ∆𝑟𝑗〉/(〈∆𝑟𝑖
2〉. 〈∆𝑟𝑗
2〉)1 2⁄  (Eq 6) 
 
Where ∆𝑟 is the displacement from the mean position for the 𝑖th or 𝑗th atom. The value 
obtained will be between 1 and −1, with 1 indicating perfectly correlated motion, −1 
indicating perfectly anti-correlated motion and 0 indicating no correlation between the 
atoms. In the above terminology, anti-correlated motion between two particles would 
mean the two particles movements are correlated with one another but they move (on 
average) in the opposite direction to one another (as opposed to just “correlated”, in which 
case they move in the same direction as one another). Cross correlation values obtained 
through MD simulations tend to always be non-zero. A cut-off is therefore often used to 
ascertain whether the correlation observed between the two atoms should be considered 
meaningful. Commonly, the correlation between the Cα carbon of each residue is used as 
a proxy to measure the degree of cross correlation between residues. Calculating the 
degree of cross correlation between all residues would give a matrix of these values 
(referred to as a dynamic cross correlation matrix, DCCM).  
 
2.4.2 Community Network Analysis (CNA)  
 
Community Network Analysis (CNA, sometimes also referred to as correlation network 
analysis) is an approach which builds upon a pre-determined DCCM for a given system 
by clustering groups of highly correlated residues together into communities and 
calculating the degree of correlation (which acts as a proxy for communication) between 
different communities.78 This data can be represented in a graphical manner, in which a 
node on a graph corresponds to a community, and the edges between nodes indicate the 




indicating increased correlation/communication). Clustering of residues into communities 
is performed using the Girvan–Newman algorithm,79 which uses a “non-hierarchal” 
approach to cluster communities. This means edges are progressively removed from the 
protein network if they are more likely to be between communities (the smaller the 
magnitude of correlation, the more likely the edge should be between communities and 
not in the same community). The quality of the clustering partition can be evaluated by 
calculating the “modularity”. The modularity provides a value between 0 and 1 and 
assesses the overall degree of inter-community correlation against the intra-community 
correlation. A higher modularity value is desired as it is indicative of increased inter-
community correlation and decreased intra-community correlation. 
2.5 Molecular Mechanics Poisson-Boltzmann/Generalised Born Surface 
Area Calculations  
 
The following section describes the theoretical basis for the Molecular Mechanics 
Poisson-Boltzmann/Generalised Born Surface Area (MMPB/GBSA) approach in order to 
predict binding free energies. Practical considerations for the application of 
MMPB/GBSA based on prior literature findings are also discussed.  
 
2.5.1 Theoretical basis.  
 
Unlike free energy perturbation methods which slowly transition from one state to another 
through a series of intermediates, MMPB/GBSA is an end-state free energy calculation 
method.39 This means the Gibbs free energy of the complex, receptor and ligand are 
calculated separately and then combined in order to obtain the Gibbs free energy of 
binding (∆𝐺𝑏𝑖𝑛𝑑, as shown in Figure 10).  
As indicated in Figure 10, ∆𝐺𝑏𝑖𝑛𝑑 is obtained by constructing a thermodynamic cycle 
such that the solvation free energy change is calculated separately from the gas phase free 
energy change. The general equation used in MMPB/GBSA to calculate all the terms 
required for ∆𝐺𝑏𝑖𝑛𝑑 is shown in (Eq 7).
80  
∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑖𝑛𝑡 +  ∆𝐸𝑒𝑙 + ∆𝐸𝑣𝑑𝑤 + ∆𝐺𝑝𝑜𝑙 + ∆𝐺𝑛𝑝𝑜𝑙 − 𝑇∆𝑆 (Eq 7) 
 
Where ∆𝐸𝑖𝑛𝑡, ∆𝐸𝑒𝑙 and ∆𝐸𝑣𝑑𝑤 are the change in internal, electrostatic and vdWs energies 
upon binding respectively. ∆𝐺𝑝𝑜𝑙 is the polar contribution to the solvation free energy and 
is obtained by solving either the Generalised Born (GB) or Poisson–Boltzmann (PB) 
equations. ∆𝐺𝑛𝑝𝑜𝑙 is the nonpolar contribution to the solvation free energy. Finally, 𝑇∆𝑆 
is the change in entropy of the solutes upon binding, which in combination with ∆𝐸𝑖𝑛𝑡, 
∆𝐸𝑒𝑙 and ∆𝐸𝑣𝑑𝑤 form the parts of the equation responsible for gas phase contributions to 






2.5.2 Calculation of Internal Energy, Electrostatic and van der Waals Terms  
 
In the case of ∆𝐸𝑖𝑛𝑡, ∆𝐸𝑒𝑙 and ∆𝐸𝑣𝑑𝑤, these terms can be obtained directly from the chosen 
force field potential energy terms (∆𝐸𝑖𝑛𝑡 in this case covers all bonding, angle, dihedral 
and improper torsions terms). These terms can be provided by a single point energy 
calculation on the given snapshot/structure.  
 
2.5.3 Calculation of the Solvation Free Energy  
 
The polar contributions to the solvation free energy are obtained most commonly by 
solving either the Poisson–Boltzmann (PB) or Generalised Born (GB) equations (other 
methods have also been used such as 3DRISM81). Both the PB and GB models are 
“implicit” as instead of explicitly treating the solvent molecules as particles, they are 
described by a continuum model (CM).66 In a CM, the solute polarises the continuum 
(from the partial charges on its atoms) to build up charge density at the border between 
the solute and continuum. The charge density will be of opposite sign to the local solute 
charge, with the magnitude of the charge density regulated by both the magnitude of the 
partial charges in the solute and the dielectric constant (i.e. the polarity) of the solute. If 
Figure 10: Schematic Representation of the thermodynamic cycle used in MMPB/GBSA 
calculations.  (The top three molecules are depicted inside a blue background to indicate 
they are solvated, whilst the bottom three are depicted as being in the gas phase). The 
model system shown is a TCR-pHLA complex, with the pHLA shown as the receptor and 




one can calculate the charge density over the entire surface of the molecule (𝜎(𝑟)), it can 
be used to calculate the polar solvation free energy of the molecule (𝐺𝑝𝑜𝑙), see (Eq 8).  
𝐺𝑝𝑜𝑙 =  
1
2
∫ 𝜎(𝑟). 𝑉(𝑟) 𝑑𝑟
𝑠
0
  (Eq 8) 
 
Where 𝑉(𝑟) is the electrostatic potential at position 𝑟 on the surface of the molecule. The 
integration is performed over the entire surface of the calculation, with a reduced 
integration grid spacing resulting in increased accuracy but increased computational cost. 
To obtain 𝜎(𝑟) one can solve either the PB or GB equation. The solution to the PB 
equation is shown in (Eq 9).82  






) ∇𝑉(𝑟). 𝑛(𝑟) (Eq 9) 
 
Where 𝜀(𝑟) is the position dependant dielectric constant and 𝑛(𝑟) is a unit vector (vector 
with magnitude of one) perpendicular to the solute surface.  
The GB equation approximates the PB equation, by treating the point charges exposed to 
the surface individually before summing the resulting terms together to obtain 𝐺𝑝𝑜𝑙 (see 
(Eq 10).66 
















 (Eq 10) 
 
Where 𝑞𝑖 and 𝑟𝑖 is the charge and radii of atom 𝑖 respectively. 𝑅𝑖𝑗 is distance between the 
atoms 𝑖 and 𝑗. 
Both the PB and GB models calculate the electrostatic contribution to the solvation free 
energy but do not consider the role of the solute in organising/ordering water molecules 
(or solvent more generally) to form a hydration layer over the protein. This phenomenon 
(referred to commonly as the hydrophobic effect) is what is calculated in the term “𝐺𝑛𝑝𝑜𝑙” 
and can be estimated by assuming the solvent accessible surface area (SASA) of the 
protein has a linear relationship with 𝐺𝑛𝑝𝑜𝑙.
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2.5.4 Calculation of Solute Entropy  
 
The final term left to calculate is 𝑇∆𝑆, the change in solute entropy (solvent entropy 





calculate this term, with the most commonly used approach being normal mode analysis 
(NMA). This approach is computationally expensive in terms of the time taken per 
snapshot, as well as being memory intensive to store the Hessian. The time taken is further 
exacerbated by the need to optimise the snapshots to its local minimum prior to NMA 
(otherwise the first derivative of the potential energy with respect to the atomic 
coordinates will not be zero). It has often been observed that the variation between 
snapshots from NMA can be quite large, meaning that obtaining meaningful results 
requires a lot of sampling and the use of lots of snapshots. For the above reasons, alongside 
the fact that MMPB/GBSA is often primarily used for relative (not absolute) binding free 
energies, explains why many studies skip the calculation of 𝑇∆𝑆 altogether.84,85 One 
approach developed by Ryde and co-workers to deal with some of the limitations 
associated with NMA is to truncate the protein around the binding site for the optimisation 
and frequency calculations, whilst retaining a small buffer region that is fixed in place to 
stabilise the protein over these steps. This approach can significantly reduce the time taken 
to run NMA as well as the errors obtained.86,87  
An alternative approach is to calculate the mass-weighted covariance matrix from a 
simulation trajectory or trajectories. This approach is known as “quasi-harmonic analysis” 
(QHA), with the eigenvalues obtained from the covariance matrix corresponding to the 
vibrational frequencies of the system.88 A severe limitation of this approach is the length 
of time required in order to converge, which is likely to be on the µs or ms time scale for 
biomolecules.89 One way to increase the rate of calculation could be to strip the hydrogen 
atoms from the calculation (reducing the number of modes and therefore time taken to 
converge). The vibrational modes of bonds containing hydrogen are relatively high 
(~3000 cm−1), meaning they will have a small impact on the total entropy value obtained.  
A recently developed approach by Duan et al. known as the interaction “Interaction 
Entropy” (IE) method has gained popularity due to the fact that separate calculations are 
not required to calculate 𝑇∆𝑆.90 In this method, the variance (over the course of a 
simulation(s)) of the gas phase interaction energy (𝐸𝑒𝑙 and 𝐸𝑣𝑑𝑤 terms) is used to calculate 
the entropy of the given state.  
 
2.5.5 Practical Considerations When Performing MMPB/GBSA Calculations 
 
The approximations associated with the MMPB/GBSA approach mean it is not generally 
considered reliable for accurately calculating absolute binding free energies.85 Instead, 
MMPB/GBSA can be used to rank or predict relative binding free energies for a series of 
similar ligands. Each calculation is performed on a single snapshot/conformation at a time 
making the procedure well suited for parallelisation.39 Whilst MMPB/GBSA can be 
performed on a single structure, it is generally accepted that sampling (normally via MD 




MD simulations, several studies have shown that running multiple short simulations 
achieves more (statistically) reliable and accurate results as opposed to one or a few long 
MD simulations.91–93 The benefit of taking MD simulations snapshots more often than 
every 10 ps appears to be limited of value, as inclusion of intermediary frames are unlikely 
to be decorrelated from one another.91 MMPB/GBSA calculations should theoretically be 
performed in vacuo as solvent contributions are calculated implicitly. However, as both 
PB and GB methods represent bulk solvent behaviour (and therefore may not particularly 
well describe the first few solvation layers) some studies have tested the effect of 
including a small shell of explicit water molecules around the binding site, with mixed 
success.94–96 Finally, a common approximation used in MMPB/GBSA is to perform 
simulations of only the complex and obtain structures for the receptor and ligand by 
deleting either part as appropriate. This procedure (referred to as the single trajectory 
approach) makes the ∆𝐸𝑖𝑛𝑡 term cancel out, reduces the calculation time significantly (as 
less MD simulations needs to be run) and tends to result in a reduction in the magnitude 







Chapter 3: Peptide Dependant 
Allosteric Regulation of the pHLA 
Complex 
 
In this chapter, we applied pressure/temperature perturbation experiments, and 
molecular dynamics (MD) simulations, to explore how different peptide cargo could 
govern the molecular flexibility of the overall pHLA complex. We found that the 
motions of the pHLA were dependent on and mediated by (relatively) small alterations 
in the peptide cargo, suggesting that allosteric mechanisms can meditate HLA 
flexibility. Differences in protein dynamics for different peptide cargo manifested 
primarily in the HLA molecule (as opposed to the peptide). Changes in flexibility were 
found in several regions known to be involved in antigen processing (via tapasin, 
TAPBPR interactions) and CD8 co-receptor interactions, calling into question the role 
of the peptide in mediating these interactions. Additionally, these motions might directly 
influence TCR-mediated antigen discrimination through flexibility motions transmitted 
to the HLA-binding groove. This work is of significant interest to those studying the 
molecular mechanisms that govern T-cell mediated antigen recognition, as well as the 
growing community of researchers and companies developing T-cell based therapies 
(vaccine design, CARs, bi-specifics, etc). My role in this chapter was in performing all 
of the MD simulations and subsequent analysis. I also wrote the results and discussion 
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Most biomolecular interactions are thought to increase the (local) rigidity of a complex, and this 
paradigm is applied when designing new drugs. Here, we focussed on the Human Leukocyte 
Antigen (HLA), which plays a crucial role in the adaptive immune system by presenting 
peptides for recognition by the αβ T cell receptor (TCR). The role that the peptide plays in 
tuning HLA flexibility during TCR recognition is potentially crucial in determining the 
functional outcome of an immune response, with obvious relevance to the growing list of 
immunotherapies that target the T-cell compartment. We have applied high-
pressure/temperature perturbation experiments, combined with molecular dynamics simulations, 
to explore the drivers that affect molecular flexibility for a series of different peptide-HLA 
complexes. We find that different peptide sequences affect peptide-HLA flexibility in different 
ways, with the peptide cargo tuning a network of correlated motions throughout the pHLA 
complex, including in areas remote from the peptide binding interface, in a manner that could 




The T-cell receptor (TCR), expressed on the surface of T-cells, scans for antigens on the surface 
of virtually every cell in the body. TCR-antigen recognition can mediate clearance of germs and 
neoplasms, and plays a major role in autoimmunity and transplantation.44,97–100 As such, a better 
understanding of the molecular determinants that govern TCR-antigen interactions is key to 
identifying novel therapeutic interventions that can enhance (cancer immunotherapy, vaccines), 
or inhibit (regulation of autoimmunity) T-cell activation. The natural TCR ligands are the peptide-
human leukocyte antigens (pHLA) class I and class II. Classically, pHLA class I is recognized by 
CD8+ T-cells, and pHLA class II is recognized by CD4+ T-cells. These ligands feature a number 
of unique characteristics (analogous in both the pHLA class I and pHLA class II systems) that 
have important implications for both protein dynamics and T-cell mediated immunity. First, the 
antigen binding site is composed of a composite that includes the HLA-binding groove (formed 
by the HLA α1 and α2 domains for HLA class I, the focus from hereon in) and a short 9-13 amino 
acid peptide that can be derived from a completely unrelated protein (the source of these peptides 
is generally the immune-proteasome that degrades the majority of intracellular proteins, which 
can derive from foreign or mutated self-proteins).101,102 Intriguingly, although the peptide only 





the entire complex together, i.e. HLA molecules do not generally form a stable structure without 
a bound peptide.103 These peptides are edited by the antigen processing machinery in the 
endoplasmic reticulum (ER) before being transported to the cell surface for TCR interrogation.104 
Second, during binding, the TCR interacts directly with both the HLA surface and the peptide 
(composite antigen binding site).105,106 How the TCR retains the delicate balance between HLA 
binding and peptide dependence (peptide-independent recognition of HLA would result in T-cell 
activation against virtually every nucleated cell in the body) is still not fully understood. Finally, 
pHLA is unique in biology because it can form a trimeric complex with both the TCR and co-
receptor molecules (CD8 for pHLA class I and CD4 for pHLA class II).107–110 Although the co-
receptors bind to an invariant site distal from the TCR, this interaction is known to play a role in 
TCR thymic selection111, and can tune TCR cross-reactivity by altering T-cell potency.112,113 
 
Many studies have focused on understanding the relationship between the biophysical 
characteristics of the TCR-pHLA interaction and T-cell potency18,23,114–117, and the role of TCR 
flexibility during pHLA engagement.25,99,126,118–125 These studies have demonstrated that the 
optimal TCR-pHLA interactions can be mediated by a highly flexible binding mode, probably 
contributing to the ability of TCRs to recognize multiple different pHLAs.16,23,127–130 This 
flexibility has been observed in the flexible loops that form the binding site of the TCR, 
contributing towards the notion that TCRs ‘meld’ around the pHLA surface during binding.131 
Although flexibility has also been reported in both the HLA-bound peptide50,132–135 and the HLA 
helices136–138, the role that different peptides play in modulating HLA dynamics globally, and what 
impact the dynamics might have on T-cell antigen recognition, is only beginning to be 
explored.139,140 On the one hand, a more dynamic pHLA molecule could enable TCR binding of 
the peptide cargo in an ‘optimal’ conformation for T-cell activation, or to enable recognition by a 
greater range of different TCRs. On the other hand, a more dynamic pHLA may confer a higher 
entropic cost during TCR binding that might reduce affinity, or could lead to the unwanted 
recognition of self-antigens leading to autoimmunity.  
 
In the context of protein-protein and protein-ligand interactions, molecular flexibility is defined 
by a multi-dimensional free energy landscape (FEL), comprising a large number of energetic 
minima and maxima that define differently stable conformational sub-states of the same protein 
(or protein complex). Peptide-dependent effects on HLA dynamics could influence the functional 




receptors. We hypothesized that nature of the peptide cargo might alter the equilibrium of 
conformational states that exist and are accessible to the HLA molecule (i.e. its FEL). To address 
this hypothesis, we use combined pressure/temperature (p/T) dependent fluorescence 
spectroscopy and molecular dynamics (MD) simulations to expose differences in the 
thermodynamics of the differing pHLA complexes and to identify the atomistic determinants of 
pHLA flexibility. These data provide new insights in the role that the peptide plays in tuning the 
flexibility of HLA, a feature that might contribute to modulation of TCR antigen recognition and 
T-cell mediated immunity. 
 
Results and Discussion 
 
Pressure-temperature matrices expose differing thermodynamic contributions to pHLA flexibility. 
We focused on the well characterized 1E6 TCR system, a TCR that naturally recognizes the HLA-
A*02:01-restricted ALWGPDPAAA15-24 peptide from the preproinsulin protein, and plays a 
biological role in human type 1 diabetes.98,141–143 We have previously reported a number of altered 
peptide ligands (APLs) for the 1E6 TCR using structural, biophysical and cellular analysis. These 
data demonstrated that, despite a highly conserved, hotspot driven, binding mode (Figure 11A), 
the binding affinity and cellular potency of the 1E6 TCR for the different APLs was substantially 
affected, independently of pHLA stability (Figure 11B).23 Thus, this well characterized set of 
APLs provided a biological relevant model system to further examine the contribution of the 







Molecular flexibility is usefully thought of as the transitions between different conformational 
states (energetic minima) on the protein FEL. Combined pressure/temperature (p/T) denaturation 
studies have been used in several cases to extract the complete suite of thermodynamic parameters 
that define the FEL for protein folding, so called elliptical phase diagrams.144 In the present study 
we wish to explore the FEL specifically relating to native protein conformational change. Non-
denaturing hydrostatic pressure is an excellent probe of native protein dynamics since it acts by 
perturbing the pre-existing equilibrium of states, favouring more compact conformations.145 Non-
denaturing pressure therefore gives access to the conformational changes that are natively 
accessible on the proteins FEL. Intrinsic Trp emission is a ready reporter of the effect of p/T 
perturbation because Trp emission intensity is sensitive to changes in the immediate molecular 
environment through a range of mechanisms.146 Changes in Trp emission are therefore reporters 
of protein conformational change and as such can be used to calculate an equilibrium constant for 
Figure 11: (A) Structural representation of the 1E6 TCR-pHLA interaction with the inset showing 
a zoom in on the TCR-pHLA binding site. The conserved GPD motif in the peptide and TCR 
residues that interact with these residues are shown as sticks. For the 4 peptides that also interact 
with the TCR via their position 1 residue (X), the side-chain of this residue is also indicated with 
orange sticks. (B) Peptide sequences and their respective pHLA melting temperatures (Tm) as 




the change across a perturbation series. The change in Trp emission can be converted to an 





1 + 𝐾(𝑝, 𝑇)
 (Eq 11) 
 
Where 𝐹𝑖 is the integral of the emission intensity of Trp for a given pressure/temperature. For a 
simple 2 state transition, e.g. an equilibrium between 2 conformational sub-states, the temperature 
dependence of the equilibrium constant is given by (Eq 12). 
𝑙𝑛𝐾 = (−∆𝐺)/𝑅𝑇 (Eq 12) 
 
The combined p/T dependence of ΔG reflects the free energy difference between the 2 notional 
sub-states and so is a proxy for the degree of conformational ‘flexibility’. ΔGP,T is then given by 
(Eq 13).  





− ∆𝑆0(𝑇 − 𝑇0) − ∆𝐶𝑃 [𝑇 (𝑙𝑛 (
𝑇
𝑇0
) − 1) + 𝑇0] 
(Eq 13) 
 
Where T0 is a reference temperature. ΔH, ΔS, ΔG0, ∆𝐶𝑝, ΔV0, Δβ and Δα reflect the changes in 
enthalpy, entropy, Gibbs free energy, heat capacity, activation volume, compressibility and 
expansivity between the 2 notional conformational sub-states that define the equilibrium, 
respectively. Note that this model assumes both ∆𝐶𝑝 and Δα are constant with respect to both 
pressure and temperature. The model assumes a two-state transition because the model for a more 
complex number of states would be intractable when fitting the experimental data. 
 
These analyses demonstrated that the p/T relationship clearly differed for different pHLA 
complexes (Figure 12, Table 1). The contribution of the different thermodynamic parameters to 
the magnitude of ΔG were highly specific for each peptide sequence. For example, with RQFa 
and RQFi, the contribution from ΔS was large compared to other parameters; for ALW the 
contribution from ∆𝐶𝑝 was large compared to other parameters. MVW, RQW and YQF peptides 
had significant contributions from ΔV0 and Δβ, which were not observed for RQFa, RQFi and 
ALW peptides. These data point to a peptide sequence specific effect on the FEL reflecting HLA 
conformational flexibility. That is, different peptide sequences affect pHLA molecular flexibility 





a complex interplay of a range of different thermodynamic contributions, which do not have an 
obvious relationship to peptide sequence. 
 




Molecular dynamics simulations identify both local and distal changes in flexibility for different 
peptide cargo. The p/T analysis demonstrated significant differences in the global molecular 
flexibility and thermodynamics of the pHLA binary complexes, dependent on the peptide cargo. 
In an attempt to rationalise the differences observed experimentally, we used molecular dynamics 
 





(kJ mol-1 K-1) 
ΔV (cm3  
mol-1) x 10-3 
Δβ (cm3 mol-1 
mPa-1) x 10-5 
Δα  
(K-1) x 10-5 
RQFi 58.8 8.1 ± 0.1 -0.07 ± -0.6 -0.6 ± 0.2 2 ± 1 -1.3 ± 1.1 3.4 ± 3.5 
YQF 60.3 8.3 ± 0.1 -0.02 ± 0.33 0.3 ± 0.3 5 ± 1 -3.6 ± 1.5 8.5 ± 4.9 
RQW 54.3 8.7 ± 0.2 -0.04 ± 0.02 0.6 ± 0.4 4 ± 2 2.4 ± 2.1 5.0 ± 6.7 
RQFa 49.4 8.8 ± 0.1 -0.06 ± 0.01 -0.3 ± 0.2 0 ± 1 6.3 ± 1.0 1.1 ± 3.1 
ALW 60 8.7 ± 0.2 -0.01 ± 0.02 1.7 ± 0.3 0 ± 2 -7.1 ± 2.0 -4.6 ± 6.3 
MVW 56.7 8.8 ± 0.2 -0.06 ± 0.02 0.0 ± 0.4 6 ± 2 -4.8 ± 2.4 8.7 ± 7.7 
 
Figure 12: Combined p/T matrices for each pHLA studied. Solid spheres represent the 
experimental data, transformed to ΔG by (Eq 12). The coloured surfaces are the resulting fit of 




(MD) simulations, performing 10 replicas of 150 ns each for each pHLA under investigation, 
giving a total of 9 µs of simulation time. Using this approach, the (backbone) flexibility of the 
pHLA can be inferred by calculating the root mean square fluctuations (RMSF) of each residues 
Cα carbon over the course of the simulations.  
 
To investigate the impact of different peptide cargo on the flexibility of the HLA, we first 
calculated the Cα RMSF for the peptide and the α1 and α2 domains of the pHLA (Figure 13, 
Supp Figure S1). We then extended this analysis to the α3 and β2m domains for each pHLA 
(Figure 14, Supp Figure S1). As we were primarily interested in the differences in pHLA 
flexibility with different peptides cargos, we calculated the average RMSF value for each residue 
in all complexes, and subtracted this from each pHLA complex RMSF value, meaning a residue 
with a positive ΔRMSF value indicates an increased flexibility against the average.  
 
Significant differences (p < 0.05) were observed for only 2 of the peptide residues (of 10 total). 
Interestingly, flexibility differences were not necessarily correlated with regions of the peptide 
that differed between APLs, demonstrating the interconnected nature of the peptide.  For instance, 
the N-termini had largely very similar flexibility (with the exception of RQW), despite the N-
terminal residues differing substantially between peptides. In contrast, ΔRMSF analysis of the 
central ‘GPD’ motif of peptide (known to be the main binding site for the TCR and conserved in 
all APLs investigated in terms of sequence and conformation) demonstrated significant changes 
in flexibility, particularly between RQW and MVW, which showed increased and decreased 
flexibility relative to the average, respectively. This is of particular interest as the conserved 
‘GPD’ motif accounts for 41-50% of all contacts between the 1E6 TCR and the 6 pHLA 
complexes investigated.23 These changes in peptide flexibility could, therefore, have a direct 
impact on the interaction between the TCR-pHLA complex (for instance by modulating the 








Figure 13: Differences in flexibility at the peptide binding groove for all 6 pHLA complexes 
investigated. (A-B). Change in Cα RMSF (Average – pHLA) for the α1 and α2 domain (A) and 
peptide (B), meaning a positive ΔRMSF value indicates an increase in rigidity for that pHLA 
complexes residue relative to the average. C) ΔRMSF values as shown in A-B colour mapped on 
the pHLA structure (HLA as cartoon, peptide as ball-and-stick), with blue indicating increasing 
rigidity, and red indicating increasing flexibility (again relative to the average RMSF value for that 
residue). Heat mapping is scaled from -0.5 – 0.5 Å for all complexes. The black dots towards the 
bottom of each graph indicate residues with significantly different ΔRMSF values as determined by 




In contrast to the peptides, which demonstrated relatively small changes in flexibility, significant 
differences (p < 0.05) in flexibility were detected in 45 residues (out of 180 total) for the α1 and 
α2 helices, 35 residues (out of 97 total) residues in the α3 domain and 54 residues (out of 100 
total) in the β2m domain of the HLA. Whilst it is possible that additional HLA residues show 
differences in flexibility for different peptide cargo, our results demonstrate the importance of 
performing many replicas and statistical analysis on those replicas to prevent the observation of 
what may be false positives.147 The observed significant differences in flexibility were largely 
confined to the solvent exposed loops in the HLA domains, including loops 3 and 5 in the α1 and 
α2 domains, respectively. These loops are known to play a role during interactions with tapasin 
and TAPBPR during peptide editing in the ER.148,149 Additionally, loops 8 and 10 on the α3 
domain and loop 6 on the β2m domain, which are known to play a role in interactions with the 
CD8 co-receptor107, demonstrated high degrees of differences in flexibility. We also note that the 
statistically significant changes in flexibility we detected in loop 10 in the α3 domain with 
different peptide cargo are consistent with a previous report demonstrating flexible tuning of this 
loop during peptide binding.140 Thus, these changes in flexibility, dependent on peptide cargo, 
could play a role in tuning the antigen processing pathway, or in modulating the interaction with 
the CD8 co-receptor, which is known to play a key role in altering T-cell potency and cross-
reactivity.112,150–152 Overall, differences in flexibility identified by MD analysis were largely 
observed in the HLA, despite the differences in sequence being confined to the peptide cargo. 
This unexpected finding of ‘the tail wagging the dog’ may be indicative of allosteric mechanisms 
in which the sequence of the peptide modulates regions of the HLA known to play a role in 






Figure 14 Differences in flexibility at the peptide binding groove for all 6 pHLA complexes 
investigated. (A-B) Change in Cα RMSF (Average – pHLA) for the α3 domain (A) and β2m (B), 
meaning a positive ΔRMSF value indicates an increase in rigidity for that pHLA complexes residue 
relative to the average. (C) ΔRMSF values as shown in A-B colour mapped on the pHLA structure, 
with blue indicating increasing rigidity, and red indicating increasing flexibility (again relative to 
the average RMSF value for that residue). Heat mapping is scaled from -0.5 – 0.5 Å for all 
complexes. The locations of the α3 and β2m solvent exposed loops are indicated throughout the 
figure. The black dots towards the bottom of each graph indicate residues with significantly 
different ΔRMSF values as determined by a two-sample t-test (p < 0.05). A colour bar is also 






Identification of correlated motions between the peptide and HLA. With the observed significant 
differences in flexibility for regions both local and distal from the peptide binding site in mind, 
we computed dynamic cross correlation matrices (DCCMs) for all 6 pHLAs under investigation 
(Supp Figure S2). DCCMs measure the degree of correlated motion between each atom (in this 
case the Cα carbon of each residue) over the course of the simulation(s). The measurement assigns 
a value between +1 (perfectly correlated motion) and –1 (perfectly anti-correlated motion), with 
0 indicating no correlation between the residues. This analysis can therefore be used to identify 
residues distal from one another that are dynamically linked. To focus primarily on the 
relationship between the peptide and the HLA, we truncated the obtained DCCMs to allow for 
easier analysis of their relationship (Figure 15). Large differences in the overall degree of 
correlated motion between the peptide and HLA occur, with RQW most strikingly showing a 
decreased level of correlated motion. Further, a much larger degree of coupling between the C-
terminal end of the peptide and the rest of the HLA is observed, as compared to the N-terminus 
and central portion of the peptide. Thus, these data suggest that the C-terminal residues of the 
peptide may play a more important role in regulating the global dynamics of the HLA, possibly 
via the F-pocket of the HLA binding groove.  In particular, we observed consistently positively 
correlated motion between the C-terminal residues of the peptide and the α1 helix as well as 
residues 114-134, which make up a large part of the F-pocket. Interestingly, we also observed a 
consistent change across all pHLA complexes of positively correlated to anti-correlated motion 
along the α2 helix (positive starting at the α2-1 portion of the helix). The degree of correlation 
between the peptide and domains distal from the peptide binding site (α3 and β2m domains) also 
showed consistent regions of correlated motions for different pHLA complexes. Whilst in the case 
of RQW, and to a lesser extent RQFa, these correlations were weaker, residues within the range 
210-250 on the α3 domain showed correlated motion to the peptide. These residues include those 
in loop 10, which we herein, and others140, observed significant differences in flexibility 






Peptide dependent tuning of the allosteric communication network. The observed differences in 
flexibility and correlated motions for different peptide cargo in the HLA point to an allosterically 
linked network across the pHLA complex. With this in mind, we turned to community network 
analysis (CNA)79 to determine the mechanisms by which the peptide communicates dynamical 
changes to regions distal from the binding site. In CNA, residues are grouped into ‘communities’ 
of similar dynamics (communities are groups of residues local to one another that share highly 
correlated motions). The strength of the communication pathway between different communities 
is determined by the overall amount of correlated motion between members of the 2 given 
different communities. These data can therefore be represented in graphical form, in which a node 
corresponds to a community (with the size of the node indicating the number of residues in that 
community), and edges between nodes indicating the strength of the communication pathway 
(with an increased thickness indicating increased correlation) (Figure 16).  
Figure 15: Dynamic cross correlation matrices (DCCMs) for all 6 pHLA complexes simulated. 
On the Y-axis is each residue of the peptide, which is plotted against all other residues (377 total) 
on the HLA. The matrices are colour mapped according to the degree of correlated motion between 
the two residues, with a value of +1 meaning perfectly correlated and –1 meaning perfectly 
anticorrelated motion. Complete DCCM plots of the pHLA against the pHLA are provided in 





The pHLA complexes were partitioned into 9 communities each (chosen based on a consistently 
high modularity score and an ability to partition the different pHLA complexes as similarly as 
possible), apart from RQW, which was partitioned into 10 communities because the first 6 
residues of the peptide consistently grouped into their own community even at much lower overall 
community numbers (Supp Figure S3). All communities located in the peptide binding groove 
(peptide and α1 and α2 domains) were highly interconnected to one another. Communication from 
the binding groove to the β2m domain appeared to occur through a single community, generally 
located towards the end of the α1 helix and part of the residues that form the F-pocket (peptide C-
Figure 16: Peptide dependent tuning of the allosteric communication network. Community 
networks determined for all pHLA complexes studied. Networked communities are shown as 
coloured spheres, with the radii of the sphere indicating the number of residues within the 
community. Edges between the nodes/communities represent communication pathways between 
the nodes, with the thickness of the edge indicting the degree of correlation between the two 
communities (thicker = greater correlation).  All pHLA complexes are shown from the same 
orientation, such that N-terminus of the peptide is in the foreground. The results here are provided 





terminal binding site). This contrasted with observations made for the top portion of the α3 
domain, in which multiple communities in the peptide binding groove showed a significant level 
of directly correlated communication with residues belonging to the α3 domain. These 
observations may help to rationalise why the C-terminal peptide residues tended to show a much 
greater degree of correlated motions with HLA residues. That is, the residues responsible for 
binding the C-terminal portion of the peptide appear to be dynamically linked to both the α3 and 





Here, we used cutting edge experimental approaches and molecular dynamic simulations to 
demonstrate that the peptide cargo is able to tune the conformational dynamics of HLA. More 
specifically, the precise amino acid composition of the peptide cargo differentially engages a 
network of correlated protein dynamics that spans the HLA. For instance, the C-terminus of the 
peptide appears to be able to regulate the conformational dynamics of the entire pHLA complex 
as well as the main TCR-peptide contact zone, potentially modulating TCR binding. Our data 
point to the peptide cargo having the ability to tune a network of allosteric dynamics in the pHLA 
complex and may play a role in tuning a number of pathways involved in T-cell mediated 
immunity. These include peptide editing during antigen processing, interactions with the CD8 co-
receptor, and direct TCR interactions with the peptide and HLA. These findings may be pertinent 
for peptide vaccine design and may help explain why even minor alterations in peptide sequence 
can completely alter the direction of the immune response.134,153,154 Our study also has broader 
implications for the understanding of protein interaction networks, particularly allosteric 
mechanisms, in which changes in a relatively small component of the protein complex (in this 
case a few mutations in a 10 amino acid peptide) can a modulate flexibility distal to the changes 
and throughout the complex (in this case HLA, a 4 domain protein complex made up of nearly 





Materials and Methods 
 
Protein expression and refolding. HLA-A*02:01 and β2m were expressed and refolded using 
competent BL21 DE3 E. coli cells transfected with pGMT7 expression plasmids as previously 
described.155,156 Refolded protein was purified by anion exchange using a Poros50HQ column, 
followed by size exclusion into phosphate buffered saline using gel filtration column - Superdex™ 
200 Increase 10/300 GL. Purification followed previously described protocol.155,156 Dynamic light 
scattering (Zetasizer) was used to confirm sample homogeneity. For pressure/temperature varying 
fluorescence measurements samples were exchanged into a HEPES buffer (50mM HEPES, 
150mM NaCl, pH 7.4) using a PD-10 desalting column containing Sephadex™ G-25 medium, 
following manufacturer instructions. 
 
Pressure/temperature dependent fluorimetry. Pressure/temperature measurements were 
performed using an ISS high-pressure cell (ISS, Champaign, IL, USA) fitted with a custom fibre 
optic mounting connecting to the fluorimeter and the water bath. Peptide-HLA complexes were 
excited at 295nm, tryptophan emission was measured between 325-500 nm. Emission and 
excitation slits were set to 15nm to minimise the signal to noise ratio (due to optimal set up of the 
pressure cell). Initial measurements were made at 10 °C and increased in 5 °C increments up to 
30 °C. The pressure dependence at each temperature was measured at 50, 400, 800, 1200, and 
1600 bar. Measurements were taken in triplicate. Following each full pressure/temperature range, 
repeat scans were taken at lower pressure/temperature conditions to ensure extreme the 
pressure/temperature conditions had not denatured the protein. For all measurements the 
appropriate buffer controls were subtracted prior to data processing.  
 
MD simulations. Previously solved X-ray crystal structures of the 6 pHLA complexes 23,98 were 
used as the starting point for all MD simulations (see Supp Table S1 for a list of structures used). 
Any missing residues were added using Modeller v9.157 PropKa 3.0158 was used to predict the 
protonation states of all proteins investigated for a pH 7 (resulting in all residues being simulated 
in their standard protonation states). MolProbity75 was used to determine the optimum 
tautomerisation states for every His residue (tautomerisation states used for all simulations are 
provided in Supp Table S1) and make any required Asn/Gln side chain flips (under the criteria 
of optimising the hydrogen bonding network). The results were visually inspected and care was 
taken to ensure consistency between all pHLAs investigated. All systems were then solvated in 





of the box boundary. Simulations were performed at an effective [NaCl] of 150 mM (to match 
experiments), with excess Na+ ions added as required to ensure neutrality. MD simulations were 
performed using Amber16, describing the protein and water molecules with the ff14SB force 
field60 and TIP3P water model159 respectively. Following a protocol of minimisation, heating and 
equilibration (see section “Structure Equilibration Procedure” below), all pHLA complexes were 
subjected to 10 x 150 ns of production MD simulations in the NPT ensemble (at 300 K and 1 atm), 
with snapshots collected every 10 ps. Production MD simulations were performed using a 2 fs 
time step and with the SHAKE algorithm applied. An 8 Å direct space non-bonded cut-off was 
applied with long range electrostatics evaluated using the particle mesh Ewald algorithm.72 
Temperature was regulated using Langevin temperature control (collision frequency of 1 ps−1), 
whilst pressure was controlled with a Berendsen barostat (setting the pressure relaxation time to 
1 ps).  
 
Structure Equilibration Procedure Upon preparation of all six pHLAs complexes investigated, 
the following procedure was used to equilibrate structures for production MD simulations 
performed at 300 K and 1 atm. Minimisation of all hydrogen atoms and solvent molecules 
(including Na+ and Cl−), using 500 steps of steepest descent followed by 500 steps of conjugate 
gradient. To keep all other atoms (i.e. the protein heavy atoms) in place during the minimisation, 
10 kcal mol−1 Å−1 positional restraints were applied. Retaining the positional restraints on all 
protein heavy atoms, the system was then heated rapidly from 50 K to 300 K in the NVT ensemble 
over the course of 200 ps. This system was again minimised for a further 500 steps of steepest 
descent followed by 500 steps of conjugate gradient, this time only applying positional restraints 
(of size 5 kcal mol−1 Å−1) to the Cα carbon atoms. These Cα restraints were retained as the system 
was again heated from 25 K to 300 K over the course of 50 ps in the NVT ensemble. Simulations 
were then performed in the NPT ensemble (1 atm, 300 K), first gradually reducing the 5 kcal mol−1 
Å−1 Cα carbon restraints over the course of 50 ps of simulation time. This was done in 5 steps (5, 
4, 3, 2, 1 kcal mol−1 Å−1) of 10 ps each. A final 1 ns long simulation was then performed in which 
no restraints were used. The end structure from this run was then used as the starting structure for 
a production MD simulation. All dynamics steps used the SHAKE algorithm. Simulations 
performed in the NVT ensemble used Langevin temperature control (with a collision frequency 
of 1 ps−1) and used a simulation timestep of 1 fs. Simulations performed in the NPT ensemble 
again used Langevin temperature control (collision frequency of 1 ps−1) and a Berendsen barostat 




performed by taking the structures after the second minimisation step (and before the second 
heating step). Replicas were therefore assigned different random velocity vectors on the 
subsequent heating step.  
 
MD Trajectory Analysis. Routine trajectory analysis was performed with CPPTRAJ.160 Cα RMSF 
calculations were performed for all complexes after discarding the first 10 ns of simulation time 
(for equilibration) and averaged over each run. RMS fitting was performed to the Cα of stable 
(over the course of our MD simulations) secondary structure residues of the HLA. We used the 
following residues for RMS fitting: 4-13, 22-38, 51-54, 58-86, 95-104, 111-127, 134-181, 187-
196, 199-209, 215-220 and 242-263 of Chain A (i.e. the α1, α2 and α3 domains), and residues 6-
11, 21-30, 36-41, 60-70, 78-83 and 91-94 of Chain B (i.e. the β2m domain). For both RMSF 
DCCM and CNA calculations, RMS fitting was first performed to the crystal structure in order to 
create an average structure. Following this, all snapshots were then re-fitted to the average 
structure for the subsequent calculations. Dynamic cross correlation matrices (DCCMs) and 
community network analysis (CNA) were calculated using a combination of the Bio3D161 and 
igraph162 libraries within the package R. Briefly, all ten independent simulations were combined 
into a single trajectory, RMS fitting each frame to an average structure of all ten simulations 
combined. DCCMs were calculated for all 387 x 387 residues in each pHLA before truncating the 
matrix to show the degree of correlated motion between the peptide and all HLA residues. CNA 
was performed on the aforementioned complete DCCM results, using a Girvan-Newman 
clustering protocol79 to cluster communities of similar dynamics together. Edges with a correlation 
score of < |0.4| were discarded prior to clustering. The resulting communities were further filtered 
using a maximum distance cut-off between pairs of atoms of 8 Å (throughout 100% of the 
simulation time). Whilst the standard procedure in CNA is to plot the community number that 
gives the highest modularity, it is also acceptable when comparing multiple similar complexes, to 
choose a high scoring modulatory value that better groups the resulting structures.163 The 
modularity is an overall measure of the level of correlation between community members and 
non-community members, with a higher score indicating increased intercommunity correlation 
and decreased intra-community correlation, and therefore a better division of the data. We choose 
a community number of 10 for RQW and 9 for all other pHLA complexes based on the above 
criteria and in all cases, the difference between the maximal possible modularity score and the 
selected community score was no greater than 0.02 (Supp Figure S3). A value of 10 was selected 
for RQW as the N-terminal portion of the peptide consistently grouped to itself even at much 
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Figure S1: Per residue Cα RMSF values of (A) the peptides, (B) the α1 and α2 domains, (C) 
the α3 domains and (D) the β2m domains for all 6 pHLA complexes investigated, with the 
average per residue value also indicated. with the average per residue value also indicated. 
Below the plot is the p-value obtained from a two-sample t-test between the most and least 
flexible RMSF value of each residue. A red dotted line is plotted at a p-value of 0.05, which is 





Figure S2: Complete dynamic cross correlation matrices (DCCMs) for all six pHLA complexes 
investigated. Both x and y-axis consist of 387 residues total (287 HLA, 100 β2m and 10 peptide), 
with regions indicated on the figure. The Cα carbon of each residue is used for the measurement. 
All Matrices are colour mapped according to their degree of correlated motion calculated from the 
aggregate 1.5 µs of MD simulations per pHLA complex. A value of +1 (red) indicates perfectly 












Figure S3: Modularity vs number of communities for each pHLA. The red line on each plot 
indicates the number of communities chosen for community network analysis as seen in Figure 





Supplementary Table S1. PDB IDs used and histidine tautomerisation state assignments for all 
MD simulations.  
pHLA Complex 
and peptide sequence 
PDB ID HIDa Tautomerisation State 
MVW: 
MVWGPDPLYV 
5C0H Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
ALW: 
ALWGPDPAAA 
3UTQ Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
RQFa: 
RQFGPDWIVA 
5C0J Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
RQW: 
RQWGPDPAAV 
5C0F Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
YQF: 
YQFGPDFPIA 
5C0E Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
RQFi: 
RQFGPDFPTI 
5C0I Chain A: 4, 71, 115, 189, 193, 261. 
Chain B: 51. 
a, HID corresponds to a histidine residue which is singly protonated on its Nδ1 nitrogen, with all 
















Supplementary Table S2. Community Assignments and total correlation values between 
communities for all pHLA complexes studied. (This data is represented graphically in Figure 16 
of the main text of the publication). Residues are broken down into their PDB chain IDs (e.g. 
“A:” corresponds to Chain A). 











1---2, 0.881, 1---2, 0.881,  
1---3, 0.820, 1---4, 0.882,  
1---5, 0.898, 1---8, 0.570,  
2---3, 0.872, 2---5, 0.908,  
2---8, 0.736, 3---4, 0.924,  
3---5, 0.900, 4---6, 0.702,  
5---8, 0.715, 6---7, 0.965,  











1---2, 0.862, 1---3, 0.904,  
1---4, 0.929, 1---5, 0.623,  
1---6, 0.879, 2---3, 0.814,  
2---4, 0.899, 2---5, 0.819,  
3---5, 0.490, 3---6, 0.569,  
3---9, 0.500, 4---5, 0.908,  
5---9, 0.935, 6---7, 0.790,  











1---2, 0.885, 1---3, 0.894,  
1---4, 0.464, 1---5, 0.884,  
2---3, 0.688, 2---4, 0.861,  
2---5, 0.863, 2---8, 0.685,  
3---4, 0.826, 3---6, 0.664,  
3---8, 0.424, 6---7, 0.947,  













1---2, 0.835, 1---3, 0.901,  
1---5, 0.835, 1---6, 0.685,  
1---10, 0.453, 2---3, 0.720,  
2---4, 0.858, 2---5, 0.902,  
2---8, 0.918, 3---4, 0.910,  
4---5, 0.689, 6---7, 0.961,  












1---4, 0.858, 1---6, 0.733,  
1---8, 0.478, 2---3, 0.907,  
2---5, 0.882, 2---8, 0.806,  
3---4, 0.863, 3---5, 0.850,  
3---8, 0.753, 6---7, 0.974,  











1---2, 0.838, 1---3, 0.811, 
1---4, 0.636, 1---5, 0.886, 
1---6, 0.707, 1---8, 0.495, 
2---3, 0.833, 2---4, 0.804, 
2---5, 0.901, 2---8, 0.935, 
3---4, 0.856, 3---8, 0.408, 
4---5, 0.776, 6---7, 0.968, 





Design Principles for Engineering 
Highly Specific TCRs  
 
The use of soluble TCRs as therapeutics requires high affinities towards the pHLA 
target and a large therapeutic window to avoid unwanted side-effects. Experimental 
testing of engineered high affinity TCRs for specificity is both time-consuming and 
expensive, requiring a large number of cell-based assays. Therefore, a clear 
understanding at the atomistic level of how to rationally engineer TCRs specific for their 
targets has clear benefits in the field of rational drug design. In this chapter we applied a 
combination of structural, biochemical and computational approaches to investigate the 
molecular rules that define pHLA specificity. In this manuscript we compare three 
different examples of a TCR and TCR-mimic (antibodies engineered to bind pHLA) 
targeting the same pHLA. We determine thoroughly characterise their specificity 
experimentally before using computation to rationalise these observations and suggest 
design principles for producing highly specific TCRs or TCR mimics. My role in this 
project was in performing all of the MD simulations and free energy calculations. I also 
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Tumour-associated peptide-human leukocyte antigen complexes (pHLA) represent the largest 
pool of cell surface expressed cancer-specific epitopes, making them attractive targets for cancer 
therapies. Soluble bispecific molecules, that incorporate an anti-CD3 effector function, are being 
developed to redirect T cells against these targets using two different approaches. The first 
achieves pHLA recognition via affinity-enhanced versions of natural TCRs (e.g. ImmTAC 
molecules), whereas the second harnesses an antibody-based format (TCR-mimic antibodies). For 
both classes of reagent, target-specificity is vital considering the vast universe of potential pHLA 
molecules that can be presented on healthy cells. Here, we made use of structural, biochemical 
and computational approaches to investigate the molecular rules underpinning the reactivity 
patterns of pHLA-targeting bispecifics. We demonstrate that affinity-enhanced TCRs engage 
pHLA using a comparatively broad and balanced energetic footprint, with interactions distributed 
over several HLA and peptide side-chains. As ImmTAC molecules, these TCRs also retained a 
greater degree of pHLA-selectivity, with less off-target activity in cellular assays. Conversely, 
TCR-mimic antibodies tended to exhibit binding modes focussed more towards hotspots on the 
HLA surface and exhibited a greater degree of cross-reactivity.  Our findings extend our 
understanding of the basic principles that underpin pHLA selectivity and exemplify a number of 
molecular approaches that can be used to probe the specificity of pHLA-targeting molecules, 




The ability to selectively target tumour-specific antigens holds great promise for the development 
of specific cancer treatments, but their identification remains a key challenge. Peptide fragments 
presented on the cell surface by human leukocyte antigens (pHLAs) represent the intracellular 
proteome, and because this also includes dysregulated and cancer-specific proteins7,164, pHLAs 
constitute an important source of tumour-specific antigens. However, targeting these molecules is 
difficult for two reasons. First, their natural presentation levels can be very low (often below 10 
copies of each specific peptide epitope per cell)19; and second, peptides are co-recognised in the 
context of HLA, a molecule expressed by most cells (i.e. peptide-selectivity could be lost if HLA 





The immune system naturally overcomes these hurdles via selective T cell receptor (TCR) 
recognition of pHLA, enabling T cell triggering towards low-level antigens.167–169 Although the 
mechanisms that determine peptide-selectivity by natural TCRs are not fully understood, the 
binding mode employed by the TCR is likely to be fundamentally important, evidenced by the 
conserved binding mode observed for virtually all TCR-pHLA structures solved to date.6 This 
canonical interaction places the TCR diagonally across the HLA binding groove, positioning the 
somatically rearranged TCR CDR3 loops centrally over the antigenic determinant (peptide) with 
the germline-encoded CDR1/2 loops positioned primarily over the HLA helices, enabling natural 
TCRs to detect pHLA in a peptide-dependent manner. Despite the need for precise peptide-
selectivity, a limited number of TCRs must still maintain the ability to recognise millions of 
potential target antigens.127,128 Consequently, TCRs have been shown to cross-react with a vast 
array of different peptides16,127,129,130, but are selected in the thymus to avoid having specificities 
overlapping with abundant self-epitopes to maintain self-tolerance. Although the mechanisms that 
underpin these characteristics have yet to be determined, the relatively weak binding affinity of 
thymically selected TCRs (KDs in the micromolar affinity range18,170) has been shown to be 
important for T cell sensitivity116, and is likely also important for maintaining self-tolerance.  
 
The weak affinity of naturally selected TCRs, combined with difficulties manufacturing a 
membrane-bound protein as a soluble reagent, imposes certain challenges on their use for 
therapeutic applications. Consequently, the most widely used T cell-based therapies involve the 
adoptive transfer of either expanded antigen-specific T cells, or T cells genetically modified to 
express an artificial antigen-specific TCR (specific peptide affinity-enhanced receptor; SPEAR)171 
or antibody (chimeric antigen receptor; CAR).172 Although promising, these therapies are 
complicated by the need to prepare therapeutic T cells on a patient-by-patient basis and an inability 
to control dosing in response to potential toxicities.28 
 
Soluble bispecific T cell redirectors, consisting of antigen recognition and T cell engaging 
domains, bypass many of the limitations of the adoptive transfer approach.173 The antigen 
recognition of pHLA-targeting reagents can be via a TCR or antibody domain. ImmTAC 
molecules (Immune-mobilising monoclonal T cell receptors Against Cancer) are bispecific 
molecules with an engineered soluble TCR fused to an anti-CD3 effector function33; thus, it that 
redirects T cells specifically towards cells presenting a target pHLA.33 The TCR component of 
ImmTAC molecules are stabilised with an inter-chain disulphide bond174 and affinity-enhanced 





low-picomolar affinities, and with binding half-lives of several hours (in comparison to half-lives 
of seconds for natural soluble TCRs).33,175 These attributes enable ImmTAC molecules to elicit 
anti-tumour responses at picomolar concentrations against cells expressing very low levels of 
pHLA on the cell surface. In comparison, BiTEs can utilise antibodies to target pHLA (TCR-
mimic antibodies) as soluble T cell engaging bispecific molecules.34,35,183–186,36,176–182 Antibodies, 
unlike TCRs that are anchored in the cell membrane, can exist naturally as soluble effector 
molecules (and as such are easier to engineer as soluble reagents) and typically have a natural 
strong affinity for their antigen (nanomolar range), making them attractive for development as 
soluble therapeutics173. The main challenge for a targeted pHLA therapeutic is achieving sufficient 
specificity in the context of a vast landscape of potential self-antigens. For instance, even on 
individual cell types, data from our in-house mass spectrometry database and published direct 
evidence demonstrates that the number of unique peptides can be in the range of tens of 
thousands.187–190 Considering the full human protein coding genome, the number of peptides 
presented has been estimated to be over 11 million.191 
 
In this study, we used a combination of structural, molecular and computational approaches to 
understand the molecular mechanisms underpinning the pHLA-selectivity and, consequently, the 
potential cross-reactivity of soluble bispecific T cell redirectors. We demonstrate that utilisation 
of a native TCR-like binding mode was not predictive of peptide-selectivity. In fact, peptide-
selectivity, as defined by lower levels of pHLA cross-reactivity and less off-target activity in 
cellular testing, was associated with an energetic signature characterised by broad interactions 
with several peptide side-chains as well as the peptide backbone. These findings have important 
implications for the underlying rules that determine pHLA discrimination and identify key 




Structural analysis of pHLA-targeting reagents 
We selected TCR-mimic antibodies (TCR-mimics) according to in vitro and in vivo testing and 
based on the availability of crystal complex structures to enable molecular analysis 
(Supplementary Table S1). Several additional TCR-mimics have been reported; however, most 
lacked sufficient published information for inclusion (sequence, structure, and specificity data). 




close homology to self-peptides), we chose affinity-enhanced TCRs based on their recognition of 
identical, or closely related, pHLA determinants compared to the TCR-mimics. Here, we assessed 
reagents designed to recognise the NY-ESO-1157-165 cancer testis antigen-derived peptide, 
SLLMWITQC, presented by HLA-A*02:01 (A2-SLL), the MAGE-A1161-169/MAGE3-A3168-176 
melanoma-associated antigen-derived peptides, EADPTGHSY (A1-EAD) and EVDPIGHLY 
(A1-EVD), presented by HLA-A*01:01, and the WT126-134 Wilms tumour antigen derived peptide, 
RMFPNAPYL, presented by HLA-A*02:01 (A2-RMF). Although not a direct comparison, the 
A1-EAD and A1-EVD still represented a useful system to include due to the similar tumour 
expression patterns of both proteins, the same HLA restriction, and similar peptide sequences ‒a 
consequence of both peptides representing the same region of the highly related MAGE proteins.   
 
In addition to the previously published crystal structures for TCR-mimic antibodies and affinity-
enhanced TCRs in complex with A2-SLL34,43,45, A2-RMF36, and A1-EVD/A1-EAD192,193 (Figure 
17A), we solved the structure of the affinity-enhanced WT1_α7β2 TCR in complex with A2-RMF 
at 2.8 Å to complete the set (Table 2). Together, these data were analysed to identify any structural 
features that might influence the peptide-selectivity of each reagent. We compared the normal 
range of binding (crossing and engagement zone) of natural TCRs6 with both affinity-enhanced 
TCRs and TCR-mimic antibodies. The affinity-enhanced TCRs (1G4_α58β61 TCR, MAG-IC3 
TCR and WT1_α7β2 TCR) bound within the normal range of natural TCR topologies with the 
CDR3 loops of both chains focussed over the central peptide bulge (amino acids 4-6) (Figure 
17B). This binding mode enabled the affinity-enhanced TCRs to form contacts with five of the 
nine amino acids in the peptide, and multiple interactions with the α1 and α2 domains of the HLA 






Figure 17: Structural analysis of pHLA-targeting reagents. Structures of the TCRs and TCR-mimics, in 
complex with pHLA, were analysed to determine the structural mechanism underpinning their binding 
characteristics. (A) TCRs (blue ribbon) or TCR-mimics (orange ribbon) binding to peptide (red sticks) and 
HLA (green ribbon) compared to the binding range employed by all published wild-type TCR structures 
(grey cartoon). Yellow arrows indicate unconventional binding modes.  (B) Coloured as in A, top down view 
of TCR, or TCR-mimic binding to pHLA. Black circles represent the center of binding. Yellow arrows 
indicate unconventional binding modes. (C) Structural analyses of TCRs versus TCR-mimics binding to 
pHLA. Bonds were assessed using the program contact (CCP4), implementing a 3.4 Å cut-off for H-bonds 
and a 4 Å cut-off for Van der Waals interactions. Any peptide residue with at least one interaction with the 
TCR is documented, with peptide residues with >10 contacts shown in bold, and the residue making the most 
contacts underlined. Any HLA residue with >5 interactions with the TCR is documented, with HLA residues 




Table 2: Data collection and refinement statistics for WT1_α7β2-A2-RMF and NYBR1-A2-SLS 
structures. One crystal was used for solving each structure. Figures in brackets refer to the highest 
resolution bin. 




Data collection     
Space group P 21 21 21 P 1 21 1 
Cell dimensions     
    a, b, c (Å) 94.6, 114.8, 185.4 52.2, 99.3, 111.4 
    a, b, g  ()  90, 90, 90 90, 90.5, 90 




Beam time code In17077-18 14843-1 
Rmerge (%) 32.6 (220.4) 20.7 (108.9) 
I / sI 8.8 (1.2) 9.7 (1.3) 
Completeness (%) 99.9 (99.9) 99.7 (99.7) 
Redundancy 14.1 (14.3) 3.7 (3.6) 
No. reflections 700,229 (54,486) 188,042 (13,553) 
Refinement     
No Rfree reflections  2,370 2,435 
Rwork / Rfree 25.1/29.1 21.4/26.5 
R.m.s. deviations     
Bond lengths (Å) 0.006 0.011 
Bond Angles (°) 1.253 1.853 
Mean B value (Å2) 75.5 40.0 
Wilson B factor (Å2) 75.8 25.9 
Estimated coordinate error based on 








The 1G4_α58β61 and WT1_α7β2 TCRs were more peptide focussed than the MAG-IC3 TCR in 
terms of the percentage (57%, 36% and 14%, respectively) and number (115, 64 and 16, 
respectively) of peptide bonds. The 1G4_α58β61 and WT1_α7β2 TCRs also exhibited a larger 
buried surface areas (BSAs) than MAG-IC3, but all were within, or near to, the normal range 
(1240 – 2400 Å2)6. The 3M4E5 TCR-mimic antibody bound in a very similar fashion to natural 
TCRs, making contacts with five peptide residues, 38% peptide contacts, and a BSA of 2502 Å2. 
However, the structural analysis revealed focussing of interactions at peptide residue W5, where 
half of the peptide contacts were concentrated (24/51). Although the 1G4_α58β61 TCR also made 
many contacts with the large exposed side chain of W5 (54/115), binding was less focussed on 
this residue and additional important contacts were made with other peptide residues, particularly 
M4 (31/115) and Q8 (15/115). Peptide binding hotspots have been detected for natural 
TCRs23,130,194; however, this structural feature has been associated with auto-reactive TCRs and 
can correlate with a high level of TCR cross-reactivity.16,23 In contrast, the Hyb3.3 and ESK-1 
mimic antibodies both bound to their respective pHLA using unconventional topology. Hyb3.3 
binding was C-terminally shifted with an engagement angle substantially outside of the natural 
TCR-pHLA range. Despite this unusual topology, Hyb3.3 retained broad peptide contacts across 
6 of the 9 amino acids, making 25% peptide contacts and a BSA of 2024 Å2 (Figure 17C). ESK-1 
binding was N-terminally shifted with an unconventional engagement angle. This binding mode 
positioned the TCR-mimic antibody so that the CDR3 loops were focussed over the α2 helix of 
the HLA, resulting in a very limited interaction with the peptide. This binding mode resulted in 
ESK-1 making only 10% peptide contacts and the majority of these were formed with peptide 
residue 1. This HLA-centric binding mode, where only one peptide residue was contacted, raised 
questions about the ability of the ESK-1 TCR-mimic to retain specificity. However, for all the 
other HLA-targeting reagents considered here, their structures appear to retain many of the 
features observed for natural TCR-pHLA interactions.  
 
Alanine scan analysis reveals distinct molecular recognition patterns 
Alanine scan mutagenesis was used to investigate the molecular recognition pattern of the affinity-
enhanced TCRs and TCR-mimic antibodies using surface plasmon resonance (Figure 18; Suppl 
Figure S1). For each reagent, we generated a panel of soluble pHLAs in which each peptide 
residue was replaced with an alanine (or a serine if the native residue was already an alanine), 
except for the canonical anchor residues at positions 2 and 9. The 1G4_α58β61 TCR bound to 




mutated to alanine, and the affinity was substantially reduced when residues 7 and 8 were mutated 
(Figure 18A). These findings are consistent with the 1G4_α58β61-A2-SLL co-complex crystal 
structure showing that the central MW motif forms a central peptide bulge making multiple 
contacts with the TCR CDR3 loops, and peptide residue Q8 points up away from the HLA surface 
enabling contacts with the TCR CDR1β loop (Figure 17). A similar pattern was observed for the 
1G4_α5β51 A2-SLL restricted TCR (KD of 1.4nM), with small reductions in affinity also 
observed a peptide positions 1 and 3, whereas the 1G4_α5β100 A2-SLL restricted TCR, that 
bound with a weaker affinity (KD of 5 nM) was highly sensitive to alanine mutations at every 
position along the peptide backbone (Figure 18A). We repeated the alanine scan analysis on the 
A2-SLL-reactive 3M4E5 TCR-mimic and included two published higher affinity versions of 
3M4E5 (3M4E5_T2 and 3M4E5_T3) because they were closer in affinity to the 1G4_α5β100 and 
1G4_α5β51 affinity-enhanced TCRs, allowing a more direct comparison. The 3M4E5 (KD = 44 
nM in scFv format) and 3M4E5_T2 TCR-mimic antibodies (KD = 2.8 nM in scFv format) were 
both sensitive to alanine mutation at peptide residues 4, 5 and 6 (Figure 18B), whereas mutations 
at all other positions of the peptide did not reduce binding affinity. 3M4E5_T3 (KD = 5.5 nM in 
scFv format) demonstrated a similar trend, being sensitive to alanine substitution at peptide 
residues 4 and 5 (Figure 18B). Alanine substitutions at peptide residues 1, 3, 7, and 8 had no 
impact on binding affinity for any of the A2-SLL TCR-mimics, demonstrating a more focussed 
binding mode around peptide residues 4, 5, and 6, compared to the affinity-enhanced TCRs. These 
findings were also consistent with the crystal structure of 3M4E5-A2-SLL that demonstrated 
binding was focussed towards these central residues of the peptide.  
 
The high level of sensitivity to alanine substitutions across the peptide backbone was also 
observed for the A1-EVD specific MAG-IC3 (KD = 3.8 nM) and MAG-IC5 (KD = 17 nM) TCRs 
(Figure 17C). The stronger affinity MAG-IC3 TCR demonstrated reduced or abrogated affinity 
towards every alanine mutant tested, whilst the MAG-IC5 TCR was sensitive to mutations at all 
positions apart from peptide residues 6 and 7. The MAG-IC3-A1-EVD co-complex crystal 
structure was consistent with this finding, demonstrating a complex network of contacts across 
the peptide backbone (Figure 17). The Hyb3.3 TCR-mimic antibody recognises the same peptide 
region as MAG-IC3 and MAG-IC5 but derived from a different MAGE protein (MAGE-A1) and 
binds with an affinity of KD = 18 nM. The MAGE-A3 and MAGE-A1 peptides are conserved at 
all positions except for the N-terminal anchor (position 2), position 5 and position 8. Although the 
Hyb3.3-A1-EAD complex structure demonstrated non-canonical topology, the interactions with 






Figure 18: Alanine scan analysis reveals distinct molecular recognition patterns. The contribution of 
peptide side chains to binding specificity was analysed using alanine scan mutagenesis (by surface 
plasmon resonance). Binding affinities of the TCRs and TCR-mimic antibodies were determined 
using single cycle kinetic analysis. Bar graphs show binding affinity as a % relative to the binding 
affinity to the index peptide. (A) A2-SLL affinity-enhanced TCRs, (B) A2-SLL TCR-mimics, (C) 




This observation was reflected in the alanine scan analysis that demonstrated some degree of 
sensitivity to alanine substitutions at all positions tested apart from peptide residue 1 (Figure 
18D). The WT1_α7β2 TCR, which bound A2-RMF with a KD of 70 nM, exhibited abrogated or 
highly reduced binding for all residues except at peptide position 6. The WT1_α27β2 (KD = 13 
nM) and WT1_α42β2 (KD = 0.76 nM) TCRs showed a similar trend, with the strongest binding 
WT1_α42β2 TCR exhibiting the greatest level of sensitivity to alanine substitutions across the 
peptide backbone (Figure 18E). The ESK1 TCR-mimic antibody, which has a relatively weak 
affinity for A2-RMF of KD = 2 µM in scFv format (Supp Figure S1), demonstrated broad 
degeneracy in peptide binding, being tolerant to alanine substitutions at all positions of the peptide 
except for peptide residue 1 (Figure 18F). Here, availability of the ESK-1-A2-WT-1 structure 
provided insight into this observation, confirming that virtually all contacts between ESK-1 and 
the WT-1 peptide were focussed on peptide residue 1 (Figure 17). 
 
TCR-mimic antibodies bind to several commonly expressed self-peptides  
Although alanine scan analysis is useful to understand positional sensitivity of pHLA-targeting 
receptors, it is unclear how these data relate to the broader cross-reactivity of these reagents, 
particularly their ability to discriminate against common self-peptides. To gain further insight into 
self-discrimination, we designed a new experimental approach for screening multiple pHLA 
complexes in a high throughput format by modifying the MAGPIX platform. We designed 
multiplex experiments using MagPlex beads coated with HLAs in complex with a range of 
commonly expressed self-peptides. Self-peptide-HLAs recognised by affinity-enhanced TCRs or 
TCR-mimics were detected using MAGPIX analysis (Table 3+Table 4). In all cases, the affinity-
enhanced TCR reagents only generated a signal against their respective index peptides, whereas 
the TCR-mimic antibodies (in scFv format to avoid avidity-mediated binding) were more 
promiscuous. The 3M4E5_T2 scFv was reactive against four broadly expressed HLA-A*02:01 
restricted self-peptides and the ESK1 scFv demonstrated reactivity against six broadly expressed 
HLA-A*02:01 restricted self-peptides, in addition to their target antigens A2-SLL and A2-RMF, 
respectively (Table 3). The Hyb3.3 scFv was reactive against almost all the HLA-A*01:01 
restricted self-peptides tested (9/12), as well as A1-EAD (Table 4). In all cases, the self-peptides 
recognised by the TCR-mimic antibodies shared very little sequence similarity revealing a high 
level of potential cross-reactivity compared to the affinity-enhanced TCRs developed to target 





Table 3: MAGPIX analysis to investigate a panel of commonly expressed HLA-
A*0201-restricted self-peptides. Peptides generating a signal above background (3 times 
median intensity of all bead regions bound to native helper-phage) were classified as 
positive binders, and binding expressed as a percentage of signal obtained from binding 
to index peptide in each case.  Percentage binding for each interaction is reported as the 
average of several experimental repeats. 













165) 100.0 100.0 100.0 0.0 0.0 
A2 RMFPNAPYL WT1(126-134) 0.0 0.0 0.6 100.0 100.0 
A2 AIVDKVPSV COPG1(147-155) 0.0 0.0 0.0 0.0 0.0 
A2 ALVVQVAEA HEXB(34-42) 0.0 0.0 0.0 0.0 0.1 
A2 SLDQPTQTV EIF3C(834-842) 0.0 0.0 0.0 0.0 0.0 
A2 GLATDVQTV PSMB3(55-63) 0.0 0.0 0.0 0.0 0.0 
A2 ILTDITKGV EEF2(661-669) 0.0 0.0 0.0 0.0 0.0 
A2 IMLEALERV 
SNRPGP15(68-
76) 0.0 0.0 0.0 0.0 0.0 
A2 VMDSKIVQV KPNA1(434-442) 0.0 0.0 0.1 0.0 0.2 
A2 RLQEDPPAGV UBE2A(15-24) 0.0 0.0 0.0 0.0 0.3 
A2 KIYEGQVEV RPL5(117-125) 0.0 0.0 0.0 0.0 0.2 
A2 NLAENISRV PYGM(271-279) 0.0 0.0 0.0 0.0 0.0 
A2 LLDVPTAAV IFI30(16-24) 0.0 0.0 0.0 0.0 0.0 
A2 SLSEKTVLL CD59(106-114) 0.0 0.0 0.0 0.0 0.0 
A2 ALNEKLVNL EIF3F(349-357) 0.0 0.0 0.0 0.0 0.0 
A2 ILDKKVEKV 
HSP90AB1(570-
578) 0.0 0.0 0.1 0.0 0.3 
A2 ILDQKINEV ODC1(23-31) 0.0 0.0 0.0 0.0 0.0 
A2 VLIDYQRNV XPO1(784-792) 0.0 0.0 0.0 0.0 0.0 
A2 GLIEKNIEL 
DNMT1(425-
433) 0.0 0.0 0.0 0.0 0.0 
A2 FLDPNNIPKA ALG8(305-314) 0.0 0.0 0.0 0.0 0.0 




Table 4: MAGPIX analysis to investigate a panel of commonly expressed HLA-A*0101-
restricted self-peptides. Peptides generating a signal above background (3 times median intensity 
of all bead regions bound to native helper-phage) were classified as positive binders, and binding 
expressed as a percentage of signal obtained from binding to index peptide in each case. 
Percentage binding for each interaction is reported as the average of several experimental repeats. 
HLA Antigen Peptide MAG-IC3 TCR Hyb3.3 scFv 
A1 EVDPIGHLY MAGE-A3(168-176) 100.0 70.0 
A1 EADPTGSHY MAGE-A1(161-169) 0.0 100.0 
A1 YSDKYGLGY PLK1(417-425) 0.0 90.7 
A1 DTDHYFLRY PIGT(165-173) 0.0 16.8 
A1 STDHIPILY GFPT1(218-226) 0.0 0.4 
A1 HSDPSILGY GIGYF1(1012-1020) 0.0 15.2 
A1 KSDVHLNFY HLTF(499-507) 0.0 0.0 
A1 HTDILKEKY DTWD1(262-270) 0.0 0.0 
A1 IADMGHLKY PCNA(241-249) 0.0 1.0 
A1 LTELPDWSY MRPL52(43-51) 0.0 0.0 
A1 ASDPFFRHY GPN2(210-218) 0.0 77.3 
A1 ETEKDFSRY AQR(1757-895) 0.0 4.3 
A1 GTVYEDLRY UBE2C(71-79) 0.0 0.1 
 
Deep sequencing of peptides from randomised pHLA phage-libraries demonstrates the binding 
degeneracy of pHLA-targeting reagents 
Despite the ability of 3M4E5 to bind pHLA in a TCR-like conformation, the alanine scan profile 
and MAGPIX analysis revealed lower levels of peptide-selectivity compared to the affinity-
enhanced TCRs. To probe this discrepancy further, we developed a novel approach for the 
characterisation of TCR-peptide degeneracy using randomised pHLA libraries displayed on phage 
(Coles C et al. Submitted). We used this system to identify peptide motif preferences for the 
affinity-enhanced TCRs and TCR-mimics that recognised A2-SLL. In broad agreement with the 
structural and alanine scan analyses, the affinity-enhanced TCRs, 1G4_α5β100, 1G4_α5β51 and 
1G4_α58β61 showed strong preferences for the native SLL peptide sequence at residues W5, T7, 
Q8 and V9 (Figure 19A-C). In contrast, the TCR mimic 3M4E5 demonstrated a preference for 
the native SLL peptide sequence only at W5, with all other positions showing very little amino 
acid preference (Figure 19D-F). Although W5 was selected by 3M4E5_T2 and 3M4E5_T3, it 
was not the dominant amino acid preference at this position, with phenylalanine (F) being 





terms of amino acid preference at any other position. These findings are consistent with the alanine 
scan results demonstrating that the A2-SLL reactive TCR-mimics could tolerate alanine 
substitutions at any residue outside of the central MW-peg in the SLL peptide, while the affinity-
enhanced TCRs were selective across the peptide backbone.  
 
Using this information, we assessed the number of unique peptides selected by each reagent to 
gain insight into their comparative cross-reactivity. Analysis of next generation sequencing data 
identified an average of 7,068 unique peptides (687,241 total reads) for 1G4_α5β51, 4,455 unique 
(689,928 total reads) for 1G4_α5β100, and 9,012 unique (696,992 total reads) for 1G4_α58β61. 
The TCR-mimics selected between three and fifteen times more unique peptides compared to the 
affinity-enhanced TCRs with 50,765 unique peptides (740,196 total reads) for 3M4E5, 60,699 
unique (692,455 total reads) for 3M4E5_T2 and 32,934 unique (727,824 total reads) for 
3M4E5_T3. Overall, these data suggest that the A2-SLL affinity-enhanced TCRs are less cross-
reactive (in terms of total number of peptides recognised) and less promiscuous in terms of their 





















Figure 19: Deep sequencing of peptides from randomised pHLA phage-libraries demonstrates 
the binding degeneracy of pHLA-targeting reagents. Sequence logos (Icelogo software) and heat 
maps were generated from NGS sequencing of pan 3 data identifying the distribution of amino 
acid identities per position of the peptide selected by A2-SLL-reactive affinity-enhanced TCRs 
and TCR mimic antibodies. The abundance of an amino acid is shown by intensity of colour. 
Outlined boxes identify the amino acids of the cognate antigen SLL. Data shown is the average 
of two experimental repeats. (A) 1G4_α5β100 (B) 1G4_α5β51, (C) 1G4_α58β61, (D) 3M4E5, 





Molecular dynamics simulations reveal peptide-selectivity is associated with distinctive energetic 
modes of binding 
Although the structural and alanine scan analyses provided useful insights into the recognition 
mode employed by the pHLA-targeting molecules described here, they were not fully predictive 
of the recognition patterns observed in the MAGPIX and randomised pHLA library analysis. For 
example, despite the A2-SLL and A1-EAD reactive TCR-mimics forming seemingly broad 
peptide contacts, according to the structural analysis, and promising alanine scan profiles, these 
reagents bound substantially more self-peptides in the MAGPIX analysis than the affinity-
enhanced TCRs. Furthermore, the A2-SLL reactive TCR-mimics were characterised by more 
degenerate peptide binding in the randomised pHLA library analysis. Consequently, we 
performed molecular dynamics (MD) simulations to extend the ‘snapshot’ view available from 
crystal structures. We subjected all six structures described in Figure 17 to two, 500 nanosecond 
long MD simulations to investigate the biochemical nature and lifetime of contacts formed 
between the peptide and affinity-enhanced TCRs or TCR-mimics. Interactions were dissected into 
contacts formed between the peptide side chain (amino acid specific) and main chain 
(conformation specific) versus time and separated into hydrogen bonding and Van der Waals 
(VdW) type interactions. In all cases, the affinity-enhanced TCRs made a higher number of long-
lived contacts with side chain atoms across the peptide compared to main chain interactions 
(Figure 20A-C). In contrast, 3M4E5 made a lower number of peptide side chain contacts (Figure 
20D), reflected by a lower overall ratio of peptide side chain contacts (Hbond ratio: 0.5, vdW 
ratio: 2.23) compared to the 1G4_α58β61 TCR (Hbond ratio: 1.49, vdW ratio: 5.41) (Supp Figure 
S2). Hyb3.3 made virtually no contacts with peptide side chain residues (Hbond ratio: 0.16, vdW 
ratio: 0.24), focussing primarily or exclusively on interactions with the peptide backbone (Figure 
20E, Supp Figure S2). ESK-1 did make peptide side-chain interactions, but only with the exposed 
R1, in line with the alanine scan analysis (Figure 20F, Supp Figure S2). These data suggest that 
more limited side chain-mediated recognition pattern, as observed for the TCR-mimics, might 





Figure 20: Molecular dynamics simulations reveal broad side chain contacts with the peptide 
drive specificity. Relative number of Hydrogen bonds (H-bonds) and Van der Waals (vdWs) 
interactions formed between either the main or side chain of each peptide residue to the 
TCR/TCR-mimic over the course of our MD simulations. Total side versus main chain ratios for 
H-bonds and vdWs interactions are shown, with the larger value (side or main for each category) 
scaled to 100 % (absolute values for all contacts are provided in Supp Figure S2).  (A) 
1G4_α58β61-A2-SLL, (B) MAG-IC3-A1-EVD, (C) WT1_α7β2-A2-RMF, (D) 3M4E5-A2-





The energetic landscape of each affinity-enhanced TCR/TCR-mimic-pHLA complex was 
characterised by calculating their binding free energies (using the Molecular Mechanics Poisson–
Boltzmann Surface Area (MMPBSA) approach).39 The MMPBSA approach has been used 
extensively to predict relative protein-ligand and protein-protein binding free energies.85,195 More 
specifically, it has been used to rationalise the effect of mutations on antibody-antigen 
complexes196, the role of a water bridged interaction in TCR-pHLA affinity197, and to predict 
reliable relative binding free energies of pHLA complexes.92 Here, we performed 25 x 4 
nanosecond  MD simulations per complex for MMPBSA analysis, to ensure reliable and 
converged results.85,91,92 MMPBSA calculations have the advantage that they can be decomposed 
into per-residue contributions to the binding free energy, allowing one to predict each residue’s 
preference towards binding. Analysis of the decomposition results demonstrated that the affinity-
enhanced TCRs were characterised by broad energetic signatures, whereby the binding energy 
was distributed over at least three peptide residues, with multiple disparate regions driving affinity 
across the HLA surface (Figure 21A-C; Supp Figure S3A-C). On the other hand, the TCR-
mimics were more HLA-focussed with one, or two, energetic hotspots focussed on single HLA 
residues (Figure 21D-F; Supp Figure S3D-F). For example, although the 1G4_α58β61 TCR 
made substantial energetic interactions with HLA residue R65 (-12 kcal mol-1), this was balanced 
by interactions with multiple peptide residues (W5: -11 kcal mol-1, M4: -8 kcal mol-1, Q8: -7 kcal 
mol-1) and other HLA residues (Q155: -6 kcal mol-1). No energetic hotspots were detected for the 
WT1_α7β2 TCR, with most of the binding energy being equally balanced over HLA residues 
R65, R75 and Q155 and peptide residues P4, N5 and Y8 (all around -6 kcal mol-1) and the MAG-
IC3 TCR had a balanced energetic footprint with important binding contributions from HLA 
residues E63, N66 and V158, as well as peptide residues E1, D3, P4 and H7 (all around -5 kcal 
mol-1). In contrast, all of the TCR-mimics utilised more focussed energetic binding to engage their 
cognate pHLAs. The chief energetic contribution for 3M4E5 was made by HLA residue R65 (-16 
kcal mol-1) with an additional peptide hotspot at W5 (-7 kcal mol-1). For ESK-1, energetic hotspots 
were detected at HLA residue K66 (-15 kcal mol-1) and peptide residue R1 (-13 kcal mol-1), with 
very little contribution from any other peptide residues. Finally, Hyb3.3 binding was characterised 
by strong energetically favourable interactions only with HLA residues K146 (-11 kcal mol-1) and 





Figure 21: Binding free energy decomposition analysis of TCR and TCR-mimic-pHLA 
interactions. Per-residue decomposition of the binding free energy obtained from our MMPBSA 
calculations, to identify energetic hotspots for each TCR or TCR-mimic interaction with cognate 
pHLA. A top down view of each pHLA is shown, with the peptide depicted as sticks and the HLA 
as a surface. Colour mapping of the decomposition results for each residue was performed across 
the entire binding interface and used to indicate which residues across this interface favour (blue) 
or disfavour (red) binding (with white indicating no preference). (Bar graphs for all decomposition 
results are provided in Supp Figure S3). (A) 1G4_α58β61-A2-SLL, (B) MAG-IC3-A1-EVD, (C) 





Together with the previous analyses, the molecular dynamic simulations provide further evidence 
that, rather than being driven by the recognition of a dominant amino acid at a single position on 
the HLA or peptide, broad interactions across the peptide (particularly with peptide side chains) 
was associated with greater peptide-selectivity. 
 
Re-directed T cell killing of antigen-positive and negative cell lines using pHLA-targeting 
bispecifics 
On-target versus off-target reactivity of affinity-enhanced TCRs and TCR-mimics were assessed 
in functional T cell redirection assays against antigen-positive and antigen-negative cell lines. 
Soluble bispecific molecules were generated by fusing an anti-CD3 scFv to the β-chain of the 
affinity-enhanced 1G4_α58β61 (IMC-1G4_α58β61), and MAG-IC3 TCRs (IMC-MAG-IC3), or 
the heavy chain of the TCR-mimic scFv 3M4E5_T2 (3M4E5_T2-anti-CD3), 3M4E5_T3 
(3M4E5_T3-anti-CD3), and Hyb3.3 (Hyb3.3-anti-CD3). Reagents recognising A2-RMF were not 
included because, consistent with evidence from other studies 198, we were unable to detect the 
peptide on WT1+ tumour cells by mass spectrometry analysis (data not shown). IMC-1G4_α58β61 
redirected T cell killing of A2+/NYESO+ NCIH-1755 cells was approximately twenty-times more 
sensitive when compared to 3M4E5_T2-anti-CD3 and 3M4E5_T3-anti-CD3, in line with the 
difference in affinity between these reagents (Figure 22A, Supp Figure S4). No redirected T cell 
killing of A2+/NYESO- targets was detected for IMC-1G4_α58β61, whereas 3M4E5_T2-anti-
CD3 and 3M4E5_T3-anti-CD3 both induced redirected T cell killing of the A2+/NYESO- antigen-
negative cell lines HEP-G2, Ren8 and HISMC at EC50s similar to those for the A2+/NY-ESO-1+ 
cell line NCIH-1755. Similarly, Hyb3.3-anti-CD3 demonstrated T cell redirected killing of 
multiple A1+/MAGE-A1- antigen-negative cell lines, as well as A1+/MAGE-A1+ antigen positive 
cell lines, demonstrating no, or a very small specificity window. In contrast, IMC-MAG-IC3 
mediated redirected T cell killing of A1+/MAGE-A3- antigen negative cells was absent (HISMC 
cells) or only occurred at very high concentrations (NCI-H1703 and COLO205) , demonstrating 
a clear specificity window compared to redirected T cell killing against HCC1428 A1+/MAGE-





Overall, the HLA-targeting bispecifics based on the natural TCR scaffold retained much higher 
levels of specificity in cellular testing, consistent with the MAGPIX, and randomised pHLA 
library analyses. These findings support the hypothesis that dispersed peptide contacts with the 
comparatively broad peptide side-chain focussed energetic signature is more predictive of the 
ability to discriminate between different peptides. 
 
The NYBR1 TCR exhibits no cellular off-target reactivity and utilises a broad, peptide side-chain 
centric binding mode 
In order to test the notion that peptide-selectivity is associated with broad contacts with peptide 
side chains and a dispersed energetic profile, we extended our analysis to include an affinity-
enhanced TCR that was known to be highly selective for its target pHLA. The NYBR1 TCR was 
affinity-matured against a novel cancer specific HLA-A*02:01 restricted peptide (SLSKILDTV; 
referred to as SLS peptide from hereon) derived from the NY-BR-1 lineage antigen and used to 
Figure 22: Redirected T cell killing of antigen positive and negative cell lines using pHLA-
targeting bispecifics. The activity of the ImmTAC molecules and the TCR-mimic-anti-CD3 
fusions was tested against a range of antigen positive and antigen negative cell lines (tumour and 
healthy cells) using IncuCyte killing assays. Data are plotted using area under the curve analysis. 
(A) IMC-1G4_α58β61, 3M4E5_T2-anti-CD3 and 3M4E5_T3-anti-CD3 T cell re-direction 
against HLA-A*02:01+/NY-ESO-1+ (NCI-H1755) and HLA-A*02:01+/NY-ESO-1- (HEP-G2, 
Ren8 and HISMC) cells lines. (B) IMC-MAG-IC3 and Hyb3.3-anti-CD3 T cell re-direction 
against HLA-A*01:01+/MAGE-A3+ (HCC1428), HLA-A*01:01+/MAGEA1+ (HCC1428 and 





generate an ImmTAC molecule (IMC-NYBR1). In cellular testing, as assessed by both IFNγ 
release and target cell killing, IMC-NYBR1 demonstrated exquisite specificity, as evidenced by 
absence of T cell redirection against 10 A2+/NY-BR-1- antigen-negative cell lines, even at high 
concentrations (up to 2 nM of IMC-NYBR1 for a 47 pM affinity reagent) (Figure 23A). The 
structure of the NYBR1-A2-SLS complex (solved at 2.3 Å resolution; Table 2) demonstrated that 
NYBR1 bound canonically, with a normal crossing angle (63.6°) and a BSA slightly above the 
reported range (2835 Å2), engaging with 7 of the 9 peptide residues (32% peptide contacts) 
(Figure 23B). This binding mode enabled fine specificity across the peptide, evidenced by 
sensitivity to alanine substitutions at every peptide position apart from peptide position 1 (Figure 
23C). Analysis of contacts and energetics from MD simulations demonstrated a highly peptide 
side-chain mediated interaction (Figure 23D) with important contributions from 6 of the 9 
residues in the SLS peptide (Figure 23E, Supp Figure S6). Although there was a slight energetic 
focus towards HLA residue Q155 (-6 kcal mol-1) and peptide residue K4 (-9 kcal mol-1), a number 
of energetic contributions were made across the entire HLA surface and peptide (Figure 23E). 
Thus, consistent with our other observations in this study, the fine specificity of the NYBR1 TCR 






Figure 23: The NYBR1 TCR exhibits no cellular off-target reactivity and utilises a broad, peptide 
side-chain centric binding mode. (A) The activity of IMC-NYBR1 was tested against a range of 
HLA-A*02:01+/NYBR1+ (CAMA1 and CAMA1 β2m) and HLA-A*02:01+/NYBR1- cell lines 
(MDA-MB-231, HA13, HAo14, HDMEC2, Ren8, CM12 HCC1419, NCI-H661, SNU475 and 
SNU398) using IFNγ ELISpot (bar graphs) and IncuCyte killing assays (area under the curve 
analysis) in two donors. (B) Above: Side on view of the structure of the NYBR1 TCR (blue ribbon) 
in complex with A2 (green ribbon) -SLS (red sticks). Below: Top down view of the NYBR1 TCR-
A2-SLS interaction. Black circles represent the center of binding. The table shows a structural 
analysis of the NYBR1-A2-SLS complex. Bonds were assessed using the program contact 
(CCP4), implementing a 3.4Å cut-off for H-bonds and a 4Å cut-off for vdWs interactions. Buried 
surface area (BSA) Å2 was determined using ePISA. (C) The contribution of peptide side chains 
to binding specificity was analysed using alanine scan mutagenesis (by surface plasmon 
resonance). Binding affinities of the NYBR1-A2-SLS interaction was determined using single 
cycle kinetic analysis. Bar graphs show binding affinity as a % relative to the binding affinity to 





(Figure Legend Continued) 
(D) Relative number of Hydrogen bonds (H-bonds) and vdWs interactions formed between either 
the main or side chain of each peptide residue to the NYBR1 TCR over the course of our MD 
simulations. Total side versus main chain ratios for H-bonds and vdWs interactions are shown, 
with the larger value (side or main for each category) scaled to 100 % (absolute values for all 
contacts are provided in Supp Figure S2). (E) Per-residue decomposition of the binding free 
energy obtained from our MMPBSA calculations. A top down view of the pHLA is shown, with 
the peptide depicted as sticks and the HLA as a surface. Colour mapping of the decomposition 
results for each residue was performed across the entire binding interface and used to indicate 
which residues across this interface favour (blue) or disfavour (red) binding, (with white 





The identification of cancer-specific targets for solid tumours is challenging because cell surface 
antigens are often expressed on a wide range of tissues. Molecules such as CD19 and others have 
proved effective targets for liquid tumours because on-target toxicity is limited to mainly 
haematopoietic cells that can repopulate from the bone marrow following treatment.199 Another 
key source of antigens is dysregulated or mutated intracellular proteins. However, many of these 
proteins are only presented on the cell surface in the context of pHLA. It is interesting to note that, 
even in response to very common human pathogens (i.e. influenza), natural antibodies recognising 
pHLA have not been detected, suggesting that humoral responses to pHLA are either ineffective, 
or dangerous to the host. Unlike antibodies, TCRs are selected to recognise pHLA in the thymus, 
which deletes T cells with TCRs that bind strongly to self-pHLA (and presumably removes TCRs 
that bind in a peptide-independent manner). This process is controlled in part by HLA co-
engagement by the T cell co-receptors, CD8 and CD4, removal of which in CD8/CD4 co-receptor 
knockout mice has been shown to select T cells with TCRs that can bind to non-major 
histocompatiblility complex proteins, such as CD155.111,200 A number of recent reports have also 
suggested that, probably as a consequence of thymic selection, TCRs have co-evolved to recognise 
pHLA.201–203 This ‘co-evolution’ model is consistent with findings from a recent study revealing 
that TCRs have a unique variable domain orientation compared to antibodies, the absence of 
which might restrict antibodies from reproducing the natural ability of TCRs to discriminate 
between different HLA-presented peptides.21 Thus, TCRs have multiple unique selection 
mechanism and structural features that guide pHLA recognition. We have previously 




thymically-selected wild-type progenitors, with stronger binding generally being driven through 
the formation of new interactions with both the peptide and HLA surface.43,45,129,204–206 This feature 
likely provides an advantage for generating affinity-enhanced TCRs with the ability to retain a 
similar specificity profile compared to natural, thymically-selected TCRs. 
 
The literature indicates that T cell potency is tuned by a TCR affinity threshold that is optimal in 
the low micromolar to high nanomolar range.116,180,207–211 For soluble bispecific reagents, this 
affinity threshold is controlled at the effector end of the molecule, while the affinity of the pHLA 
targeting end must be optimised according to antigen presentation. For most tumour associated 
pHLAs, their natural presentation levels can be very low (often below 10 copies of each specific 
peptide epitope per cell).19,182 Consequently, binding in the femto- to picomolar affinity range is 
needed to achieve a therapeutically relevant receptor occupancy level; a feat that has been 
achieved for monovalent TCR-based bispecifics.33,175 The literature, together with the data 
presented here, suggests that, with current technologies, engineering a TCR-mimic antibody to 
achieve this affinity range whilst maintaining peptide-selectivity is more challenging.177 Some 
soluble TCR-mimics have been designed as full antibodies, thus achieving much stronger binding 
through avidity effects.179 However, this essentially halves the number of effector molecules per 
target cell; a major issue if antigen expression is already limiting.  
 
Here, we interrogated the molecular basis of pHLA-recognition of a panel of T cell redirecting 
bispecifics using a combination of structural, biochemical and computational approaches. All the 
affinity-enhanced TCRs utilised a canonical native TCR-like binding mode, maintaining broad 
contacts across the peptide backbone. This finding likely represents the advantage of using 
reagents that have been developed from a thymically-selected TCR progenitor. Our data also 
reveal that a native TCR-like binding mode is necessary, but not sufficient for enabling peptide-
selectivity. For instance, despite the 3M4E5 TCR-mimic binding in an almost identical fashion to 
a native TCR, with peptide contacts across the peptide backbone, it still performed poorly in 
cellular cross-reactivity assays. Our MD simulation analysis demonstrated that 3M4E5 bound via 
two main hotspots: one on peptide residue W5 and one on HLA residue R65. These findings were 
mirrored in the randomised pHLA library analysis that demonstrated the A2-SLL-reactive TCR-
mimics were all more degenerate (in terms of amino acid preferences across the peptide backbone) 
as compared to the A2-SLL-reactive affinity-enhanced TCRs and were predicted to select a far 
larger number of unique peptide sequences. Interestingly, this hotspot mediated binding mode has 





TCR cross-reactivity and has been implicated in autoimmunity.23,212 The ESK-1 and Hyb3.3 TCR-
mimics also employed hotspot-binding modes, especially focussed towards residues on the HLA 
surface, and demonstrated loss of peptide-selectivity in biochemical (ESK-1 and Hyb3.3) and 
cellular (Hyb3.3) testing. In contrast, the TCR-based reagents tested all exhibited superior peptide-
selectivity in biochemical and cellular tests and were characterised by binding modes that included 
a greater combination of balanced energetic interactions across the peptide and HLA surface. This 
was exemplified by the NYBR1 TCR (by far the cleanest molecule tested in both the molecular 
and cellular analysis), which also demonstrated a broad energetic binding mode with the majority 
of peptide contacts through side-chain interactions. Although the TCR-mimics selected in this 
study were generated using a different approach to the affinity-enhanced TCRs, our data suggest 
that the reagents based on the natural TCR-scaffold were better able to discriminate between 
different peptides by utilising peptide-specific binding interactions. 
 
Even though we focussed on three published TCR-mimic antibodies because of available 
structures34–36, our data also have implications for other published studies of TCR-mimics. For 
instance, the TCR-mimic ESK-1 has been shown to target the Wilms tumour antigen in mouse 
models178,179, despite evidence demonstrating that the A2-RMF antigen is not expressed.198 This 
finding, combined with the data shown here, suggest that the activities reported for ESK-1 may 
be mediated by recognition of another peptide, or in a peptide-independent fashion. Although it is 
clear that engineering pHLA selectivity is still one of the major challenges for TCR-mimics213, 
there are emerging reagents that exhibit more promising specificity profiles, including reagents 
targeting an HLA-A*02:01 restricted EBV LMP2A426-434 (CLGGLLTMV) epitope214, and an 
alpha-fetoprotein158-166 (FMNKFIYEI) epitope215, the second of which has entered clinical trials 
as a CAR for the treatment of liver cancer. Our data demonstrate the importance of robust 
specificity testing of pHLA-targeting molecules, in line with our own preclinical safety testing 
package216, that should be considered for the development of soluble pHLA-targeting bispecifics.   
 
In summary, we demonstrate that by combining structural and biochemical data with atomistic 
MD simulations, the interactions underpinning pHLA recognition can be dissected in detail and 
can be used to better understand the specificity of pHLA-targeting reagents. Overall, these 
findings extend our understanding of the molecular rules that determine selective recognition of 




Finally, these observations also highlight the challenges associated with engineering pHLA-





To obtain TCRs with affinity-enhanced for HLA-A*02:01 SLLMWITQC (NY-ESO-1157-165), 
HLA-A*01:01 EVDPIGHLY (MAGE-A3161-134) and HLA-A*02:01 RMFPNAPYL (WT-1126-134), 
the wild-type 1G4, MAGE-A3 and WT1 TCRs were subjected to phage display as previously 
described 175. A panel of high affinity TCRs were obtained with mutations in the α and/or the β 
chain (data not shown). TCRs from these panels were selected for this study according to their 
similarity in affinity to available TCR-mimic antibodies. Additionally, some stronger affinity-
engineered TCRs were selected according to the availability of corresponding TCR-pHLA 
complex structures, to enable direct structural comparisons with the TCR-mimic antibodies. 
 
Construct design, protein expression and purification  
The modified TCRs, the TCR-mimics, β2m and the HLA-A*01:01, and HLA-A*02:01 heavy 
chains were cloned into the pGMT7 vector and expressed in the BL21 (DE3) Rosetta pLysS E.coli 
strain as described previously.110,170 TCR constructs for biophysical analysis were designed to 
include the variable and constant domains of both chains (α and β) with an engineered inter-chain 
disulphide bond as previously described.174 Antibody reagents for biophysical analysis were 
generated as single chain fusions (scFv) with a linker between the variable heavy and light chains 
(the constant domains were not included in the construct). Hyb3.3 scFv expression cassette was 
cloned into pCEP4, and protein expressed in mammalian cells using the ExpiCHO Expression 
System (ThermoFisher Scientific), as it did not express in E. coli. TCR constructs for T cell re-
direction experiments were generated with an anti-CD3 scFv fused to the TCR β-chain as 
previously described (ImmTAC molecules). TCR-mimic antibody constructs for T cell re-
direction experiments were designed as scFv with an anti-CD3 scFv fused to the heavy-chain. The 
HLA-A*01:01 and HLA-A*02:01 heavy chains were expressed with a biotinylation tag (for SPR 
experiments), or without it (for crystallisation screens) and refolded in the presence of β2m and a 
specific peptide, as previously described.98 TCRs and scFv were both refolded and purified using 
a previously described TCR refolding protocol.174 For a 250 ml ImmTAC molecule refold, 6.5 mg 





pH8 at 8°C and purified by Poros50HQTM 10/100, Poros50HSTM 10/100 (Life Technologies) and 
Superdex S200HRTM 10/300 (GEH) columns.33 
 
Analysis of on-target and off-target T cell reactivity via re-direction using anti-pHLA/anti-CD3 
bispecific reagents 
The activity of the ImmTAC molecules (TCR-CD3 scFv fusions) and the TCR-mimic scFv-CD3 
scFv fusions was tested through their ability to redirect T cells against a range of antigen-positive 
and antigen-negative cell lines (tumour and healthy cells). Incucyte killing assays were performed 
according to the manufacturer’s instructions (Sartorius, UK). Briefly, 100,000 PBMCs per well 
were added to 10,000 target cells per well. Target cells included HLA-A*02:01 and HLA-A*01:01 
positive tumour cell lines, which were positive or negative for expression of target protein, as well 
as a panel of healthy cell lines. Target cells were incubated on plates overnight at 37°C in 5% 
CO2 before addition of ImmTAC molecules, or TCR-mimic bispecific reagents at 10-7 – 10-12 M 
followed by PBMCs and CellPlayer kinetic caspase apoptosis assay kitTM. Cells were scanned 
every 3 hours for 70 hours, and data were quantified using IncuCyte ZOOM softwareTM (Sartorius, 
UK). Results were analysed using GraphPad Prism. For IFNγ ELISPOT assay, experiments were 
performed according to the manufacturer’s instructions (BD BioSciences, UK). Briefly, 80,000 
PBMCs per well were added to 50,000 target cells per well. Target cells included HLA-A*0201 
positive tumour cell lines, positive or negative for expression of target protein, as well as a panel 
of healthy cell lines. ImmTAC molecules, or TCR-mimic bi-specific reagents were added at 10-7 
– 10-12 M and incubated overnight at 37°C in 5% CO2. Data were quantified after development 
using an automated ELIspot reader (ImmunoSpot Series 5 analyser, Cellular Technology Ltd.). 
 
MAGPIX peptide screening 
Affinity-enhanced TCRs and TCR-mimic scFvs were subjected to peptide cross-reactivity 
analysis using a MagPLEX bead kit (Invitrogen, UK). Several common peptides expressed by 
healthy cells were refolded with either biotin-tagged HLA-A*02:01, or biotin-tagged HLA-
A*01:01 (detailed in Table 3). Phagemid-encoded TCRs/TCR-mimics were expressed on the 
surface of bacteriophage M13, fused to capsid protein pIII217, and binding to biotinylated self-
peptide-HLA complexes attached to neutravidin-conjugated MagPLEX™ magnetic beads 
assayed. Positively bound beads were identified by MAGPIX analysis using a phage- specific PE-
conjugated antibody. Peptides generating a signal above background (3 times median intensity of 
all bead regions bound to native helper-phage) were classified as positive binders, and binding 




of triplicate measurements for each interaction were determined within each experiment, and 
percentage binding for each interaction is reported as the average of several experimental repeats. 
SPR Single cycle kinetic analysis  
Purified TCRs and TCR-mimic scFv were subjected to SPR analysis using a BIAcore3000TM. 
Briefly, pHLAs were biotinylated as described previously 150 and were immobilised onto a 
streptavidin-coupled CM5 sensor chip. For alanine scan analysis, 500 RUs of each alanine scan 
mutant were loaded onto individual flow cells. Flow cell one was loaded with free biotin to act as 
a control surface. All measurements were performed at 25°C in PBS buffer (Sigma, UK) at a flow 
rate of 30 µl/min. Binding profiles of the TCRs and TCR-mimic antibodies were determined using 
single cycle kinetic analysis as previously reported.205,206  TCRs and TCR-mimic antibodies were 
injected at a top concentration of around 20 µM, followed by four injections using serial 1/3 
dilutions. KD values were calculated assuming Langmuir binding (AB = B*ABmax / (KD + B)) and 
data were analysed using the kinetic titration algorithm (BIAevaluationTM 3.1).218 
 
Generation of scHLA libraries and panning 
scHLA libraries were generated as previously described (Coles et al. Submitted). Briefly, scHLAs 
were displayed on the surface of phage with the peptide component disulphide trapped in a single 
chain trimer (dsSCT). Diversity was encoded at the peptide level by introducing a flat distribution 
of 19 amino acids (excluding cysteine, to avoid cyclic peptide formation). All 19 amino acids 
were represented at the HLA primary anchors, Pos2 and Pos9, however, to maximise the 
functionality of the library with peptide correctly bound in the antigen binding groove, the amino 
acid distribution was biased towards to known anchor residue preferences for HLA-A*02:01. This 
phagemid library was introduced by electroporation into E. coli  TG1 cells and grown in  2xYT 
amp 2% glucose media to OD600 = 0.5 and HelperPhage added at an infection ratio of ~ 20:1 
phage to E. coli. Phage particles were isolated by PEG precipitation and 0.45 μM filtration. 
Panning was performed using 200nM for pan 1, and then decreasing concentrations (0.048 nM – 
94nM) in subsequent pans to increase selection pressure. Biotinylated affinity-enhanced TCRs 
(1G4_α5β100, 1G4_α5β51 and 1G4_α58β61) and TCR-mimic antibodies (3M4E5, 3M4E5_T2 
and 3M4E5_T3) were captured on streptavidin-coated paramagnetic beads and incubated with the 
library of purified phage particles preblocked in 3% MPBS buffer. Phage particles were eluted in 
trypsin and used to infect early log phase TGI E. coli cells and plated onto YTEag plates at 30°C 






Deep sequencing of pHLA libraries 
DNA was isolated from each glycerol stock by miniprep (Zymoprep II kit, Zymo Research). 
Sequencing libraries were prepared with molecular indexing based on a method described in.219 
Briefly, a primer containing molecular index was annealed to a region upstream of the peptide 
sequence on the scHLA-pIM627 phagemid DNA and single primer extension reaction was carried 
out with Kapa HiFi DNA polymerase (Roche Diagonostics). Following a reaction cleanup with 
ExoProStar (GE Healthcare) and column purification (Macherey-Nagel), second PCR reaction 
was carried out with primers specific to the primer containing molecular index and a reverse 
primer designed to the β2M gene. Sequencing libraries were prepared from purified PCR products 
(Ampure XP beads, Beckman coulter) using NebNext Ultra II DNA library prep kit (NEB) 
according to manufacturer’s instructions. Library QC was performed with Agilent bioanalyser HS 
kit (Agilent biosystems) and library DNA concentrations were measured with Qubit HS dsDNA 
kit (Life technologies). Libraries were sequenced using Illumina V3 SBS chemistry on the MiSeq 
sequencer. Basecalling and sample demulitplexing was performed using MiSeq reporter to 
generate fastq files and were processed with custom analysis pipeline. Peptide repertoire analysis 
was performed using excel and sequence Logos were generated using IceLogo standalone tool.220 




Crystals were grown at 18°C by vapour diffusion via the sitting drop technique. All crystallization 
screening and optimisation experiments were completed with an Art-Robbins Phoenix dispensing 
robot (Alpha Biotech Ltd, U.K.). 200 nL of 10-15 mg/ml TCR-pHLA complex mixed at a 1:1 
molar ratio was added to 200 nL of reservoir solution. Intelli-plates were then sealed and incubated 
in a crystallization incubator at 18°C (RuMed, Rubarth Apperate GmbH, Germany) and analyzed 
for crystal formation using a Rock Imager 2 (Formulatrix, Bedford, MA USA). Crystals selected 
for further analysis were cryoprotected with ethylene glycol to 25% and then flash-cooled in liquid 
nitrogen in Litho loops (Molecular Dimensions, UK). For WT1_α7β2-A2-RMF, optimal crystals 
were obtained in 0.1 M HEPES pH 7, 0.1M ammonium, 20% v/v Sok-CP7. For NYBR1-A2-SLS, 
optimal crystals were obtained in Pact premier (Molecular Dimensions) condition B07 (0.2 M 
sodium chloride, pH 6.0, 0.1 M MES and 20% PEG 6000. Diffraction data were collected at 
several different beamlines at the Diamond Light Source, Oxford, using a Dectris Pilatus 6M 
detector. Using the rotation method, 1000 frames were recorded each covering 0.2° of rotation. 




and analysed with AIMLESS and the CCP4 package. TCR/pHLA complex structures were solved 
with molecular replacement using PHASER, using PDB 4I4W as a starting model for pHLA, and 
PDB 3O4L as a starting model for NYBR1 TCR. Accession code WT1_α7β2-A2-RMF: TBD and 
NYBR1-A2-SLS: 6R2L. 
 
MD Simulations and MMPBSA calculations 
Periodic boundary simulations and Molecular Mechanics Poisson–Boltzmann Surface Area 
(MMPBSA) calculations were performed with the Amber16 suite of programs.222 X-ray crystal 
structures of the seven TCR/Fab-pHLA complexes investigated were used as the starting points 
for molecular dynamics (MD) simulations. Missing residues were added using Modeller v9.75 
MolProbity was used to modify histidine tautomerisation states (tautomerisation states used can 
be found in Supp Table S1) and Asn/Gln side chain orientations under the criteria of optimising 
the internal hydrogen bonding network. PropKa 3.0158 was used to check the likely protonation 
states of all titratable residues for pH 7 (all residues were modelled in their standard protonation 
states). Each system was solvated in a rectangular box of water (with all crystallographic waters 
retained), extending at least 10 Å away from any protein atom. Sodium or chloride ions were 
added as necessary to neutralise the total system charge. The ff14SB 60 and TIP3P 159 force-fields 
were used to describe protein and water molecules, respectively. Following minimisation, heating 
and equilibration (see section titled “Structure Equilibration Procedure” below for further details), 
each system was subjected to two, 500 ns long production MD simulations (random velocity 
vectors assigned upon heating) in the NPT ensemble (1 atm, 298 K). Production MD simulations 
were run with the SHAKE algorithm applied, a 2 fs time step and a collision frequency of 1 ps−1. 
An 8 Å direct space non-bonded cut-off was applied with long range electrostatics evaluated using 
the particle mesh Ewald algorithm.72 Hydrogen bonding (including water bridged hydrogen 
bonds) and vdW interactions were evaluated from snapshots saved every 10 ps, using the last 450 
ns of each trajectory (900 ns per TCR/Fab-pHLA). A hydrogen bond was defined as ‘on’ if the 
donor acceptor distance was within 3.0 Å and the donor hydrogen acceptor angle was within 45° 
to 180°. A vdW interaction was defined as ‘on’ if two heavy atoms were within 4 Å of one another. 
 
Molecular Mechanics Poisson–Boltzmann Surface Area (MMPBSA) calculations were performed 
using MMPBSA.py.MPI39, using 25 independent (random velocity vectors assigned upon heating) 
4 ns long MD simulations (see Supporting Information for further details) for each structure. From 
each run, 300 equally spaced snapshots were taken from the last 3 ns of each MD simulation for 





performed with an implicit salt concentration of 150 mM, and with 30 explicit water molecules 
(which were all defined as part of the receptor) retained in each snapshot. The 30 closest water 
molecules to any binding site residue heavy atom were retained in each snapshot by using the 
‘closest’ command in CPPTRAJ160, (see section titled “Selection of explicit waters for MMPBSA 
calculations” below for further details).  
 
Structure Equilibration Procedure.  
The following procedure was used to prepare for production MD simulations for both the long 
time-scale (2 x 500 ns) and short time scale (25 x 4 ns) simulations used in this study. First, 
hydrogen atoms and solvent molecules were relaxed with 500 steps of steepest descent followed 
by 500 steps of conjugate gradient (using 10 kcal mol−1 Å−1 positional restraints on all protein 
heavy atoms). The system was then heated linearly from 50 K to 298 K (NVT ensemble) over the 
course of 200 ps (retaining the 10 kcal mol−1 Å−1 positional restraints on all protein heavy atoms). 
The whole system was then minimised for a further 500 steps of steepest descent followed by 500 
steps of conjugate gradient with 5 kcal mol−1 Å−1 positional restraints on all Cα carbon atoms. 
Retaining the Cα carbon restraints, each system was again heated from 25 K to 298 K over the 
course of 50 ps in the NVT ensemble. The Cα carbon restraints were then gently removed in linear 
steps of (5, 4, 3, 2, 1, 0 kcal mol−1 Å−1) of 10 ps each in the NPT ensemble. Following this, 
production MD simulations were run. For NVT simulations, the timestep was set to 1 fs (with the 
SHAKE algorithm applied) and a collision frequency of 1 ps−1 was used with Langevin 
temperature control. Simulations in the NPT ensemble were performed with a timestep of 2 fs 
(with the SHAKE algorithm applied), using a Berendsen barostat for pressure control (1 ps 
pressure relaxation time) and Langevin temperature control (collision frequency of 1 ps−1). 
 
Selection of explicit waters for MMPBSA calculations 
The InterfaceResidues.py script (available at https://pymolwiki.org/index.php/InterfaceResidues) 
run through PyMOL on each crystal structure was used to identify in an unbiased manner the 
binding site residues for each TCR/Fab-pHLA. Criteria for selecting interfacial residues were set 
based on the results of Maffucci et al.223 (Cut-off for change in solvent accessible surface area 
was set to 0.5 Å2 for all residues). Following this, CPPTRAJ160 (part of the AmberTools suite of 
programmes), was used to select the closest 30 water molecules to the selected interfacial residues 
using the ‘closest’ command. Stripping solvent using large residue selections such as the ones 
generated in these calculations can be time consuming if performed on the entire water box. To 




remove most of the waters in the periodic box, and the second to select the 30 closest waters 
molecules for MMPBSA calculations). An example script of how to do this within CPPTRAJ is 
available upon request. 
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Supplementary Figure S1: – Binding affinity analysis of affinity-enhanced TCRs and TCR-mimics. 
The interaction between each affinity-enhanced TCR, or TCR-mimic with cognate pHLA molecules were 
analysed using surface plasmon resonance. Binding affinities of the affinity-enhanced TCRs and TCR-
mimics were determined using single cycle kinetic analysis, or equilibrium binding analysis (for ESK-1). 
Five injections of each reagent were performed using 3:1 dilution between injections. Raw data (dotted line) 
and fits (solid line) are shown for each plot. Representative data from three independent experiments are 
shown. (A-B) A2-SLL affinity-enhanced TCRs (1G4_α58β61 and 1G4_α5β100), (C-E) A2-SLL TCR-
mimics (3M4E5, 3M4E5_T2 and 3M4E5_T3), (F-G) A1-EVD affinity-enhanced TCRs (MAG-IC3 and 
MAG-IC5), (H) Hyb3-A1-EAD, (I-K) A2-RMF affinity-enhanced TCRs (WT1_α7β2, WT1_α27β2 and 







Supplementary Figure S2: – Molecular dynamic analysis of the TCR and TCR-mimic-peptide 
interface. Molecular dynamics was performed to access the average number of side chain or main chain 
peptide contacts over time. Average number of hydrogen bonds and vdWs interactions formed per 
frame between the peptide and the TCR/Fab over the course of our long time scale MD simulations. Per-
residue peptide contributions are divided into main (blue and light blue) and side (red and light red) chain 
contributions.  A) 1G4_α58β61-A2-SLL, B) MAG-IC3-A1-EVD, C) WT1_α7β2-A2-RMF, D) 3M4E5-
A2-SLL, E) Hyb3.3-A1-EAD, F) ESK-1-A2-RMF. G) NYBR1 TCR, H) Ratio of total peptide side chain 
against peptide main chain hydrogen bonds (red) and vdWs interactions (blue) for each TCR/Fab-pHLA. 
Ratios are stated above each bar to 3 significant figures. The red and blue dotted lines represent the y-axis 
location for a ratio of 1 for Hydrogen bonds and vdWs interactions respectively. A black dotted line denotes 









Supplementary Figure S3: Per-residue decomposition of the binding free energy obtained from 
MMPBSA calculations for key regions of (A) 1G4_α58β61-A2-SLL, (B) MAG-IC3-A1-EVD, (C) 
WT1_α7β2-A2-RMF, (D) 3M4E5-A2-SLL, (E) Hyb3.3-A1-EAD, (F) ESK-1-A2-RMF. A more negative 
value indicates increased favourability towards binding. Bars are coloured as follows: blue, less than -1 
kcal mol
-1
; green, between -1 and 1 kcal mol
-1










Supplementary Figure S4: The activity of IMC-1G4_α58β61, 3M4E5_T2-anti-CD3 and 
3M4E5_T3-anti-CD3 was tested against HLA-A*02:01+/NY-ESO-1+ (NCI-H1755) and HLA-
A*02:01+/NY-ESO-1- (HEP-G2, Ren8 and HISMC) cells lines using Incucyte killing assays. 
Experiments were performed according to the manufacturer’s instructions (Sartorius, UK). 
100,000 PBMCs per well were added to 10,000 target cells per well. Target cells were incubated 
on plates overnight before addition of ImmTAC molecules, or TCR-mimic bispecific reagents 
followed by PBMCs. Cells were scanned every 3 hours for 70 hours. Data are plotted using cell 





Supplementary Figure S5: The activity of IMC-MAG-IC3 and Hyb3.3-anti-CD3 was tested 
against HLA-A*01:01+/MAGE-A3+ (HCC1428), HLA-A*01:01+/MAGEA1+ (HCC1428 and 
NCI-H1703) and HLA-A*01:01+/MAGE- (COLO205 and HISMC) cells lines using Incucyte 
killing assays. Experiments were performed according to the manufacturer’s instructions 
(Sartorius, UK). 100,000 PBMCs per well were added to 10,000 target cells per well. Target cells 
were incubated on plates overnight before addition of ImmTAC molecules, or TCR-mimic 
bispecific reagents followed by PBMCs. Cells were scanned every 3 hours for 70 hours. Data are 






Supplementary Figure S6: Per-residue decomposition of the binding free energy obtained from 
MM-PBSA calculations for key regions of NYBR1-A2-SLS. A more negative value indicates 
increased favourability towards binding. Bars are coloured as follows: blue, less than -1 kcal 
mol
-1
; green, between -1 and 1 kcal mol
-1







Supplementary Table S1. Summary of cancer-targeting TCR-mimic antibodies reported in the 
literature. 
 TCR-mimic Target/peptide HLA-A* In vivo data Structure Refs 
3M4E5 NY-ESO-1/SLIMWITQC 02:01 3M4E5_T2 3M4E5 34,177,224 
ESK-1 WT1/RMFPNAPYL  02:01 ESK-1 ESK-1 36,178,225 
Hyb3.3, G8 MAGE-A1/EADPTGHSY  01:01 Hyb3.3 Hyb3.3 35,181,226 
PR20 PRAME/ALYVDSLFFL 02:01 PR20 No 176 
38 LMP2A/CLGGLLTMV 02:01 38 No 214 
G2D12 GP100/KTWGQYWQV  02:01 No No 227 
1A9, G1 GP100/IMDQVPFSV 02:01 No No 227 
2F1 GP100/YLEPGPVTA 02:01 No No 227 
GPA7 GP100/ITDQVPFSV 02:01 GPA7 No 228 
4A9 hTERT/ILAKFLHWL 02:01 No No 229 
3H2 hTERT/RLVDDFLLV 02:01 No No 229 
M2B1 MUC1/LLLTVLTVV 02:01 No No 230 
7D4 MAGE-A3/FLWGPRALV 02:01 No No 231 
RL4B/3.2G1, 1B10 hCGβ/GVLPALPQV 02:01 RL4B/3.2G1 No 232,233 
3F9 hCGβ/TMTRVLQGV 02:01 No No 233 
1B8 Her2/ KIFGSLAFL 02:01 No No 234 
CAG10 MART-1/EAAGIGILTV 02:01 CAG10 No 235 
Fab-D2 TARP/FLRNFSLML 02:01 No No 236 
T1-116C, T1-29D p53/RMPEAAPPV 02:01 T1-116C No 237,238 
T2-108A p53/GLAPPQHLIRV 02:01 No No 238 
TA2 Tyrosinase/YMDGTMSQV 02:01 No No 182 
RL6A p68/YLLPAIVHI 02:01 RL6A No 239 
RL21A MIF/FLSELTQQL 02:01 RL21A No 240 
8F4 Proteinase 3/VLQELNVTV 02:01 No No 241 







Supplementary Table S2. Histidine tautomerisation state assignments for all MD simulations.  
Structure  HID
a
 Tautomerisation State 
α58β61 TCR Chain A: 3, 70, 74, 93, 114, 145, 260.  
Chain E: 151. 
3M4E5 Fab Chain A: 3, 70, 74, 93, 114, 145, 260.  
Chain D: 51. 
MAG-IC3 TCR Chain A: 3, 70, 93, 260. 
Chain E: 153. 
Hyb3.3 Fab Chain A: 3, 70, 93, 260.  
Chain D: 172, 212. 
Chain E: 95B , 189.  
α7β2 TCR Chain A: 3, 70, 74, 93, 114. 
Chain B: 51. 
Chain D: 77. 
Chain E: 208. 
ESK-1 Fab Chain A: 3, 70, 93, 114.  
Chain D: 192.  
NYBR1 TCR Chain A: 3, 70, 74, 93, 151, 260. 
Chain E: 158.  
aHID corresponds to a histidine residue which is singly protonated on its Nδ1 nitrogen, with all 






Drivers for High Affinity TCR-pHLA 
Interactions: Insights from Structure 
and Dynamics 
 
The focus in Chapter 4 was to determine protein engineering principles for developing 
TCRs that are highly specific towards their given pHLA target. In this chapter, we now 
turn to determining engineering principles for affinity enhancement of TCRs. In order to 
do this, we performed structural analysis, MD simulations and free energy calculations 
on four case studies of TCR affinity maturation available from the literature. We first 
demonstrated the limitations of contact analysis (either from X-ray crystal structures or 
MD simulations) to rationalise changes in affinity. We then evaluated how the flexibility 
of the TCR had changed over the course of affinity maturation, identifying instances in 
which the apo high affinity (HA) TCR was more rigid than its corresponding apo wild-
type (WT) TCR. This is an energetically favourable effect for the HA-TCR, as the 
entropic penalty associated with solute rigidification upon binding would be reduced 
(relative to the WT-TCR). This beneficial effect was largely found to be “compensated” 
for however, by the HA-TCR binding the pHLA bound structure tighter than the 
corresponding WT-TCR does. Finally, we used free energy calculations to identify at 
the per-residue level what changes/mutations to the TCR have driven affinity 
enhancement across all four case studies. Our free energy calculations were able to 
correctly predict the affinity hierarchy for all four case studies, and comparison of the 
WT and HA energetic footprints show the binding hotspots on the TCR and pHLA to be 
largely preserved. This has important implications in the design of specific TCRs, as 
preservation of the energetic footprint used by the thymically selected WT-TCR is 
arguably more likely to create a non-cross-reactive TCR. In this study, I performed all of 
the structural analysis, MD simulations and free energy calculations. I also wrote the 
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Immuno-oncology (IO) approaches that utilise T-cell receptors (TCRs) are becoming 
highly attractive because of their potential to target virtually all cellular proteins, including 
cancer specific proteins, via the recognition of peptide human leukocyte antigen 
complexes (pHLA) that are presented at the cell surface. However, because natural TCRs 
generally recognise cancer derived pHLAs with very weak affinities (high μM to low mM 
range), efforts have been made by several companies and academic laboratories to 
enhance their affinities, in some cases by several million-fold. Here, we investigate 
whether shared mechanisms drive the enhancement in affinity by studying the crystal 
structures of several published, and one new, affinity enhanced TCRs compared with 
structures of their natural progenitor TCRs. Additionally, we performed in depth 
molecular dynamic simulations to better understand the nature of the affinity 
enhancements. These data demonstrate that affinity enhancements can be achieved within 
the natural TCR-pHLA binding mode via relatively subtle modifications to the interface 
contacts. However, the individual energetic components of the TCR-pHLA interaction 
that governed the affinity enhancements were distinct and highly variable for each TCR 
under investigation. Our data demonstrate that that native TCR binding mode has the 
potential to bind pHLA with antibody-like (up to low pM) affinities via a range of 





why are natural TCRs selected to bind to pHLA in the μM affinity range? Finally, this 
first comprehensive analysis of affinity enhanced TCRs has important implications for 
the future rational design of affinity enhanced TCRs for cancer therapy.  
 
Introduction   
 
αβ T-cell receptor (TCs) recognition of short antigenic peptide fragments presented at the 
cell surface by human leukocyte antigens (pHLA) governs T-cell immunity. These 
peptide fragments represent virtually all intracellular proteins, allowing TCRs to access a 
much larger pool of potential therapeutic targets than monoclonal antibodies (mAbs), 
which primarily bind to extracellular antigens.32 This advantage has encouraged the 
development of soluble engineered TCRs as therapeutics for viral and cancerous 
diseases.43,174,175 These soluble TCRs have been designed as bispecific T-cell engagers, 
making use of their pre-existing antigen recognition site to bind a specific pHLA molecule 
on a target cell, and an immune effector function to recruit and activate T-cells.26 This 
approach of utilising a soluble bispecific TCR to target cancer has been shown to induce 
tumour regression33 and clinical trials are currently under way for multiple diseases.  
However, unlike mAbs, which can utilise somatic hypermutation to generate affinities for 
their target antigen in the nM-pM range, naturally occurring TCRs bind pHLA with 
relatively weak affinities (~µM) and short half-lives (on the timescale of seconds).18 These 
characteristics are undesirable for therapeutic molecules. Thus, a number of 
approaches46,47,175,242–244 usually focussed on introducing affinity enhancing mutations 
within the six complementarity-determining region (CDR) loops that comprise the TCR 
binding site (see Figure 32A+B), have been used to improve the binding characteristics 
of the TCR-pHLA interaction. One approach, using phage display, has been shown to 
yield TCRs with affinities up to the low pM range, and subsequently much longer half-
lives (in the hours to days range) for their target pHLA complex.175  Soluble bispecific 
TCRs generated using this phage display approach (ImmTAC molecules) can re-direct T-
cell responses against cancer cells, leading to tumour regression33, presenting as a few as 
10 antigen specific pHLA per APC19.  
To ensure coverage against all possible peptide antigens, the ~2x107 TCRs (produced per 
human) are highly cross-reactive128, with prior studies showing that a single TCR is able 
to bind over a million different peptide antigens presented on a single HLA.16 This cross-
reactivity has been rationalised as being induced by specific residue “hotspots” on the 
pHLA, meaning if all or most of these residues are present, the TCR will bind to a 
reasonable degree.212 The dangers of such cross-reactivity (binding endogenous pHLA 
molecules to induce an autoimmune response) for TCRs are largely abrogated by thymic 
selection, in which TCRs with affinities too high for any endogenous pHLA molecule are 




perspective, the mutations made to increase their affinity come with the risk of inducing 
cross-reactivity with endogenous pHLA molecules.22 It is therefore of significant interest 
to understand if affinity matured TCRs tend to preserve the “energetic footprint”/residue 
hotspots used by the thymically selected wild-type (WT) TCR, as this is likely to reduce 
cross-reactivity with a self-pHLA molecule. Further, the development of computational 
“assays” that would allow one to determine the extent to which mutations have altered 
this energetic footprint could be of value in rational design approaches.  
With many possible mechanisms for affinity enhancement (such as improved 
electrostatics, burial of hydrophobic matter, expulsion of unfavourable water molecules 
and a reduction in the entropic cost of solute binding, by rigidification of the protein(s)), 
one would like to know if there are common methods by which TCRs can enhance 
affinity. It would be very challenging to ascertain the above information experimentally, 
whereas computational methods can provide detailed insight at the atomic level regarding 
the features of affinity enhancement. Further, the development of computational “assays” 
that would allow one to determine the extent to which mutations have altered this 
energetic footprint could be of value in rational design approaches.   
Our study aims to provide fundamental insight into what drives affinity maturation in 
TCR molecules targeting pHLA. Such increased understanding is of direct importance in 
the rational design of high affinity and antigen-selective TCRs. Herein, we consider four 
separate case studies of TCR affinity maturation from the literature, and perform a 
combination of structural analysis, molecular dynamics (MD) simulations and binding 
free energy calculations to determine the drivers for affinity enhancement in all four cases. 
All case studies chosen, crystal structures of both the WT TCR and the corresponding HA 
variant(s) of the TCR in complex with the pHLA were compared, providing input for 
structural analysis and good starting points for MD simulations. Our first case study 
(Figure 32C) is composed of the WT and four HA variants targeting the NY-ESO-1157-
165 cancer-testis antigen-derived peptide (sequence: SLLMWITQC), presented by HLA-
A*02:01 (A2-SLL).43,45,245 The remaining three case studies are pairs of a single WT and 
HA variants with two of the three pairs (DMF5 and MEL5, Figure 32C) targeted towards 
the MART-126–35 peptide bound to HLA-A*0201, with peptide sequence 
ELAGIGILTV.175,246 The final pair of TCRs (Tax A6, Figure 32C) recognise the HTLV-






Results and Discussion 
 
Structural comparisons of WT and affinity matured TCRs show preservation of the WT 
binding mode. We analysed the crystal structures of all TCR-pHLA complexes 
investigated herein (Table 5), focussing first on how the TCR engaged with the pHLA 
molecule. We first measured how the relative orientation of the TCR variable domains 
(Vα and Vβ) may have changed as a result of affinity maturation by measuring their 
Figure 32: (A) Exemplar structure of a TCR-pHLA complex, with a different portions of 
the TCR and pHLA labelled. (B) Zoom in on the binding TCR-pHLA showing the 6 CDR 
loops responsible for binding the pHLA. (C) Table of all TCR-pHLA complexes 
investigated in this study. Note the α and β-chain framework (FWα and FWβ) are non-
hypervariable loops that flank the CDR loops. (A complete list of all mutations made onto 





TRangle21 parameters. To compare how similar the variable domain orientations are for 
two different TCRs, one can calculate the dTRangle (see Methods) between the two TCRs, 
with values <10° suggesting the orientations are highly similar.21 Comparison of the 
dTRangle values (for WT vs HA, see Table 5) structures show no significant change in the 
relative orientation upon affinity maturation. We also calculated the “docking angle” for 
each TCR (Table 5), which measures the angle at which the TCR engages the pHLA, 
with canonical TCR docking angles in the range of 40-85°.5 For all cases, we observe no 
significant change in the docking angle upon affinity maturation. Interestingly, we note 
that the docking angles of both Tax A6 and DMF5 sit just below the previously described 
canonical docking angle range (Table 5). The above observations suggest (at least in these 
cases) that affinity maturation has not significantly impacted the core scaffold of the TCR 
or how it docks to bind the pHLA.  
 
We next considered the number of hydrogen bonds (H-bonds) and van der Waals (vdWs) 
interactions between the TCR and pHLA (Table 5). No clear relationship between affinity 
and the number of H-bonds and/or vdWs interactions formed was observed. As neither 
measure considers the relative strength or occupancy of different H-bonds or vdWs 
Table 5: Structural analyses of all TCR-pHLAs complexes under investigation. The dTRangle 
is a measure of the TCR variable domains orientational similarity for 2 different structures 
(see Methods).41 For this, we compare the WT to each HA TCR. The docking angle (which 
describes the angle the TCR engages the pHLA) and dTRangle were determined using the 
STCRDAB server. Buried solvent accessible surface area (BSASA) was determined using 
the LCPO algorithm within CPPTRAJ. Hydrogen bonds (H-bonds) are defined for donor-
acceptor distances ≤ 3.5 Å and donor-hydrogen-acceptor angles 135-225°. Van der Waals 





contacts, these results are unsurprising. We also note that water-bridged H-bonds (which 
were not considered in Table 5, as resolving water in crystal structures is resolution 
dependent) may play an important role in driving affinity. For example, the crystal 
structure of the HA MEL5 TCR (MEL5 α24β17) contains 9 observed bridged water H-
bonds between the TCR and pHLA, which cannot be compared to the WT MEL5 TCR, 
as its X-ray resolution is not sufficient (3 Å) to place water molecules.206 Comparisons in 
the change of the buried solvent accessible surface area (BSASA) show an increase upon 
affinity maturation in the three pairs (MEL5, DMF5 and Tax A6) of WT and single HA 
variants (Table 5). This observation is consistent with an increase in the number of vdWs 
contacts formed for each of the HA TCRs (Table 5), which suggests that a larger amount 
of interfacial water is expelled upon binding. In the case of the NY-ESO TCRs, no clear 
trend was established between the change in BSASA and affinity.  
Contact analysis of molecular dynamics simulations. Our X-ray analysis showed no 
obvious structural differences between WT and their counterpart HA TCRs, perhaps 
because one cannot estimate the strength/occupancy of H-bonds/vdWs from single 
structures and because bridged water interactions cannot be fairly compared. To overcome 
these limitations, we turned to molecular dynamics (MD) simulations to obtain insight 
into how the number of contacts between the TCR and pHLA change over time and 
consider the role (if any) of molecular flexibility in driving affinity. In order to do this, 
we performed ten 100 ns long MD simulations of all TCRs in both their apo and pHLA 
bound forms (totalling 22 µs of MD simulation). The use of many independent replicas 
(such as the 10 performed here) is important for obtaining reliable and reproducible 
results.147   
From our MD simulations with pHLA bound, we calculated the average number of H-
bonds (including water bridged H-bonds) and vdWs contacts formed between the TCR 
and pHLA (Figure 33A+B). For MEL5 and DMF5 there was a small increase in both the 
average number of H-bonds and vdWs contacts between the TCR and pHLA for the 
higher affinity complexes, contrasting with the NY-ESO and Tax A6 TCRs which showed 
no clear relationship between affinity and number of contacts. To measure the extent to 
which contacts to individual pHLA residues were preserved upon affinity maturation, we 
calculated the total number of H-bonds and vdWs contacts formed between the TCR and 
each pHLA residue. Of the 10 pHLA residues most contacted by the WT NY-ESO TCR, 
8 or 9 are also preserved in the top 10 for all NY-ESO variants (in terms of both the 
average number of H-bonds and vdWs contacts, see Tables S4+S5). For the Tax A6 
TCRs, the affinity matured variant preserved between 9-10 of the top 10 WT contacts 
(Tables S6+S7), whilst for the DMF5 and MEL5 TCRs, between 7-9 of the top 10 WT 
contacts were preserved in the affinity matured variants (Tables S6+S7). These results 
demonstrate that the affinity matured TCRs studied here mostly preserve the contacts 






We also applied our MD simulations to determine how the average BSASA differed for 
all TCR-pHLA complexes (Figure 33C). Further, the variance of the BSASA can be used 
to provide insight into how the overall rigidity of the binding interface differs for each 
TCR-pHLA complex (a smaller variance would suggest a less flexible binding interface). 
Whilst the DMF5 and MEL5 TCRs show an increase in the BSASA for the affinity 
matured variant (consistent with the crystal structure analysis, Figure 32), the Tax A6 
TCRs show essentially no change in BSASA for the affinity matured TCRs (inconsistent 
with the crystal structure analysis). For the NY-ESO TCRs, a small general increase in 
the BSASA was observed for the affinity matured variants, however these results were all 
within error of one another. Interestingly, all NY-ESO TCRs showed a reduction in the 
variance of the BSASA, suggesting the binding interface has become overall more rigid 
(standard deviations of 157 Å2 for the WT as compared to between 75-90 Å2 for all HA 
TCRs). A reduction in variance for the higher affinity variant was also observed for the 
MEL5 TCRs (from 291 to 182 Å2) and to a lesser extent the DMF5 TCRs (from 365 to 
297 Å2), whilst the Tax A6 TCRs show essentially no difference (from 147 to 154 Å2).  
Reductions in flexibility are not required for affinity maturation. Changes in 
rigidity/flexibility of the unbound (apo) TCRs could occur over the course of affinity 
maturation (due to multiple mutations). Rigidification of the CDR loops (and/or the 
scaffold as a whole) could act as a mechanism by which affinity is enhanced (by reducing 
the entropic penalty associated with rigidification upon binding). We therefore made use 
of our MD simulations of all TCRs in their apo and pHLA bound states to calculate the 
Figure 33: Differences in the average number of H-bonds, vdWs contacts and the 
BSASA from our MD simulations. All WT TCRs are coloured in green and all affinity 
matured TCRs are coloured in purple. Bars for the H-bonds and vdWs contacts are divided 
in two based on HLA-TCR interactions (darker colour and hashed bars) and peptide-TCR 
interactions (lighter colour). The totals obtained are from 10 independent 100 ns long MD 
simulations of each TCR-pHLA complex (using the last 90 ns of each simulation). Error 
bars plotted for A and B are the standard deviation of the averages from the 10 replicas. 
Error bars plotted for C are the standard deviation obtained from combining all snapshots 





changes in root mean square fluctuation (ΔRMSF) upon affinity maturation (Figure 34). 
Further, we evaluated the significance of the ΔRMSF differences observed by performing 
a two-sample t-test (p < 0.05). Our results demonstrate the importance of using many 
replicas and performing subsequent statistical tests to determine if the observed 
differences in ΔRMSF were in fact significant or not. 
For the NY-ESO TCRs, we observed a large decrease in the flexibility of the CDR3α loop 
for the three variants that contain mutations in this loop (c5c1, c58c61 and c58c62, see 
Figure 34A+B). This increase in rigidity can be rationalised by the substitution of a 
glycine residue for a more conformationally restricted amino acid (G97D). Furthermore, 
the carboxyl side-chain of this mutated residue was able to form an interloop hydrogen 
bond with T99 (S99 in the WT TCR), which would further rigidify the loop. For all three 
other mutated CDR loops in the NY-ESO TCRs (CDR2α, CDR2β and CDR3β), no 
significant changes are observed between the apo TCRs. An increase in the flexibility of 
the HVα loop is observed for TCR variants c49c50, c58c62 and c58c61, which is likely 
induced by mutations made in the CDR2α loop given the close proximity between the two 
loops (see Figure 32) and that fact that c5c1 does not contain CDR2α mutations. 
Comparison of the crystal structures of the CDR2α mutated and WT loops shows the 
mutated loops to be translated further away from the HVα loop in order to form additional 
contacts with the pHLA, meaning the flexibility of the HVα loop is likely increased due 
to a reduction in the number/strength of contacts formed to the CDR2α loop. 
Whilst there was a clear example (CDR3α loop) of affinity maturation increasing the 
rigidity of the apo TCR, it is important to consider that a higher affinity TCR is likely to 
bind the pHLA with increased rigidity relative to the WT. This would mean the beneficial 
increases in rigidity seen for the apo simulations could therefore be offset by a more rigid 
TCR when bound to the pHLA. We therefore calculated the ΔRMSF values for pHLA 
bound simulations of the NY-ESO TCRs (Figure 34C+D). Comparison of the apo and 
pHLA bound ΔRMSFs show that for the CDR3α loop, the increased rigidity in the apo 
TCR was largely compensated for by increased rigidity when bound to pHLA, suggesting 
no beneficial entropy gain for the higher affinity TCR variants with CDR3α mutations. 
Whilst mutations in the CDR2α and CDR3β loops appear to have an insignificant impact 
on the flexibility of either the apo or pHLA bound states, the CDR2β and HVβ loops are 
more rigid in the c5c1 and c58c61 variants pHLA bound form, which share the same set 
of CDR2β loop mutations and a single HVβ loop mutation (T69I). This data would 
therefore suggest these mutations to have an entropically unfavourable impact on the 






Figure 34: Differences in flexibility between the affinity matured TCRs variable regions 
and their counterpart WT TCRs. (A–D) ΔRMSF values (HA variant RMSF – WT RMSF) 
for all NY-ESO TCRs, with panels A and B corresponding to the CDRα and CDRβ of the Apo 
TCRs respectively, and panels C and D corresponding to CDRα and CDRβ of the TCRs in 
complex with pHLA respectively. (E–H) ΔRMSF values (HA variant RMSF – WT RMSF) for 
the three pairs of HA and WT TCRs, with panels E and F corresponding to the CDRα and 
CDRβ of the Apo TCRs respectively, and panels G and H corresponding to CDRα and CDRβ 
of the TCRs in complex with pHLA respectively. A more negative ΔRMSF value indicates 
increased rigidity for the HA variant relative to the WT. The points towards the bottom of each 
graph indicate residues with significantly different ΔRMSF values as determined by a two-
sample t-test (p < 0.05). Crosses are used to indicate the locations of mutated regions of the 
TCRs (using the same colouring as line graph). Complete RMSF plots for all TCRs simulated 







The affinity matured MEL5 TCR contains a total of 17 mutations from the WT spread 
over seven loops and a further two mutations located in the remainder of the variable 
domain scaffold. Comparison of the apo ΔRMSFs (Figure 34E–F) indicated only the 
HVα and CDR2β loops at the TCR binding interface to change significantly upon affinity 
maturation. The large (both positive and negative) scale changes seen in the CDR2β loop 
is likely the result of the large scale rearrangement of this loop upon affinity maturation206. 
The increased rigidity observed in the residues between the CDR1β and CDR2β loops in 
both the apo and pHLA bound simulations can be rationalised by the L44Q mutation, 
which is located ~15 Å from the closest pHLA residue. Whilst this mutation may well 
have had a beneficial effect on the pHLA binding affinity, it is possible this mutation (and 
others) were selected because they instead stabilised the TCR such that it could be better 
expressed on phage particles during affinity selection. This could ultimately lead to 
mutations being taken forward that do not impact the affinity of the TCR-pHLA complex. 
The pHLA bound simulations of the MEL5 TCRs show several regions of increased 
rigidity for the higher affinity variant, including the CDR1α, CDR3α, and CDR3β loops. 
This observation of a generally more rigid binding interface for the higher affinity TCR 
is consistent with the previously discussed reduction in the variance of the BSASA for the 
higher affinity MEL5 TCR.  
Prior thermodynamic analysis on both the WT and HA MEL5 TCR suggested an 
improvement in the entropy term of the binding free energy upon affinity maturation 
(from a TΔS° of ∼8.3 kcal mol−1 to ∼18.1 kcal mol−1).206 The ΔRMSF data discussed 
above suggest this favourable effect is likely not (at least primarily) driven through 
changes in rigidity, and is would instead be the result of an improved of entropy of 
solvation term (which would be consistent with an large increase in the BSASA for the 
higher affinity MEL5 TCR-pHLA complex, see Figure 33C).   
For the pair of Tax A6 TCRs (which differ by four point mutations in the CDR3β loop), 
we observed little significant changes in flexibility for both the apo and pHLA bound 
simulations. This lack of difference (in the pHLA bound simulations) is consistent with 
the BSASA calculations described above and would therefore suggest changes in 
flexibility are largely insignificant in affecting binding affinity. The WT and affinity 
matured DMF5 TCRs only differ by two point mutations (D26Y and L98W on the CDR1α 
and CDR3β loops respectively). Comparison of the WT and affinity matured apo TCR 
simulations (Figure 34E–F) showed virtually no differences in flexibility between the 
WT and the HA variant. In the pHLA bound simulations (Figure 34G–H), no notable 
effect can be observed for the CDR3β mutation. In contrast however, the CDR1α loop 
had increased rigidity in the HA variant. This increased rigidity in the CDR1α loop is 
likely also responsible for the observed increased rigidity seen in the neighbouring 




From the four examples discussed, it is clear that changes in flexibility/rigidity during 
TCR maturation can play a role in increasing or decreasing affinity in some cases (NY-
ESO TCR, MEL5 TCR and to a lesser extent DMF5), but not all (Tax A6). Entropy-
enthalpy compensation should also be considered: increased rigidity of a TCR in complex 
with pHLA (an entropic effect disfavouring binding, which may or may not be fully 
compensated for by increased rigidity in the apo TCR) can aid the formation of favourable 
contacts between the TCR and pHLA (an enthalpic effect favouring binding).   
Energetic hot spots are preserved over the course of affinity maturation. To study how the 
CDR loop mutations have enhanced the affinity between the TCR and pHLA, we 
performed binding free energy calculations using the Molecular Mechanics Generalized 
Born Surface Area (MMGBSA) method.39 This approach (described in more detail in the 
Methods) uses MD simulations to sample conformations of the complex, receptor and 
ligand and subject these snapshots to an empirical calculation in order to determine the 
binding free energy (ΔGbind). 
Comparison of our calculated ΔΔGbind values with the experimentally determined results 
showed that the differences in affinity between the WT and HA TCRs were identified 
correctly. In the case of the set of five NY-ESO TCRs, we obtained an R2 value of 0.78 
between simulation and experiment (Figure 35). In the cases of the three pairs of WT and 
affinity matured TCRs, the increase in affinity was correctly predicted for each pair 
(Figure 35). These results indicate that our simulations are able to identify the (atomic 
level) differences between the WT and HA TCR-pHLA complexes that result in increased 
affinity.  
 
Figure 35: Experimental vs computational ΔΔGbind values obtained from our MMGBSA 
calculations for all TCR-pHLA systems studied. For the three pairs of TCRs with a single 
WT and affinity matured TCR, lines are drawn to guide the eye. Error bars plotted are the 





 Decomposing the calculated binding energies onto the per residue level can indicate 
which interactions are the main drivers for the increased binding affinity in the HA TCR 
variants. Whilst our primary focus was on the differences between WT and HA TCR 
variants (i.e. ΔΔGbind), we showed that WT energetic hotspots across the TCR-pHLA 
interface are largely conserved upon affinity maturation (Figure S5), in line with the 
contacts analysis above.  
Mutations can directly or indirectly drive affinity enhancement. Overall analysis of the 
per-residue decomposition indicated that the NY-ESO TCR loop mutations had a largely 
additive effect on TCR-pHLA binding, i.e. the contribution of mutations in one loop was 
not affected by mutations in other loops. This additivity could be expected, because the 
overall TCR conformation was well preserved across all the NY-ESO TCRs studied. For 
example, the X-ray Cα RMSD (vs. the WT TCR) of the TCR variable domains for all 
affinity matured variants is < 0.4 Å.  
The two different CDR2α loop mutations (see Figure 36A–C) both appear to have 
enhanced affinity via the same mechanism: large hydrophobic (and aromatic) groups were 
introduced where they can be effectively buried at the interface (either S53W or S52F + 
S53W). The G97D mutation in the CDR3α loop was predicted to be unfavourable for all 
three cases in which it occurred (Figure 36A+D). This is not surprising as the mutation 
results in the partial burial of a negatively charged residue upon binding (which will incur 
a large desolvation penalty). However, the mutation had two clear benefits. The first was 
the formation of an internal hydrogen bond within the CDR3α loop to T99 (S99 in the 
WT TCR), which helped to rigidify the Apo HA CDR3α loops relative to the WT (see 
above and Figure 3A). Second, the mutation occurred at the same time as the S96L and 
S99T mutations, which more than compensate for the negative effect introduced by G97D 
(likely partly because the loop is more rigid, so the other residues can form strong and 
persistent interactions with the pHLA). This raises an important point: whilst one mutation 
(in isolation) can have a negative effect on binding affinity, this can be offset by inducing 
improvements in the contribution to binding affinity of other residues nearby. Further 
analysis of the impact of CDR3α mutations suggested enhanced interactions with HLA 
residue R65 and CDR2β residue D54. This improvement may again be in part due to the 
decreased mobility of the loop, which allows for an increase in the total average number 
of hydrogens bonds formed between the TCR and R65 (WT and non CDR3α mutated 
c49c50 combined H-bond occupancies of 2.3 and c5c1, c58c62 and c58c61 occupancies 
of 2.9-3.2, Table S5).  
For the CDR2β mutations, the substitution of the methyl side chain of A50 for a larger 
hydrophobic side chain (A50V or A50I) was primarily responsible for the increased 
binding affinity. Furthermore, the G49A mutation (seen only in c58c61) further increased 
the favourability towards binding, which was in contrast to the more polar G49S mutation 
in c49c50 and c58c62 (Figure 36A+E+F). These results would suggest affinity 
enhancement is driven in the same way as described earlier for the CDR2α mutations (by 





Figure 36: NY-ESO variants show largely additive energetic effects upon affinity 
maturation. A. Per-residue ΔG differences between the high affinity (HA) variants and WT-
NY-ESO (i.e. ΔΔG), with positions mutated indicated throughout in red. ΔΔG differences 
between the WT and the given HA TCR are coloured blue if < –0.5 kcal mol–1 (favourable for 
binding) and red if > 0.5 kcal mol–1 (unfavourable for binding), with values in between coloured 
green. (B–G) Colour mapping of the above per residue ΔΔG values onto all carbon atoms of 
the high affinity variants (with the WT-NY-ESO structure shown in green for reference). 
Colour mapping is performed from blue to white to red with blue indicating a favourable change 
and red indicating an unfavourable change for the affinity matured variant. Figures are divided 
to focus on the different regions of the TCR subjected to affinity maturation (CDR2α, CDR3α, 
CDR2β and CDR3β), and subdivided when mutations are not consistent between HA TCRs. 





The above observations are in contrast with the CDR3β mutations that appeared to have 
increased affinity largely through indirect effects, by increasing the favourability towards 
binding of the CDR1β loop residue E28. This improvement in E28 (seen only in TCRs 
with CDR3β loop mutations) is likely the result of increased preorganisation of E28 for 
binding through an increased strength hydrogen bond between the side chain carboxyl 
group and the backbone of residue V/L94 (average occupancy in WT and c49c50 
simulations is between 0.50-0.56, compared to c5c1, c58c62 and c58c61 where it is 
between 0.83-0.86).  
HLA residue Q155 showed an improvement in affinity for all NY-ESO affinity matured 
TCRs. This includes c5c1 and c49c50 that did not contain any CDR2α or CDR3β 
mutations, respectively, and are the loops responsible for engaging Q155 (see Figure 
36B+C+G), suggesting mutations in either loop (CDR2α or CDR3β) can improve the 
favourability of Q155 towards binding.  
Differences between the WT and HA Tax A6 TCRs all occurred on the CDR3β loop 
(A99M, G100S, G101A and R102Q), and prior structural analysis of the differences 
between the WT and HA complexes suggested the increased affinity to be due to an 
increased number of contacts between the TCR and pHLA.204 Mutations A99M and 
G100S were primarily responsible for the enhanced affinity (Figure 37A+B). In line with 
the prior structural characterisation, we see an increase in the total average number of 
contacts made between the TCR and the pHLA residues A149 and A150, which sit below 
the CDR3β loop residues A99M and G100S. Specifically, the total average number of H-
bonds formed to both A149 and A150 doubled from 0.4 to 0.8 for both residues (Table 
S6), alongside an increase in the total average number of vdWs contacts formed (Table 
S7).  
In the case of MEL5, a total of 19 mutations on 7 loops gave rise to the approximate 3x105 
fold increase in affinity, which was found to be primarily entropically driven.206 It is 
therefore unsurprising to see that alongside the reduced mobility of the affinity matured 
TCR (see Figure 34), several of the most favourable of mutations (CDRα D27F and 
CDRβ G52P and I53F) increased the total amount of buried hydrophobic matter at the 
binding interface (Figure 37A+E–G). This would likely be an entropically favourable 
process due to the expulsion of ordered water molecules that surround these hydrophobic 
or aromatic groups upon binding. The only mutation which showed a large negative effect 
on affinity was V93D CDRα, which can be rationalised in the same manner as seen for 
NY-ESO CDR3α G97D (Figure 36A+D). That is, D93 (V93 in the WT) forms an 
interloop hydrogen bond with K96R, which would help to rigidify the loop (as seen in 
Figure 37E+G) and therefore reduce the entropic penalty associated with binding.  
Interestingly, of the 19 mutations present in MEL5 α24β17, only 9 showed substantial 
energetic differences. Of the remaining 10 mutations, two positions (CRD1α R28L and 
CDR3β T100M) made direct and favourable interactions with the pHLA but were of 




direct contact with the pHLA and are instead likely to be involved in regulating the 
flexibility, stability and/or conformational sampling of the TCR. 
Two point mutations (D26Y on CDR1α and L98W on CDR3β) on DMF5 gave rise to an 
approximate 400-fold enhancement in affinity.47 Analysis of the effect of the D26Y 
mutation (Figure 37A+C) suggested that not only is the mutation itself directly 
favourable, but it also enhances the contribution to affinity of K66 on HLA, through the 
formation of a hydrogen bond between the two residues. The reduced favourability 
towards binding observed for the other nearby charged residues (peptide E1 and HLA 
E58) was likely a desolvation effect induced by the burial of the tyrosine side chain (which 
would displace some of the solvent around these charged residues). In the case of L98W 
(Figure 37A+D), the burial of a large hydrophobic residue unsurprisingly leads to 
increased contribution to the binding affinity. 
The affinity matured TCRs discussed here provide examples of mutations whose effects 
are largely localised around the mutation site, as well as mutations that cause significant 
effects on the contributions to binding affinity of residues distal from the mutation site. In 
some cases, such non-local effects can be induced due to a change in the long-range 
electrostatics (in particular when a charged residues is introduced/removed). 
Alternatively, if the motions of different CDR loops are strongly correlated to one another, 
one may see a change in the conformational sampling of both loops upon mutation of 
either loop. A prior study on the degree of coupling between the CDR loops in WT Tax 
A6 and DMF5 found Tax A6 CDR loops to be largely uncoupled, whereas the dynamics 
of DMF5 loops where strongly correlated to one another.123 This would help to rationalise 
the observation that energetic changes in Tax A6 are largely localised to the mutation 








Figure 37: Changes in Energetics at the TCR-pHLA Interface upon affinity 
maturation. (A) Per-residue ΔG differences between the three high affinity (HA) 
variants and their counterpart WT TCRs (i.e. ΔΔG), with positions mutated 
indicated throughout in red. ΔΔG differences between the WT and the given HA 
TCR pair are coloured blue if < –0.5 kcal mol–1 (favourable for HA) and red if > 
0.5 kcal mol–1 (unfavourable for HA), with all values in-between coloured green. 
(B–G) Colour mapping of the above per residue ΔΔG values onto all carbon atoms 
of the high affinity variants (with the WT-TCR structure shown in green for 
reference). Colour mapping is performed from blue to white to red with blue 
indicating a favourable change and red indicating an unfavourable change for the 
affinity matured variant respectively. Figures are divided up to show the regions 






Here, we used structural analysis, MD simulations and free energy calculations to 
extensively characterise four case studies of TCR affinity maturation. Our data 
demonstrates the limitations of contact analysis only (both on X-ray structures and from 
MD simulations) for rationalising changes in affinity for TCRs. In some cases (NY-ESO 
and MEL5), rigidification of the apo TCRs occurred upon affinity maturation, which led 
to an entropic advantage for binding affinity. However, this entropic advantage was by 
and large negated for by the HA TCRs binding the pHLA tighter than their counterpart 
WT TCRs do (entropically unfavoured). However, this effect was not significant in the 
other two cases. These results are in agreement with a large scale study on the relationship 
between antibody affinity maturation and rigidity, where in some cases rigidification was 
observed to help drive affinity enhancement, however it was by no means a global trend 
nor a requirement.247 Our free energy calculations reproduce the experimental affinity 
relationships for all four cases studies and demonstrate the energetic footprint was by and 
large preserved upon affinity maturation. This ability to accurately predict affinity 
hierarchies (which we are currently investigating in more detail) has promise in rational 
design efforts. We have demonstrated the use of atomistic simulation to characterise the 
energetic footprint of different HA TCRs, allowing comparison with the their thymically 
selected (WT) counterparts. This could be used to “filter” potential therapeutic candidates 
prior to extensive experimental specificity/safety validation. Our analysis indicates that 
the introduction and burial of large aromatic or hydrophobic side chains is a common 
occurrence in affinity maturation. This observation ties in with the fact that the most 
commonly identified residues in protein-protein binding sites are Trp, Met and Phe.248 
However, relying too much on hydrophobic interactions (vs. more directional and thus 
specific electrostatic interactions) to drive affinity enhancements could have negative 




Molecular Dynamics Simulations. Starting structures for all simulations were obtained 
from previously solved X-ray crystal structures from multiple studies(see Table S2+S3 
for a complete list of structures used).43–45,47,105,204–206,245,249 Molecular dynamics (MD) 
simulations of apo TCR structures were initiated from either the apo X-ray structure 
coordinates (if available) or from the TCR-pHLA bound structure if not. MolProbity75 
was used to determine the optimum tautomerisation states for all histidine residues 
(tautomerisation states used for all simulations are provided in Table S2+S3) and make 
any required Asn/Gln side chain flips (under the criteria of optimising the hydrogen 
bonding network). Protonation states of all titratable residues were assigned using PropKa 
3.0158 for pH 7, leading to all residues treated in their standard protonation states. The 





ensure consistency in tautomerisation and Asn/Gln flips where appropriate (i.e. same 
settings for the pHLA with different TCR variants). All structures were then solvated in 
an octahedral water box (retaining any crystal waters), ensuring all protein atoms were at 
least 10 Å away from the box boundary, with Na+ or Cl− counter ions added as necessary 
to ensure an overall neutral charge. MD simulations were performed using GPU 
accelerated Amber16222, with the ff14SB force field60 and TIP3P water model used to 
describe protein and water molecules respectively. All systems investigated were 
equilibrated to 300 K and 1 atm in the NPT ensemble (protocol described in the 
Supporting Information). Subsequently, production MD simulations were performed for 
100 ns each with 10 replicas performed per TCR-pHLA or apo-TCR (replicas assigned 
different random velocity vectors during equilibration procedure, see SI Methods). 
Production MD simulations were run using a 2 fs time step with the SHAKE algorithm 
applied to any bond containing a hydrogen atom. An 8 Å direct space non-bonded cut-off 
was applied with long range electrostatics evaluated using the particle mesh Ewald72 
algorithm. Temperature was regulated using Langevin temperature control (collision 
frequency of 1 ps−1), whilst pressure was controlled with a Berendsen barostat (setting the 
pressure relaxation time to 1 ps).  
MD Trajectory and Crystal Structure Analysis. Trajectory and X-ray structure analysis 
was primarily performed with CPPTRAJ160, using frames collected every 10 ps for 
analysis of MD simulations. H-bonds (including water bridged H-bonds) between atoms 
of the TCR and pHLA were defined as formed if the donor acceptor distance was within 
3.5 Å and the donor hydrogen acceptor angle was 180 ± 45° (crystal structure hydrogen 
atom positions were energy minimised prior to hydrogen bond analysis). If two heavy 
(non-hydrogen) atoms were within 4 Å of one another, a vdWs contact was considered to 
be formed between the two atoms. The total number of H-bonds and contacts formed 
between the TCR and a particular pHLA residue were then summed (see Tables S4–S7). 
RMSF and RMSD calculations were performed on the Cα atoms of the relevant residues 
with RMS fitting performed to a consistent set of TCR residues in the variable domains 
that are not highly flexible (N-terminal residues and all CDR loop residues were omitted, 
see SI Methods for further details), therefore ensuring a fair comparison between apo and 
pHLA bound simulations. RMSFs, H-bonds and vdWs contacts were calculated by 
discarding the first 10 ns of simulation time (meaning 10 replicas of 10-100 ns used) to 
allow for structure equilibration. Buried solvent accessible surface area (BSASA) was 
determined using the LCPO algorithm250, available with the “molsurf” command within 
CPPTRAJ160. The six TRangle terms and the TCR-pHLA docking angle was determined 
using the STCRDab webserver.251 The TRangle terms were then used to calculate the 
dTRangle as shown in Equation (14).
251  





Where 𝜃𝑖,𝑊𝑇  is the i
th TRangle parameter for the WT TCR and  𝜃𝑖,𝐻𝐴 is the i
th TRangle 
parameter for HA TCR. 
MMGBSA Methodology. The molecular mechanics generalized Born surface area 
(MMGBSA) method is a binding free energy calculation method which has been widely 
used to predict relative binding free energies.85,252 The approach uses a combination of 
MD simulations (for sampling to obtain many snapshots) and empirical calculations (on 
the obtained snapshots) to predict ΔGbind. It is important to note that these calculations 
should not be relied upon to provide accurate absolute binding free energies (i.e. ΔGbind), 
instead they can be used to provide relative binding free energies between similar ligands 
(i.e. ΔΔGbind) and identify residues that contribute (favourably or unfavourably) towards 
binding.85 In the MMGBSA approach, the different contributions to affinity are calculated 
individually and summed together to obtain ∆𝐺𝑏𝑖𝑛𝑑 (see Equation (Eq 7)). 
 ∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑒𝑙 + ∆𝐸𝑣𝑑𝑤 + ∆𝐺𝑝𝑜𝑙 + ∆𝐺𝑛𝑝𝑜𝑙 − 𝑇∆𝑆 (7) 
 
Where ∆𝐸𝑒𝑙 and ∆𝐸𝑣𝑑𝑤  are obtained directly from the molecular mechanics force field 
terms and describe the gas phase interaction energy. The polar and non-polar contributions 
to the solvation free energy are described by ∆𝐺𝑝𝑜𝑙 and ∆𝐺𝑛𝑝𝑜𝑙 respectively. ∆𝐺𝑝𝑜𝑙  is 
calculated by solving the GB equation, whilst ∆𝐺𝑛𝑝𝑜𝑙  is obtained from a function that 
assumes a linear relationship between the solvent accessible surface area and ∆𝐺𝑛𝑝𝑜𝑙. 
Finally, 𝑇∆𝑆 describes the change in entropy of the solute upon binding, most often 
calculated through normal mode analysis (NMA). NMA is computationally expensive 
(for large systems like TCR-pHLA) and also tends to produce large errors that do not 
improve the accuracy of the calculation.253 Furthermore, as it is not possible to decompose 
the results from NMA to a per-residue level, we did not perform NMA for our MMGBSA 
calculations. As shown in Figure 35, we were able to obtain good agreement with 
experiment without this term.  
MMGBSA Procedure. MMGBSA calculations were performed using 
MMPBSA.py.MPI39, using 25 independent (random velocity vectors assigned upon 
heating) 4 ns long MD simulations (separate to the above described 100 ns long 
simulations), starting from the X-ray structure, as this approach has previously been 
shown to provide converged and accurate relative binding free energies for both small 
molecule drugs91 and pHLA binding92. These simulations were run under the same 
conditions as the aforementioned longer timescale simulations (and are described in full 
in the SI). MD Simulations were performed on the complex structure only (often referred 
to as the single trajectory approach), with these simulations used to obtain snapshots of 
the free receptor and ligand. The single trajectory approximation is used throughout the 
literature, as it tends to significantly reduce the energetic noise and improve the 
predictability of the obtained results.84 From each replica, 300 equally spaced snapshots 
were taken from the last 3 ns of each MD simulation for MMGBSA calculations, giving 





= 8) solvation model and an implicit salt concentration of 150 mM. The obtained results 
were decomposed into their per-residue contributions to the total free energy, with the 
values obtained used to calculate the differences between the wild type (WT) and HA 
variants (as plotted in Figures Figure 36+Figure 37).  
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Supporting Information Methods 
 
MD Equilibration Procedure  
The following procedure was used to prepare all systems simulated for production MD 
simulations at 300 K and 1 atm. Furthermore, the equilibration protocol used is identical for 
both our “long” timescale (5 x 100 ns) and “short” time scale (25 x 4 ns) MD simulations. All 
dynamics steps applied the SHAKE algorithm to constrain all bonds containing hydrogen. 
Replicas simulations were initiated from the second heating step of the following protocol (with 
each replica therefore assigned different random velocity vectors at this stage).  
 
First hydrogens atoms and solvent molecules were energy minimised (using 500 steps of 
steepest descent followed by 500 steps of conjugate gradient minimisation). To prevent the 
movement of non-hydrogen and non-solvent atoms during the minimisation, 10 kcal mol−1 Å−1 
positional restraints were used to keep all heavy atoms fixed. Then the solvent was heated 
rapidly from 50 K to 300 K (NVT ensemble, 1 fs timestep) over the course of 200 ps, with the 
previously described restraints still maintained. The positional restraints were then replaced with 
5 kcal mol−1 Å−1 positional restraint on only the Cα carbon atoms and subjected to another round 
of energy minimisation (500 steps of steepest descent followed by 500 steps of conjugate 
gradient). Retaining these positional restraints, the system was heated from 25 K to 300 K over 
the course of 50 ps (NVT ensemble, 1 fs time step). Simulations were then performed in the 
NPT ensemble (1 atm, 300 K, 2 fs time step) by first gradually reducing the 5 kcal mol−1 Å−1 Cα 
carbon restraints over the course of 50 ps. This was done by reducing the restraint weight by 1 
kcal mol−1 Å−1 every 10 ps. The end structure from this run was then used as the starting 
structure for production MD simulations. Simulations performed in the NVT ensemble used 
Langevin temperature control (with a collision frequency of 1 ps−1) and used a simulation 
timestep of 1 fs. Simulations performed in the NPT ensemble again used Langevin temperature 
control (collision frequency of 1 ps−1) and a Berendsen barostat (1 ps pressure relaxation time). 
 
RMS Fitting Procedure 
To ensure fair comparison between the WT and HA TCR structures, RMS fitting (for RMSF 
calculations) was performed using the same set of residues in the TCR variable region. Residues 
excluded from the RMS fitting procedure were the first five N-terminal residues and all CDR 
loop residues (due to their high mobility, which would therefore provide a poor fit). Residues 
used for RMS fitting from Chain A were therefore: 6-22,33-46,55-65,73-94,103-113. Residues 
used for RMS fitting from Chain B were: 6-21,30-47,54-65,73-91,102-111. RMS fitting of MD 
simulation snapshots was first performed to the crystal structure, with this RMS fitted trajectory 
used to create an average structure. Following this, all snapshots were then re-fitted to the 





Supporting Information Tables 
 
Table S1: CDR loop mutations for all TCRs under investigation. Wild-type (WT) residues 
subject to mutations are in bold, whilst mutated residues in the affinity matured variants are 
underlined and coloured red.  

















































































Table S2. PDB IDs and histidine tautomerisation state assignments for all NY-ESO MD 
simulations.  
TCR-pHLA Systema HID Tautomerisation Statesb HIE Tautomerisation Statesc 
NY-ESO - WT 
PDB: 2BNR245 




HLA: 151, 188, 191, 192, 197, 263. 
β2m: 13, 31, 51, 84.  
CDRα: 112.  
CDRβ:  27, 45, 134, 164, 204. 
NY-ESO – c5c1 
PDB: 2PYE45 SAME AS WT SAME AS WT 
NY-ESO – c49c50 
PDB: 2F5343 SAME AS WT SAME AS WT 
NY-ESO - c58c62 
PDB: 2P5W45 SAME AS WT SAME AS WT 
NY-ESO - c58c61 
PDB: 2P5E45 SAME AS WT SAME AS WT 
a, All Apo-TCR simulations used the same tautomerisation states as those in the TCR-pHLA simulations.  
b, HID corresponds to a histidine residue which is singly protonated on its Nδ1 nitrogen. 





Table S3. PDB IDs and histidine tautomerisation state assignments for the MD simulations of 
the Tax A6, DMF5 and MEL5 WT and HA TCRs.  
TCR-pHLA Systema HID Tautomerisation Statesb HIE Tautomerisation Statesc 
DMF5 – WT 
PDB: 3QDG249 
HLA: 3, 70, 74, 93, 114, 151, 191, 
192, 260.   
β2m: 51.  
CDRα:   
CDRβ: 32, 50, 138, 168.  
HLA: 145, 188, 197, 263. 
  
β2m: 13, 31, 84.  
CDRα:  
CDRβ: 155, 208.  
DMF5 – YW 
PDB: 4L3E47 SAME AS WT SAME AS WT 
Tax A6 – WT 
PDB: 1AO7105 





HLA: 145, 151, 188, 191, 192, 260, 
263. 
β2m: 13,31, 51, 84.  
CDRα:  
CDRβ: 29, 47, 139, 156, 169, 209. 
Tax A6 – c134 
PDB: 4FTV204 SAME AS WT SAME AS WT 
MEL5 – WT 
PDB: 3HG144 




CDRβ: 5, 207.  
HLA: 93, 145, 151, 188, 191, 192, 
197, 260, 263.  
β2m: 13, 31, 51, 84.  
CDRα: 71. 
CDRβ: 137, 154, 167.  
MEL5 – α24β17 
PDB: 4JFF206 SAME AS WT SAME AS WT 
a, All Apo-TCR simulations used the same tautomerisation states as those in the TCR-pHLA simulations.  
b, HID corresponds to a histidine residue which is singly protonated on its Nδ1 nitrogen. 






















Table S4: Average number of vdWs contacts formed between the TCR to each pHLA residue for all NY-
ESO simulations. For each TCR-pHLA complex the 10 pHLA residues with the greatest number of 
contacts are coloured red, with their rank provided in brackets. 
 TCR-pHLA Complex 
Residue WT c5c1 c49c50 c58c62 c58c61 
HLA: 19 0.0 0.0 0.2 0.3 0.7 
HLA: 62 1.4 0.7 1.5 0.5 0.6 
HLA: 65 14.6 (4) 19.2 (3) 16.3 (4) 14.3 (4) 19.5 (3) 
HLA: 66 4.2 6.0 (9) 2.4 6.1 (9) 5.6 (10) 
HLA: 68 2.4 2.1 4.2 3.7 3.7 
HLA: 69 2.5 3.7 2.4 4.2 3.5 
HLA: 71 0.0 0.0 0.1 0.1 0.0 
HLA: 72 11.6 (6) 13.3 (4) 16.9 (3) 15.4 (3) 14.8 (4) 
HLA: 73 4.0 5.9 (10) 4.7 (10) 6.0 (10) 6.0 (9) 
HLA: 75 1.7 0.5 3.6 1.8 2.0 
HLA: 76 0.8 1.9 1.4 1.9 1.9 
HLA: 146 0.1 0.0 0.0 0.2 0.1 
HLA: 149 0.0 0.0 0.0 0.3 0.2 
HLA: 150 7.1 (9) 5.0 4.0 2.4 2.4 
HLA: 151 4.9 (10) 5.0 6.5 (8) 5.2 4.8 
HLA: 152 0.3 0.0 0.0 0.0 0.0 
HLA: 154 2.1 2.1 1.4 4.0 4.9 
HLA: 155 16.4 (3) 11.9 (6) 11.5 (6) 9.9 (6) 11.7 (6) 
HLA: 158 0.0 0.0 0.7 0.4 0.6 
HLA: 163 0.0 1.0 0.0 0.7 1.0 
Pep: 4 21.1 (2) 27.8 (2) 21.5 (2) 28.3 (2) 28.0 (2) 
Pep: 5 44.4 (1) 42.7 (1) 44.4 (1) 42.4 (1) 42.8 (1) 
Pep: 6 9.4 (7) 7.8 (7) 9.5 (7) 7.7 (7) 7.7 (7) 
Pep: 7 7.1 (8) 7.4 (8) 6.2 (9) 7.3 (8) 6.7 (8) 


















Table S5: Average number of hydrogen bonds formed between the TCR to each pHLA residue for all 
NY-ESO simulations. For each TCR-pHLA complex the 10 pHLA residues with the greatest number of 





 TCR-pHLA Complex 
Residue WT c5c1 c49c50 c58c62 c58c61 
HLA: 19 0.1 0.3 0.2 0.2 0.4 
HLA: 43 0.0 0.0 0.1 0.1 0.0 
HLA: 58 0.0 0.1 0.0 0.1 0.1 
HLA: 61 0.0 0.0 0.1 0.0 0.1 
HLA: 65 2.3 (2) 3.2 (1) 2.3 (2) 2.9 (1) 3.2 (1) 
HLA: 66 0.5 0.7 0.4 0.7 (10) 0.7 
HLA: 68 0.4 0.6 0.5 (10) 0.4 0.6 
HLA: 70 0.0 0.1 0.0 0.0 0.1 
HLA: 71 0.0 0.0 0.0 0.1 0.0 
HLA: 72 1.7 (4) 1.1 (8) 2.2 (3) 1.0 (7) 0.9 (8) 
HLA: 73 0.6 1.6 (5) 0.7 (9) 1.6 (4) 1.6 (5) 
HLA: 75 0.4 0.3 0.4 0.3 0.2 
HLA: 80 0.0 0.0 0.0 0.1 0.0 
HLA: 146 0.0 0.3 0.3 0.4 0.3 
HLA: 149 0.1 0.1 0.1 0.2 0.2 
HLA: 150 1.5 (6) 1.1 (7) 0.2 0.5 0.6 
HLA: 151 1.0 (8) 0.8 0.3 0.7 0.7 (10) 
HLA: 154 0.2 0.3 0.0 0.4 0.4 
HLA: 155 2.1 (3) 1.8 (4) 1.2 (5) 1.2 (5) 1.6 (4) 
HLA: 163 0.1 0.0 0.0 0.0 0.0 
Pep: 1 0.0 0.1 0.0 0.0 0.1 
Pep: 4 1.1 (7) 1.4 (6) 1.0 (6) 1.2 (6) 1.3 (6) 
Pep: 5 1.0 (9) 0.9 (10) 0.9 (8) 0.9 (9) 0.9 (9) 
Pep: 6 1.7 (5) 1.8 (3) 1.8 (4) 1.8 (3) 1.8 (3) 
Pep: 7 1.0 (10) 1.0 (9) 1.0 (7) 1.0 (8) 1.0 (7) 









Table S6: Average number of hydrogen bonds formed between the TCR to each pHLA residue for our 
simulations of WT and HA DMF5, MEL5 and Tax A6. For each TCR-pHLA complex the 10 pHLA 
residues with the greatest number of contacts are coloured red, with their rank provided in brackets.   
TCR-pHLA Complex 
 DMF5 MEL5 Tax A6 
Residue WT YW WT α24β17 WT c134 
HLA: 19 0.0 0.0 0.1 0.0 0.0 0.0 
HLA: 43 0.0 0.0 0.2 0.0 0.0 0.0 
HLA: 55 1.1 (5) 1.0 (5) 0.0 0.0 0.9 (9) 1.1 (8) 
HLA: 58 1.0 (6) 0.3 0.1 0.8 0.5 0.5 
HLA: 59 0.2 0.0 0.0 0.0 0.0 0.0 
HLA: 61 0.3 0.1 0.1 0.3 0.0 0.0 
HLA: 62 0.1 0.0 0.0 0.0 0.0 0.0 
HLA: 65 1.6 (3) 1.5 (4) 2.1 (1) 2.0 (2) 2.5 (1) 2.6 (1) 
HLA: 66 0.9 (9) 0.6 (10) 0.0 0.7 1.0 (7) 1.3 (5) 
HLA: 68 0.0 0.1 0.5 (8) 1.0 (9) 0.0 0.0 
HLA: 72 2.4 (1) 2.0 (1) 1.5 (2) 2.7 (1) 0.2 0.2 
HLA: 73 0.2 0.1 0.6 (7) 0.0 0.0 0.0 
HLA: 75 0.5 0.5 0.2 0.0 0.0 0.0 
HLA: 145 0.1 0.0 0.0 0.0 0.0 0.0 
HLA: 146 0.2 0.1 0.0 0.0 0.0 0.0 
HLA: 149 0.2 0.0 0.0 0.0 0.4 0.2 
HLA: 150 0.1 0.0 0.0 0.1 0.4 0.8 
HLA: 151 0.1 0.0 0.0 0.2 0.4 0.8 
HLA: 154 0.0 0.1 0.3 1.3 (6) 0.3 0.2 
HLA: 155 0.9 (7) 0.7 (8) 0.5 (9) 0.8 (10) 1.0 (6) 1.5 (4) 
HLA: 157 0.0 0.0 0.0 1.1 (8) 0.1 0.1 
HLA: 158 0.2 0.2 0.0 0.2 0.3 0.2 
HLA: 161 0.1 0.1 0.0 1.1 (7) 0.2 0.3 
HLA: 162 0.0 0.0 0.0 0.1 0.0 0.0 
HLA: 163 0.5 0.5 0.4 (10) 0.6 0.9 (8) 0.9 (10) 
HLA: 166 0.8  0.4 0.9 0.1 1.4 (4) 1.1 (9) 
HLA: 167 0.3 0.4 0.0 0.5 0.5 0.5 
HLA: 170 0.0 0.1 0.4 0.0 0.1 0.1 
Pep: 1 1.8 (2) 1.7 (3) 0.6 (6) 1.5 (4) 0.0 0.0 
Pep: 2 0.5 0.7 (9) 0.2 0.4 0.7 0.5 
Pep: 3 0.1 0.0 0.0 0.0 0.0 0.0 
Pep: 4 1.3 (4) 1.8 (2) 1.2 (3) 1.4 (5) 2.2 (3) 1.9 (3) 
Pep: 5 0.1 0.2 0.1 0.0 1.1 (5) 1.1 (7) 
Pep: 6 0.0 0.1 0.2 0.1 0.9 (10) 1.2 (6) 
Pep: 7 0.8 (10) 0.7 (7) 0.9 (5) 1.6 (3) 2.3 (2) 2.1 (2) 







Table S7: Average number of vdWs contacts formed between the TCR to each pHLA residue for our 
simulations of WT and HA DMF5, MEL5 and Tax A6. For each TCR-pHLA complex the 10 pHLA 
residues with the greatest number of contacts are coloured red, with their rank provided in brackets.  
TCR-pHLA Complex 
 DMF5 MEL5 Tax A6 
Residue WT YW WT α24β17 WT c134 
HLA: 43 0.0 0.0 0.4 0.0 0.0 0.0 
HLA: 55 3.0 3.5 0.0 0.0 2.7 3.6 
HLA: 56 0.0 0.2 0.0 0.0 0.0 0.0 
HLA: 58 0.1 2.9 0.3 2.0 0.1 0.5 
HLA: 59 1.2 2.3 0.0 0.3 0.4 1.0 
HLA: 61 0.0 0.9 0.0 0.0 0.0 0.0 
HLA: 62 0.0 3.2 1.6 0.2 0.0 0.0 
HLA: 63 0.0 0.3 0.0 0.0 0.0 0.0 
HLA: 65 7.1 (4) 8.5 (3) 13.9 (1) 19.9 (2) 17.1 (3) 17.1 (2) 
HLA: 66 4.1 (9) 8.3 (4) 1.8 4.0 8.3 (6) 9.1 (6) 
HLA: 68 0.0 0.0 2.2 1.6 2.7 2.8 
HLA: 69 5.6 (7) 7.1 (5) 3.6 (9) 3.1 5.7 (8) 5.7 (9) 
HLA: 70 0.1 0.5 2.3 1.4 0.0 0.0 
HLA: 72 10.4 (1) 12.2 (1) 8.0 (4) 25.4 (1) 2.2 2.5 
HLA: 73 1.3 1.5 2.9 1.7 2.2 2.1 
HLA: 75 1.3 1.7 0.9 6.6 (8) 0.0 0.0 
HLA: 76 1.7 2.1 1.3 4.2 (10) 0.0 0.0 
HLA: 145 0.0 0.1 0.0 0.0 0.0 0.0 
HLA: 146 0.0 0.8 0.0 0.0 0.0 0.0 
HLA: 149 0.0 0.7 0.0 0.0 0.8 0.2 
HLA: 150 0.8 4.8 (9) 0.0 0.1 5.1 (9) 8.4 (8) 
HLA: 151 0.2 0.0 1.0 0.7 3.5 4.6 (10) 
HLA: 152 0.0 0.0 0.0 0.0 0.5 1.2 
HLA: 154 0.1 0.6 4.2 (8) 6.3 (9) 1.2 1.9 
HLA: 155 7.6 (3) 5.8 (8) 9.2 (2) 10.4 (3) 13.3 (4) 12.9 (4) 
HLA: 157 0.0 0.0 0.0 8.0 (6) 0.5 0.1 
HLA: 158 2.1 1.8 1.4 2.2 2.3 1.6 
HLA: 159 1.9 1.6 0.7 1.4 0.9 0.8 
HLA: 161 0.0 0.0 0.0 2.2 0.0 0.1 
HLA: 162 0.0 0.0 0.0 0.3 0.0 0.1 
HLA: 163 1.7 2.0 3.5 (10) 2.8 2.4 2.6 
HLA: 166 1.0 1.8 4.3 (7) 0.4 4.2 (10) 3.6 
HLA: 167 1.4 2.7 0.3 4.2 2.2 2.0 
HLA: 170 0.7 1.7 1.5 0.7 2.1 1.0 
Pep: 1 6.5 (5) 6.1 (6) 0.8 4.2 2.8 3.2 
Pep: 2 2.3 2.0 0.4 1.2 1.6 1.2 
Pep: 3 1.7 1.7 1.2 2.1 0.2 0.0 
Pep: 4 8.4 (2) 9.1 (2) 5.5 (5) 8.7 (5) 9.5 (5) 8.9 (7) 




Pep: 6 1.9 0.1 2.3 2.9 3.0 2.7 
Pep: 7 4.2 (8) 4.3 (10) 5.1 (6) 9.3 (4) 7.4 (7) 9.3 (5) 
Pep: 8 2.7 0.0 1.8 3.0 17.2 (2) 17.1 (3) 

































Supporting Information Figures 
 
 
Figure S1: Cα RMSF values for all Apo (A + B) and pHLA bound (C + D) NY-ESO 
TCRs simulated. The α-chain RMSFs for the apo and pHLA bound simulations are plotted 
in panels A and C respectively, whilst the β-chain RMSFs for the apo and pHLA bound 
simulations are plotted in panels B and D respectively. Below each plot is the p-value 
obtained from a two-sample t-test between the WT and each affinity matured NY-ESO 
TCR (following the same colour scheme). A red dotted line is plotted at a p-value of 0.05, 






Figure S2: Cα RMSF values for both Apo (A + B) and pHLA bound (C + D) DMF5 
TCRs simulated. The α-chain RMSFs for the apo and pHLA bound simulations are plotted 
in panels A and C respectively, whilst the β-chain RMSFs for the apo and pHLA bound 
simulations are plotted in panels B and D respectively. Below each plot is the p-value 
obtained from a two-sample t-test between the WT and the high affinity DMF5 TCRs. A 







Figure S3: Cα RMSF values for both Apo (A + B) and pHLA bound (C + D) MEL5 
TCRs simulated. The α-chain RMSFs for the apo and pHLA bound simulations are plotted 
in panels A and C respectively, whilst the β-chain RMSFs for the apo and pHLA bound 
simulations are plotted in panels B and D respectively. Below each plot is the p-value 
obtained from a two-sample t-test between the WT and the high affinity DMF5 TCRs. A 







Figure S4: Cα RMSF values for both Apo (A + B) and pHLA bound (C + D) Tax A6 
TCRs simulated. The α-chain RMSFs for the apo and pHLA bound simulations are plotted 
in panels A and C respectively, whilst the β-chain RMSFs for the apo and pHLA bound 
simulations are plotted in panels B and D respectively. Below each plot is the p-value 
obtained from a two-sample t-test between the WT and the high affinity DMF5 TCRs. A 







Figure S5: Changes in the energetic footprint between the WT and affinity matured 
TCRs. For all TCR-pHLA complexes, the HLA (top) and TCR (bottom) structures are 
plotted as surfaces with the peptide shown in both structures as sticks. All plots are colour 
mapped according to the MMGBSA per residue decomposition results, going from blue 
(favours binding) to white (no preference) to red (disfavours binding). Separate scaling is 
used for each of the 4 sets of TCRs. All pHLA and TCR structures are shown in the same 
orientation, such that the peptide N-terminus is left and the C-terminus right. Several 
mutations sites are indicated on the high affinity variants (purple labels: CDRα mutations; 







Conclusions and Future Work  
 
The work from this thesis focussed on gaining fundamental insights into TCRs and their 
therapeutic targets, pHLA molecules. Chapter 3 demonstrated how different peptide 
cargo can tune the molecular flexibility of the entire HLA molecule, including areas distal 
from the peptide binding site. Whilst it is clear that different peptides will modulate the 
TCR recognition process both directly (through peptide-TCR interactions) and indirectly 
(through HLA-TCR interactions), how different peptide cargo could alter the interaction 
between the pHLA and the CD8 co-receptor (required for an immune response, see 
Section 1.3) remains an open question. Furthermore, HLA Class I (or II) pathways 
involve many protein-protein interactions prior to presentation on the cell surface8,9, 
meaning the peptide cargo could play an important role in tuning these interactions as 
well. One should also consider how impactful these changes in peptide cargo are on the 
overall conformational dynamics of the pHLA molecule, and therefore how impactful it 
is in modulating the pHLA molecules interactions with other proteins. For example, 
although we have identified several statically significant differences in flexibility for 
regions of the HLA (which are peptide cargo dependent), the effect/impact of these 
differences may still be too subtle to play an important role in the regulation of 
immunological interactions/pathways. Only through further experimentation and 
simulation could one attempt to determine the significance/role of peptide dependant 
tuning of the pHLA molecule in immunological pathways.  
To further the work outlined in Chapter 3, an increased understanding of how the peptide 
communicates conformational changes to the HLA could be achieved by studying many 
more peptides in increased detail. Our MD simulations of six relatively different peptide 
sequences (as much of the variation in the sequences was in the N and C-termini, which 
are the residues which primarily contact the HLA, see Section 1.4) consistently observed 
the C-terminal peptide residues to be primarily responsible for communication with the 
HLA. One could therefore ask if the C-terminal residues of all peptides that binds the 
HLA isoform studied in Chapter 3 are consistently responsible for the majority of the 
communication between the peptide and HLA, and if so whether this extends to all HLA 
Class I molecules. Regardless of whether the above questions are true or not, studies of 
this nature would help to inform on how to tune the conformational dynamics of the pHLA 
molecule. This could be of use in vaccine design using peptide-mimetics.254 One could 
argue that it would be most beneficial to replicate as best as possible the dynamics induced 
by the antigenic peptide onto the HLA with the peptide-mimetic. Follow on simulations 
should also consider including a lipid bilayer into the MD simulations, in order to be 





As stated above, the impact of peptide dependant tuning of the pHLA molecules 
conformational dynamics has yet to be explored. One such area that could be focussed on 
is how different peptide cargo modulate the strength of the interaction between the pHLA 
and the CD8 co-receptor (which binds the pHLA molecule far from the peptide binding 
site). A study like this would also have the benefit of providing insight into the 
conformational transitions that occur to produce an immune response from the T-cell. 
However, studying the formation of a productive immune synapse (interface between T-
cell and APC) does pose several technical challenges, with the first being correctly 
representing the biologically relevant state(s). Prior studies have shown multiple 
simultaneous TCR-pHLA binding events are required to occur between a given T-cell and 
the antigen presenting cell (APC) in order for an immune response to actually be 
triggered.168 These studies have found at least three simultaneous TCR-pHLA complexes 
needed to be formed (with higher numbers possible and perhaps even more common).168 
This could therefore make simulating the biologically relevant state(s) challenging. A 
previous MD simulation study consisting of just one TCR-pHLA complex, one CD8 co-
receptor and two lipid bilayers consisted of 329,265 atoms,255 which is already large by 
all-atom MD simulation standards. Given the likely requirement to simulate potentially 
multiple copies of the TCR-pHLA and CD8 co-receptors, this number will become even 
larger. Whilst simulations of this size are possible with all-atom MD (a recent 1 µs long 
all-atom study on a HIV capsid containing over 64 million atoms demonstrates this256), 
one would likely need specialist equipment for (reasonably long) simulations of this size 
which are not currently available to most academic labs. One could instead consider 
applying a coarse-grained force field to make the project more tractable. The loss of 
accuracy when switching from all-atom MD to coarse-grained models is likely to be 
problematic, especially as protein-protein interactions are known to be poorly described 
by coarse-grained models (protein-protein interactions tend to be over stabilised and end 
up aggregating with one another).257 
A potentially better suited part of the immune system to study is the process known as 
“peptide editing”, whereby chaperones are used to load peptides onto HLA Class I 
molecules before they are transported to the cell surface.258 Recently solved crystal 
structures of the chaperone TAP-binding protein-related (TAPBPR) in complex with 
pHLA molecules demonstrates they play an active role in both dislodging low affinity 
peptides and loading high affinity peptides onto the HLA.149,259 TAPBPR inserts a loop 
into the HLA F-pocket (C-terminal binding site of the peptide), which can dislodge low 
affinity peptides (for the given HLA) and be dislodged by high affinity peptides (for the 
given HLA).  Alike HLA Class I molecules, TAPBPR is also membrane bound and binds 
to a large portion of the pHLA, including regions distal from the peptide binding groove. 
In Chapter 3 we found several of these regions show significantly different flexibility 
dependant on the peptide cargo, making this protein-protein interaction a good system to 
study in order to evaluate the impact of different peptide cargo. Furthermore, whilst 
crystal structures have captured snapshots of this exchange mechanism, MD simulations 




changes occur, further enhancing our fundamental understanding of this immunological 
mechanism. These large scale conformational changes would be hard to study with 
“normal” MD simulations as they are likely to occur on the µs-ms timescale (making them 
very computationally expensive to sample with normal MD simulations). Enhanced 
sampling techniques such as Gaussian accelerated MD260 (GaMD) or Hamiltonian replica 
exchange261 (HREX) could therefore be used to accelerate the observation of rare events, 
making the project more feasible.  
Work in Chapters 4 and 5 focussed on determining engineering principles for generating 
high specificity and high affinity TCRs. In terms of specificity, TCRs that bind with a 
broad energetic footprint and make interactions with several peptide residues (particularly 
with the peptide side chains) tend to show increased specificity. Additionally, the affinity 
of TCRs can be enhanced by numerous mechanisms, with our findings suggesting that the 
burial of large hydrophobic or aromatic residues are commonly used to enhance affinity. 
The above observations are relatively straight forward to rationalise, and arguably of more 
importance is the validation of computational approaches that allow us to investigate these 
phenomena. Of particular note is the MMPB/GBSA decomposition procedure, which 
provides a measure of each residue’s “favourability” towards being in the bound vs 
unbound state. Care should be taken when interpreting the meaning of a “favourable” or 
“unfavourable” residue (in particular for the purpose of rational design). This is because 
whilst an individual residue may be determined by the decomposition to be unfavourable, 
it could have an overall positive impact on the binding affinity, by increasing the 
favourability towards binding for its neighbouring residues. Examples of this can be found 
in Chapter 5 (see Figure 30+Figure 31). For instance, the NY-ESO TCR mutation G97D 
was calculated to be unfavourable for that residue (likely due to desolvation of the charged 
side chain), but overall had a favourable effect on the binding affinity, by rigidifying the 
apo CDR3α loop and improving the quality of other CDR3α residues interactions with 
the pHLA. An alternative to decomposition analysis is computational alanine scanning, 
for which there are two versions available for the MMPB/GBSA approach (and more 
generally to most computational binding free energy calculation methods).39 In the first 
version, a whole new set of MD simulations are run on the alanine variant and 
MMPB/GBSA calculations are run on these new trajectories. In the second version, the 
side chain of the alanine variant is simply deleted from the previously performed WT MD 
simulations and MMPB/GBSA calculations are performed on these trajectories. Whilst 
both methods are slower than decomposition analysis (as only one MMPB/GBSA 
calculation is required for decomposition), the second alanine scanning version is notably 
faster than the first because it requires no additional MD simulations. All three methods 
ultimately provide different information and it is up to the end user to decide what is most 
relevant and most useful to them.  
Further, the MMPBSA calculations in Chapter 4 were able to rationalise the specificities 
of different TCRs or TCR-mimics, whilst the MMGBSA calculations performed in 
Chapter 5, showed how one could compare the energetic footprints of the WT and 





to predict the specificity of a given TCR towards its pHLA target, and therefore it’s 
potential use to filter which TCR variants are taken forward for experimental 
specificity/safety testing.   
The work in Chapter 5 highlighted the relatively common occurrence of large aromatic 
or hydrophobic side chains being buried into the binding site to enhance affinity, which 
is in line with observations that tryptophan, methionine and phenylalanine are the most 
commonly observed residues in protein-protein binding sites.248 If one wishes to take 
advantage of the hydrophobic effect (the entropically favourable expulsion of ordered 
water molecules at the binding interface to become “bulk-like” and therefore more 
disordered), computational calculations on the thermodynamics of water at the binding 
interface of the WT TCR-pHLA complex could be performed. Several such methods exist 
of differing levels of accuracy and speed (e.g. ordered from fastest/most approximate to 
slowest/most accurate: 3D-RISM262, GIST263 or Grand Canonical Monte Carlo264 
methods) and have been used extensively in small molecular drug discovery to rationalise 
quantitative structure–activity relationship models.265–267 The identification of 
unfavourable water binding sites could then lead one to perform experimental or 
computational mutagenesis studies on residues near to these regions (to form new contacts 
that are likely to lead to an increase in affinity as the water molecules they replace are 
relatively unstable). Further, favourable and highly ordered water molecules bound to the 
pHLA which currently do not contact the TCR are likely to be a good target for 
engineering a water bridged hydrogen-bond between the TCR and pHLA (because the 
entropic penalty associated with binding the water molecule has already been largely 
paid). Interestingly, a previous docking study on a TCR-pHLA complex showed an 
improved relationship with experimental affinity data by the inclusion of a water molecule 
that formed a bridged hydrogen bond.268  
Our simulations in Chapter 5 were able to reproduce the experimental affinity 
relationships observed between the WT and affinity matured variants. In work not shown 
in this thesis (as it is currently underway), we are testing the applicability of 
MMPB/GBSA calculations as a medium throughput screening approach for 
computational affinity maturation of TCRs. The amount of MD simulation time required 
(in Chapters 4 and 5 we use 25 x 4 ns per TCR-pHLA) for MMPB/GBSA calculations 
make it far too computationally expensive for high throughput screening. Instead, a 
docking approach such as those detailed in Section 1.8.1 would be far more suited for 
this. Following a docking calculations to predict higher affinity variants, the top X number 
of variants could be screened with MMPB/GBSA to reduce the number required to take 
forward experimentally (where X is a reasonably small number, say 30–100).  
Given the above sections on the possible applications of this work and the methods used, 
a suggested protocol for the use of computation towards TCR engineering is provided 
below. Ideally, at the beginning of the project an experimentally validated pHLA target 
along with a WT-TCR which binds to this pHLA will have been identified and crystallised 




combination of homology modelling and docking (perhaps with TCR specific docking 
algorithims52) could be used to generate the starting model for rational design. At this 
point, the WT-TCR-pHLA complex should be thoroughly characterised with both 
MMPB/GBSA decomposition analysis and water thermodynamics calculations. The 
information gleaned from these calculations can be used to suggest residues on the TCR 
that one should screen for beneficial mutations, with considerations towards both affinity 
and specificity (as outlined in Chapter 4). High throughput computational docking should 
now be performed on these residues to identify possible mutations that enhance the 
binding affinity. The water thermodynamics calculations used above could be combined 
with water placement algorithms269 to include highly energetically favourable water 
molecules as part of the receptor in these docking protocols. Following the identification 
of possible beneficial mutations, the top portion can be subjected to experimental testing 
or MMPB/GBSA calculations to re-rank the results and reduce the number of variants 
subjected to experimental testing. If MMPB/GBSA calculations are performed on the 
variants, this information can later be used to predict which variants are more likely to 
have a better specificity profile and should be prioritised for experimental 
specificity/safety validation (after confirming they are of high enough affinity). Several 
iterative rounds of computational mutagenesis and screening may need to be performed 
to obtain the target affinities.  
In conclusion, the work from this thesis has extensively characterised the TCR-pHLA 
interaction. This has provided a foundation for several areas of future work, in particular 






Appendix Chapter 1: Understanding 
the Role of Heat Capacity in Enzyme 
Catalysis  
 
The final two chapters included in this thesis are publications from collaborative projects 
produced during my PhD thesis. These publications are however not focussed on or 
around TCRs (instead enzymes). To allow for a more straightforward focus in my thesis, 
both of the following chapters have instead been included as appendices only.  
In this first chapter we used a combination of experiment and computation to gain insight 
into the heat capacity of catalysis (Δ𝐶𝑃
‡
), which is a thermodynamic parameter that can be 
incorporated into the Eyring equation to describe a non-linear relationship between 
temperature and enzyme activity that has been observed in several enzymes and cannot 
be explained by unfolding. Δ𝐶𝑃
‡
 is a measure of the change in the distribution and 
frequency of vibrational (and rotational and translational) modes between the ground and 
transition state. As isotope effects are driven by changes in the frequency of vibrational 
modes between isotopologues, we experimentally determined 𝛥𝐶𝑃
‡
 for a number of 
different substrate isotopologues using the model enzyme glucose dehydrogenase (GDH), 
which catalyses the oxidation of several sugars.   
We found small isotopic substitutions (which would have a direct effect on the value of 
ΔCP
‡
 on the order of a few j mol−1 K−1) were able to lead to large scale changes in 𝛥𝐶𝑃
‡
 on 
the kj mol−1 K−1 level. This would suggest small changes in substrate vibrational modes 
are able to give rise to relatively large changes in the distribution/magnitude of vibrational 
modes between the ground and transition state. Our QM cluster model of the enzyme 
active site predicted ~j mol−1 K−1 changes in ΔCP
‡
 upon isotopic substitution, suggesting 
the majority of the change ΔCP
‡
 is sourced from the remainder (not the active site) of the 
enzyme.  
My role in this project was to construct a QM cluster model of the enzyme reaction 
mechanism. This was used to 1) determine the chemical mechanism of the reaction (which 
we obtained to be stepwise with hydride transfer rate limiting, in agreement with the 
experimentally determined KIEs, and 2) simulate the effect of isotopic substitutions with 
the described cluster model, to predict changes in Δ𝐶𝑃
‡
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Uncovering the relationship between the change in heat 
capacity for enzyme catalysis and vibrational frequency 
through isotope effect studies  
Hannah BL Jones†Δ, Rory M Crean#†Δ, Christopher Matthews†, Anna B Troya†, Michael 
J Danson†, Steven D Bull‡, Vickery L Arcus§*, Marc W Van der Kamp%* and Christopher 
R Pudney†* 
†Department of Biology and Biochemistry, ‡Department of Chemistry, #Doctoral Training 
Centre in Sustainable Chemical Technologies, University of Bath, Bath BA2 7AY, United 
Kingdom 
§School of Science, Faculty of Science and Engineering, University of Waikato, Hamilton 
3240, New Zealand 
%School of Biochemistry, University of Bristol, Biomedical Sciences building, University 
Walk, Bristol BS8 1TD, United Kingdom. 
Abstract: Understanding how enzyme catalysis varies with temperature is key to 
understanding catalysis itself, and ultimately, how to tune temperature optima. 
Temperature-dependence studies inform on the change in heat capacity during the 
reaction, Δ𝐶𝑃
‡
,  and we have recently demonstrated that this can expose links between the 
protein free energy landscape and enzyme turnover. By quantifying Δ𝐶𝑃
‡
, we capture 
information on the changes to the distribution of vibrational frequencies during enzyme 
turnover. The primary experimental tool to probe the role of vibrational modes in a 
chemical/biological process is isotope effect measurements, since isotopic substitution 
primarily affects the frequency of vibrational modes at/local to the position of isotopic 
substitution.  We have monitored the temperature-dependence of a range of isotope effects 
on the turnover of a hyper-thermophilic glucose dehydrogenase. We find a progressive 
effect on the magnitude of Δ𝐶𝑃
‡
 with increasing isotopic substitution of D-glucose.  Our 
experimental findings, combined with molecular dynamics simulations and quantum 
mechanical calculations, demonstrate that Δ𝐶𝑃
‡
 is sensitive to isotopic substitution. The 
magnitude of the change in Δ𝐶𝑃
‡
 due to substrate isotopic substitution indicates that small 
changes in substrate vibrational modes are ‘translated’ into relatively large changes in the 
(distribution and/or magnitude of) enzyme vibrational modes along the reaction. 
Therefore, the data suggest that relatively small substrate isotopic changes are causing a 
significant change in the temperature-dependence of enzymatic rates. 
KEYWORDS Heat capacity, isotope effect, enzyme, catalysis, temperature-dependence  
Isotope effects are one of the most powerful tools to investigate chemical mechanism and 
the physical chemical underpinnings of catalysis.270 Enzyme mechanistic studies often 




specific steps in enzyme catalysis and to test the role of protein ‘dynamics’ in enzyme 
turnover.271–273 The power of isotope effects lies in the simplicity of their physical origin. 
That is, isotopic substitution decreases the frequency of all vibrational modes, but does 
not affect the electronic structure of the molecule.274 Therefore, where one observes an 
isotope effect, the physical chemical interpretation of the experimental observation is 
much less ambiguous compared to mutagenesis studies, for example. 
In enzymatic studies, the temperature-dependence of the KIE is often used to infer the 
presence or absence of protein motions that affect the rate of enzymatic turnover.275,276 
The microscopic interpretation of these studies is controversial (see e.g. ref. 277), but at 
least at a basic level these studies seem to validate the notion that protein motions can 
affect enzyme turnover (if not necessarily the catalytic step itself).  Recently, the potential 
role of protein ‘dynamical’ effects on the reaction catalyzed by dihydrofolate reductase 
(DHFR) or HIV-1 protease, have been  assessed based on simulations with mass 
modulated (isotopically substituted) enzymes.278–280 In both systems, a small contribution 
from these dynamical effects to reducing the free energy profile around the transition state 
of the order ~2 kJ mol-1 was found. These authors interpret this difference as arising from 
the coupling between the reaction coordinate and the degrees of freedom of the system. 
However, the major contributor to reducing the free energy barrier arises from 
electrostatic effects.271,281–283  In addition, Åqvist used simulation to reveal the molecular 
origin of entropic effects in catalysis with respect to temperature, and illustrated the 
importance of considering not just the immediate active site, but also remote parts of the 
protein (and surrounding solvent).284 We further point out that others have argued that fast 
(sub-picosecond), local active site protein modes play a role in transition state formation 
(and thereby catalysis).285 A further alternative view is that so-called protein dynamical 
effects are coupled to the reaction coordinate, but provide a small contribution to barrier 
reduction relative to, e.g., the electrostatic contribution via preorganisation.271,281–283  
Although not a catalytic ‘dynamical effect’, when strictly defined,286 differences in 
enzyme fluctuations (or vibrations) that cause a change in heat capacity along the reaction 
can affect the temperature-dependence of enzyme activity.287 Understanding this effect in 
detail may provide new tools to manipulate enzyme optimal temperatures. 
We have recently demonstrated how capturing information on the change in heat capacity 
for activation Δ𝐶𝑃
‡
, informs on differences in the distribution of frequencies of vibrational 
modes between the enzyme-substrate and enzyme-transition state complex.288,289 
Typically, the temperature-dependence of enzyme rate constants is fitted to the Eyring 
equation (Eq 15). 
 𝑘 = (𝑘B𝑇/ℎ)𝑒
∆𝑆‡/𝑅𝑒−∆𝐻
‡/𝑅𝑇 (Eq 15) 
 
This model assumes that ΔH‡ and ΔS‡ are temperature independent. However, if ΔH‡ and 
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incorporates temperature-dependence of ΔH‡ and ΔS‡, which we have termed 
















] (Eq 16) 
 
where T0 is an arbitrary reference temperature. Δ𝐶𝑃
‡
 is the difference in heat capacity 
between the ground and transition states. Δ𝐶𝑃
‡
 determines the change in ΔH‡ and ΔS‡ with 
temperature and thereby defines the non-linearity of the temperature-dependence of the 
Gibbs free energy difference between the ground state and the transition state (ΔG‡). 
Indeed, Roy et al. point to a temperature-dependent activation entropy as the source of 
non-linear temperature-dependence plots.277 Other models that move beyond (Eq 15 have 
been proposed, primarily relating to equilibria of different functional/non-functional 
states.292,293 Whilst we do not discount these models, it appears, based on the range of 
recently published work from different labs,287–289,291 that Eq 16 is useful and broadly 
accurate.  
We expect that the dominant contribution to Δ𝐶𝑃
‡
 in enzymes is the difference in 
distribution and frequency290,291 of the large number of vibrational modes of the molecule 
and its closely associated solvent molecules in the ground and transition states. 
Alternatively, a negative value of Δ𝐶𝑃
‡
 implies that <(δH)2> (the mean squared distribution 
of enthalpies) for the enzyme substrate complex is greater than <(δH)2> for the enzyme-
transition state complex at a given temperature.291 We suggest that the magnitude of Δ𝐶𝑃
‡
 
can therefore be used as a proxy for the changes in vibrational modes (distribution, 
frequency) during enzyme turnover.  
The origin of isotope effects lies in the difference in the frequency of vibrational modes 
between isotope changes. Observing a relationship between (i) increasing isotopic 
substitution of the substrate, (ii) an isotope effect on the rate of turnover, and (iii) Δ𝐶𝑃
‡
 
would suggest that the enzymatic Δ𝐶𝑃
‡
 is sensitive to (substrate) vibrational modes that 
affect the observed reaction rate. Bigeleisen considered the effect of isotopic substitution 
on heat capacity, though not for hydrogen.294 More recently, Tjahjono and Garland295 have 
directly measured the difference in apparent molar heat capacity, 𝐶𝑃
0, for a series of model 
compounds with different levels of deuterium substitution. As with other reports,296 the 
authors find that the deuterium isotope effect on 𝐶𝑃
0 was always positive, i.e. 𝐶𝑃
0 increases 
with the increasing number of deuterium substitutions (Nd) and that the relationship was 
essentially linear: 𝛥𝐶𝑃
0 (J mol-1 K-1) = 2.75Nd – 1.52. The increase in 𝐶𝑃
0 is attributed to 
the increased mass of the isotopologue and the concomitant decrease in frequencies of the 




In a recent appraisal of a range of previously published experimental enzyme systems,289 
we found that there was potentially an isotope effect on Δ𝐶𝑃
‡
. Longbotham et al297 recently 
performed a study exploring a range of isotope effects on labelling the flavin in a model 
flavoenzyme and found their data could only be adequately fitted using Eq 16. These 
authors find a small isotope effect on Δ𝐶𝑃
‡
 outside experimental error for some, but not 
all, labelling patterns. Based on these intriguing findings we are inspired to explore the 
potential for isotope effects combined with Eq 16 to inform on changes in enzyme 
vibrational modes along the chemical reaction coordinate and their relationship to 
temperature-dependence. Herein, we use a hyperthermophilic enzyme, Sulfolobus 
solfataricus glucose dehydrogenase (ssGDH) as a model system to explore the 
contribution of enzymatic isotope effects on heat capacity differences during the reaction. 
Our data provide an experimental link between the temperature-dependence of enzyme 
turnover and (low frequency) vibrational modes. Importantly, the results raise the 
question of how subtle localized changes (through isotopic substitutions in the substrate) 
can lead to a significant change in the enzymatic heat capacity (and thus <(δH)2>) during 
the reaction. 
Results and discussion 
 
Hydride transfer in ssGDH is rate determining. ssGDH is a promiscuous 
hyperthermophilic enzyme that reduces nicotinamide adenine dinucleotide (phosphate) 
(NAD(P)+), with a variety of sugars.298 Milburn et al299 solved the X-ray crystal structure 
with both NADP+ and glucose/xylose bound using a catalytically inactive variant (T41A). 
Notionally the reduction of the nicotinamide (C4) occurs as a hydride transfer from C1 of 
the sugar, concomitant with a proton transfer from the C1 hydroxyl (Scheme S1) to a 
water molecule or hydroxide ion coordinated by a Zn2+ ion. We have performed molecular 
dynamics simulations of ssGDH (Figure 38A) in complex with both glucose and xylose 
(four independent runs of 50 ns, with all four active sites occupied). From our MD 
simulations, consistent with the X-ray crystal structures, we find that the hydride donor-
acceptor (D-A) distance is very similar for glucose and xylose, but not identical, with the 
xylose D-A being ~0.2 Å longer (Figure 38B; Supporting information). Specifically, the 
averages are 2.77 +/- 0.287 Å and 2.93 +/- 0.310 Å; medians are 2.725 Å and 2.895 Å. 
Quantum chemical cluster calculations (Figure 38C–20G) on a 148 atom model of the 
active site of ssGDH in complex with glucose (Figure 38C) suggest a stepwise chemical 
mechanism, whereby proton abstraction from a Zn2+ coordinated hydroxide forms a stable 
alkoxide intermediate on the sugar C1 prior to hydride transfer. When a water molecule 
is modelled as coordinated to the Zn2+ ion (Figure 38C), the D-A distance is 2.49 Å, 
consistent with our MD simulations (above, Figure 38B). When instead a hydroxide ion 
is modelled as coordinated to the Zn2+ ion, the proton on the sugar C1 hydroxyl is readily 
abstracted upon geometry optimization (Figure 38D) to form a reactive intermediate, with 
the resulting anion stabilised by hydrogen bonding interactions to the now Zn2+ bound 





reduces further as the glucose and NADP+ rings pucker to form a transition state (Figure 
38F) with a predicted free energy barrier relative to the reactive intermediate of 32.6 kJ 
mol−1 at 298 K. In synchrony with the hydride transfer, the Zn2+ bound water rotates away 
from glucose, returning to its original position of hydrogen bonding with Q150 and the 
C2 hydroxyl of glucono-D-lactone. In order to compare the predicted and experimental 
activation energies, one must consider the initial deprotonation into the bulk milieu 
(Reactant to Reactive Intermediate; Figure 38D and E, respectively), which cannot be 
determined reliably with the cluster based approach due to the importance of 
inhomogeneous long range interactions in modulating pKa values.
300 Instead, one can 
subtract the hydride transfer barrier from the experimental barrier to obtain a predicted 
pKa of 7.2 (Full calculation details can be found in the Supporting Information), which is 
in good agreement with the experimental pH optimum of 8.301  Finally, we note that there 
is no obvious role for water in the rate determining step (deprotonated water acts as a base 
for proton abstraction, whereas the subsequent hydride transfer is rate limiting, see below) 
and so at least this route is not giving rise to a primary solvent isotope effect (see below). 
 
 
Figure 38: A, Representative structures of glucose (green) and xylose (blue) from our MD 
simulations demonstrating they have the same binding interface with NADP+. B, 
Normalized histograms (bin width 0.1 Å) of the hydrogen transfer distance of glucose and 
xylose from MD simulations of ssGDH. C, QM cluster model created of glucose in 
complex with NADP+, with asterisks indicating atoms fixed throughout the optimisation 
process.  (D–G) Reaction mechanism obtained from the QM model, starting from the 
reactant (D), to the deprotonated reactive intermediate (E), the transition state (F), and 




Our combined computational and kinetic data (discussed below) provide evidence for the 
mechanistic step observed from our kinetic data. The slightly larger D-A distance in the 
Michaelis complex for xylose versus glucose, calculated from MD simulations, correlates 
with a ~1.6-fold larger kcat value (kcat = 95 and 58 s
-1 at 90 °C; Figure 39) and a ~5-fold 
larger Km (Km = 2.5 ±0.3 and 0.5 ± 0.2 mM at 85 °C; Figure S1A and S1B) for glucose 
versus xylose, respectively. This magnitude increase in rate seems reasonable for a 
hydride transfer given a ~0.2 Å difference in D-A distance302,303 (Figure 38B) and implies 
that the observed rate is primarily capturing the hydride transfer step. Similarly, the 
difference in Km is likely reflective of the difference in binding geometry and bonding 
(discussed below). Our QM cluster calculations provide a reasonable mechanism in which 
a Zn2+ coordinated hydroxide ion can deprotonate the glucose C1 hydroxyl to form a 
reactive intermediate. The direct nature of the enzyme assay (NADP+ reduction to 
NADPH), our QM calculations and the observation of a significant primary kinetic 
isotope effect (KIE, see below) suggests that the kinetic data primarily reflect the hydride 
transfer step. 
 
Heat capacity changes during enzyme reaction.  
We have measured the temperature-dependence of kcat for both glucose and xylose, fitted 
to Eq 16, shown in Figure 39A+B. For both glucose and xylose, the temperature vs. 
ln(kcat) data are clearly curved and are therefore appropriately fitted to Eq 16 instead of 
Eq 15. ssGDH is extremely thermally stable301 and we do not find evidence for unfolding 
on the timescales of our assays at any temperature. To capture the curvature in 
temperature-dependence plots accurately, and to capture the experimental system at its 
natural operating temperature (77 °C)301, we have focused on the temperature range 60-





 = −3.9 ± 0.3 and −2.3 ± 0.6 kJ mol−1 K−1, for glucose and xylose, respectively. 
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Figure 39: The temperature-dependence of NADP+ reduction by glucose (A) and xylose 
(B). Solid and dashed lines show the fitted to Eq 16 for the protiated and deuterated 
Glucose/xylose (D1), respectively. (C), the resulting KIE extracted from the lnkcat (ln min
-
1) in panels A and B. The solid line is the modelled KIE based on the parameters extracted 





Potentially, the difference in Δ𝐶𝑃
‡
 between glucose and xylose could arise through a 
difference in the chemical structure of the sugars, i.e. the additional CH2OH group of 
glucose. For example, the hydroxyl of the hydroxymethyl group can form hydrogen 
bonding interactions with either E114 or H297. This additional interaction may cause a 
general rigidification of the glucose and the active site, and thus decrease the absolute 
heat capacity of the ground and transition state. We cannot, however, confidently project 
how this would change Δ𝐶𝑃
‡
 (i.e. how the heat capacity of the ground state is affected 
differently from the heat capacity of the transition state), and thus cannot assign the 
physical origin of the observed differences in Δ𝐶𝑃
‡
 between glucose and xylose. 
Change in 𝜟𝑪𝑷
‡
 with substrate isotopic substitutions.  
To explore the relation between Δ𝐶𝑃
‡
 and substrate vibrational states, we determine the 
effects of substrate isotope substitutions on Δ𝐶𝑃
‡
 for sugar dehydrogenation by ssGDH. 
Figure 39A+B show the temperature-dependence of the primary kinetic isotope effect (1° 
KIE) for hydride transfer for both glucose and xylose using D-glucose (D1) and D-xylose 
(D1), respectively. For both sugars, the KIE is temperature-dependent (Figure 39C) and 
similar in magnitude (~2 – 2.5). Despite the similar magnitude of the KIE for both sugars, 
the isotope effect (IE) on the magnitude of Δ𝐶𝑃
‡
 is significantly different. The 1° IE on 
Δ𝐶𝑃
‡
 is very large for xylose [D-Xylose (D1)], bringing the Δ𝐶𝑃
‡
 value to ~0 within error 
(ΔΔ𝐶𝑃
‡
 = 4.9 ± 1.8 kJ mol−1 K−1). However, for glucose the 1° IE is smaller: D-glucose 
(D1) Δ𝐶𝑃
‡
 = −1.6 ± 0.6 kJ mol−1 K−1 (ΔΔ𝐶𝑃
‡
 = 2.3 ± 0.9 kJ mol−1 K−1). We note that this 
trend in the data is recapitulated when omitting ‘outlier’ data points (Figure S2). 
Moreover, these data do not appear to be due to significant differences in the structure or 
bonding of the reactive complex, since the Km values are the same within error for the 
protiated and deuterated substrate, Km = 3.2 ± 0.4 and 0.7 ± 0.1 mM at 85 °C c.f. Km = 2.5 
±0.3 and 0.5 ± 0.2 mM at 85 °C for glucose versus xylose, respectively. The magnitude 
of ΔΔ𝐶𝑃
‡
 for both xylose and glucose is surprising, as these differences are much larger 
than can be expected from effects on (substrate) heat-capacity for isotopic substitutions 
alone (discussed below). It indicates some (unknown) interaction between the reacting 
species and the enzyme enthalpy distribution that can be perturbed by isotopic 
substitution. 
As discussed previously, the difference in Δ𝐶𝑃
‡
 between glucose and xylose could arise 
through a difference in the sugar-enzyme interactions. However, isotope effects arise from 
differences in the frequency of vibrational modes,274 and not from changes in electronic 
structure that can lead to additional interactions. At a phenomenological level, our data 
therefore provide evidence that Δ𝐶𝑃
‡
 can be significantly perturbed by the frequency of 
bond vibrations in the reacting species. Figure 39C shows the KIE as a curve resulting 




The temperature-dependence of the KIE for both glucose and xylose show a qualitatively 
similar relationship; curvature with a maximum at 346 and 343 K, respectively. Typically, 
one observes a decrease in the magnitude of the KIE with respect to temperature when 
fitting data using the Eying/Arrhenius equation (as shown in Figure S3). Figure 40 shows 
a numerical model of the data shown in Figure 39C (using Eq 16), where the magnitude 
of Δ𝐶𝑃
‡
 for the isotopolgue is varied to explore a range of ΔΔ𝐶𝑃
‡
 values and the resulting 
effect on the KIE. From this model, we find that the curvature in the KIE plots is a direct 
result of the isotope effect on Δ𝐶𝑃
‡
. That is, as ΔΔ𝐶𝑃
‡
 tends towards zero (no isotope effect 
on Δ𝐶𝑃
‡
), the KIE plot will become ‘normal’, showing a decrease in magnitude with 
increasing temperature (Figure 22). These data show that a consequence of any significant 
isotope effect on Δ𝐶𝑃
‡
 is that the KIE will tend towards unity and this is also true for all 
temperature-dependent KIEs fitted using e.g. Eq 16. The difference when accounting for 
plot curvature is that the KIE will approach unity at both low and high temperatures. It is 
therefore not surprising that both sugars show a KIE that tends towards 1 at low and high 
temperatures and this will be the case for all isotope effects on Δ𝐶𝑃
‡
. 
Effect of increasing isotopic substitution on 𝛥𝐶𝑃
‡
.  
To explore the relationship between substrate vibrational modes and Δ𝐶𝑃
‡
 further, we use 
glucose to find if there is an isotopic mass dependence on the magnitude of Δ𝐶𝑃
‡
. We have 
increased the isotopic substitution of glucose using both per-deuterated glucose and in 
combination with deuterium oxide (D2O) and monitored the temperature-dependence of 
kcat as shown in Figure 41A. The temperature-dependence of the KIE is shown in Figure 
23B with the corresponding labelled structures shown in Figure 41D. Given that the 
ssGDH mechanism involves a concomitant hydride and proton transfer (discussed above 
 
Figure 40: Numerical model showing how the magnitude of the glucose 1° KIE versus 
temperature is affected by differences in the isotope effect on Δ𝐶𝑃
‡
. ΔH‡ and ΔS‡ values 





and Figure 38C-G), we have essentially two possible 1° KIEs for the hydride (1𝐻
o ) and 
proton (1𝑃
o) transfer. However, we note that our combined experimental and 
computational evidence above suggests that the proton transfer is fast relative to the 
hydride transfer, indicating that there would be no primary KIE for proton transfer and 
the experimental assay thus essentially captures the hydride transfer step. 
Labelling of sites distal to the transferred hydride are a secondary (2°) KIE. In the present 
case, this 2° KIE will be composed of many microscopic 2° KIEs for each labelled 
position (shown in green in Figure 41D). Finally, to label the exchangeable OH groups 
we have performed our experiments in D2O and this will lead to deuteration of all 
exchangeable protons (including amino acid side chains) that are immediately solvent 
accessible. Note that the enzyme itself is not incubated in D2O, only the substrate and so 
the enzyme deuteration occurs only on the timescale of the steady-state assay (~1 min), 
see Materials and Methods. The resulting kinetic parameters are given in Table 6 and for 
the substrate isotope effects. 
One expects an increase in mass of the substrate to alter the frequency of the C-H stretch 
in both the ground and transition state, but whether the expected change still manifests in 
the presence of the active site amino acids is not obvious. Therefore, we have performed 
frequency calculations on the stationary points obtained from the above cluster model 
(Figure 38C), for each of the isotopically substituted states shown in Figure 41 and S1. 
The resulting frequencies are given in Table S1. We find a large decrease in stretching 
frequencies of both the TS and ground state on deuteration of the transferred hydride. On 
additional isotopic substitution there is generally a small decrease in the C-H stretching 
Table 6. Kinetic parameters extracted from fits of Eq 15 and Eq 16 to the temperature-
dependence data shown in Figure 39A. 
 ΔH‡  



















76.0 ± 2.3 1.33 ± 0.01 -3.8 ± 0.5 − − − − 
D1 78.0 ± 2.1 1.33 ± 0.01 -1.6 ± 0.5 2.1 ± 0.6 2.8 2.0 ± 4.4 1.6 ± 11.7 
D5 86.1 ± 2.5 1.35 ± 0.01 -0.6 ± 0.5 4.0 ± 1.2 0.9 10.1 ± 4.8 7.2 ± 10.6 
D7 80.4 ± 2.0 1.34 ± 0.01 0.0 ± 0.5 2.4 ± 0.9 2.7 4.4 ± 4.4 3.8 ± 9.5 
D12 80.4 ± 1.5 1.33 ± 0.01 0.3 ± 0.4 3.7 ± 1.1 2.3 4.4 ± 4.4 0.9 ± 9.5 
a, Data at 348 K. b, from fits to Eq 16 (MMRT) at 348 K. c, From fits to Eq 15 (Eyring equation). d, 





frequency for both the ground state and the TS. Again, one expects small changes in 
frequency on increasing mass through isotopic substitution and our calculations suggest 
this expected trend is preserved when the first shell of protein amino acids is also present 
(as in Figure 38C). It is interesting to note that where the amino acids are deuterated 
(solvent exchangeable positions as with our experiments conducted in D2O), the 
frequencies show an additional and significant effect on the calculated frequencies in the 
order of ~1 cm-1. We would stress that clearly elucidating the relationship between the 
change in frequencies at the ground/TS, the protein and ΔΔ𝐶𝑃
‡
 would require very 
extensive (QM/MM) simulation studies. 
There is a significant effect of increased isotope substitution on both the magnitude of the 
observed rate but also the magnitude of Δ𝐶𝑃
‡
 (Figure 41A and Table 6). From Figure 
41B, the KIE increases with increasing isotopic substitution, but not in a linear fashion. 
The absolute magnitude of the KIE depends on the temperature at which the value is 
reported, the different contributions from substitutions at different positions and the fact 
that the temperature-dependence of the isotope effects is different for different isotopic 
substitutions (Table 6). Therefore, one does not necessarily expect the values to follow 
an obvious e.g. linear trend. That said, the maximal KIE does tend to increase with 
increased isotopic substitution, except in the case of Gluc-D7 (Figure 41D) and we note 
the relatively large error on these values. As with the 1° KIE, we observe curvature in the 
magnitude of the KIE for all our isotopic labelling patterns. Figure S3 shows the resulting 
curve from both fits of the data to Eq 15 and Eq 16, and the corresponding extracted data 
are given in Table 6.  
Given the complex nature of the isotopic labelling pattern for each isotopologue, we do 
not wish to overinterpret the microscopic contributions to the absolute magnitude of the 
KIEs. However, it is worth noting that comparison of Gluc-D12 with Gluc-D1 should 
reveal the combined influence of the secondary substitutions, where a ‘normal’ secondary 
KIE would be in the region ~1.1. These effects should be additive, i.e. the individual KIEs 
should be multiplied: 2.1 ± 0.6 ⨉ 1.1 ⨉ 1.1 ≈ 2.5 ± 0.6 which differs from the result 
observed (~3.7 ± 1.1). The large value suggests a significant contribution from secondary 
effects (~1.3 – 1.4). Huskey and Schowen have suggested that large enzyme secondary 
KIEs reflect strong ‘vibrational coupling’ of the secondary sites to the reaction coordinate 
at the transition state.304 More recent studies combining density functional theory (DFT) 
calculations of a model enzyme secondary KIE with high pressure measurements have 
similar findings.305 We note that the notion of vibrational coupling is itself problematic 
and we do not suggest that our data reflect such coupling, not least because no study has 
provided unequivocal evidence for so called vibrational coupling. Given our data we 







The calculated KIEs from our QM cluster model (Table 6), suggest an expected 
secondary KIE of ~3.4 (2.8 ⨉ 1.1 ⨉ 1.1), which differs from the calculated value of 2.3 
(Table 6). That is, the secondary KIE value is not as expected for either the experimental 
measurements or QM calculations. Given the excellent agreement between the 
experimentally measured and calculated 1° KIE (Table 6) the data may indicate that the 
limitations of the (static) QM cluster model and the importance of enzyme KIEs being 
calculated using as full a structural model, including conformational sampling, as 
possible. However, we note that the differences in the absolute magnitude of the 
experimental KIEs are in fact relatively small, particularly when taking into account the 
experimental error as shown in Figure 41B. As we state above, given this limitation, we 
prefer a more conservative interpretation of the labelling study, focusing on the increase 
in isotopic mass rather than the absolute contributions to the KIE from each labelled atom. 
Figure 41C shows the relationship between the extracted Δ𝐶𝑃
‡
 values (from Figure 41A) 
and the increase in isotopic mass of the substrate. From Figure 41C, the isotope effect on 
Δ𝐶𝑃
‡
 appears to increase with respect to the mass of the glucose. These data appear to show 
saturation behaviour, with Δ𝐶𝑃
‡
 trending towards zero with increasing isotopic mass. 
Whilst the initial change in Δ𝐶𝑃
‡
 is relatively large for just one mass unit increase (Gluc-
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Figure 41: The effect of isotopic labelling on ΔΔ𝐶𝑃
‡
. (A) The temperature-dependence of 
kcat for each isotopologue of glucose. Solid lines are fits to Eq 16. (B) Resulting KIEs 
extracted from the fits in panel A. C, correlation between the increase in molecular mass 
(through isotopic substitution) and the extracted magnitude of ΔΔ𝐶𝑃
‡
. The solid line is a 
simple rectangular hyperbola and is to aid the eye only to illustrate the trend. D, structures 






 = 2.2 ± 1 kJ mol−1 K−1), we find large (~1 kJ mol−1 K−1) changes in Δ𝐶𝑃
‡
 
associated with further isotopic substitutions. 
Frequency calculations from the QM cluster model indicate these additional increases in 
mass (D5-D12) should only change the frequencies of the reacting species (and immediate 
surrounding) at the ground and transition state by at most a few wavenumbers (Table S1). 
Moreover, the calculated Δ𝐶𝑃
‡
 values are 3 orders of magnitude smaller than measured 
experimentally (Table S2). Finally, the calculated KIEs from the QM cluster model show 
essentially no curvature (Figure S4) compared to the clear curvature observed 
experimentally (Figure 41B) and shown by comparative fitting of Eq 15 and Eq 16 in 
Figure S3. A simplistic conclusion from these data would be that our experimental data 
are not reflecting vibrational frequency changes on isotopic substitution. However, the 
difference between experimental and computational values is that the QM cluster model 
neglects nearly all the protein. Recent molecular dynamics simulations that correctly 
predict significant enzyme Δ𝐶𝑃
‡
 values (~kJ mol-1 K-1) have shown that the Δ𝐶𝑃
‡
 arises 
from energetic fluctuations across the whole molecule, including domains distant from 
the active site.287 It therefore seems likely that the large isotope effect on Δ𝐶𝑃
‡
 has a major 





We have monitored the isotope effect on Δ𝐶𝑃
‡
 for a hypethermophilic enzyme, finding a 
very large primary isotope effect on the magnitude of Δ𝐶𝑃
‡
 for two different substrates 
(glucose and xylose). The size of the isotope effect on Δ𝐶𝑃
‡
 is very much larger than 
predicted based on a QM cluster model. Further we illustrate an additive effect of increase 
the isotopic mass of glucose on the magnitude of Δ𝐶𝑃
‡
. Taken together, our data shows 
that the change in Δ𝐶𝑃
‡
 is coincident with an increase in isotopic mass. These significant 
changes in Δ𝐶𝑃
‡
 (~ 1-2 kJ mol−1 K−1) are accompanied by only small (~1 cm-1) changes in 
vibrational frequency of the reacting species. If the change in Δ𝐶𝑃
‡
 arises from these small-
scale frequency changes there would need to be some significant ‘amplification’ of the 
small local effect. Therefore, the key question arising from the mass modulation data 
presented here is what is behind the isotopic mass dependence on Δ𝐶𝑃
‡
  (Figure 41C). 
Specifically, if a significant change in enzymatic Δ𝐶𝑃
‡
 (and ΔH‡; Table 6), on the ~kJ 
mol−1 K−1 scale arises when there are only small changes (on the ~1 cm−1 scale) in the 
vibrational frequency of the ground and transition states of the reacting species, how 
might this occur?  
A similar conceptual challenge arises from protein mass modulation studies where 





to very large changes in the temperature-dependence of the rate (isotope effect on ΔH‡, 
ΔΔH‡, changes by ~0-10 kJ mol−1). These very large changes are difficult to rationalize 
since the expected change in the frequency of protein vibrational modes (for a protein that 
is ~10 % increase in mass) is on the scale of only a few wavenumbers. Previous efforts to 
interpret such data have suggested that large changes in ΔH‡ might be achieved where 
protein vibrational modes become ‘decoupled’ from the enzyme catalyzed 
chemistry.297,306,307 Ranasinghe et al have recently extended this rationale by suggesting 
that mass modulation not only affects protein motions coupled to the enzyme catalyzed 
chemical step, but also the electrostatics associated with longer time-scale events during 
turnover.308  We note that these works have not considered Δ𝐶𝑃
‡
. Moreover, there have 
been a significant number of studies that suggest that protein ‘dynamics’ do not affect 
enzyme catalysis286,309–312 and are not in any way coupled to the reaction coordinate. 
Our study provides a fresh perspective on current hypotheses that seek to understand the 
relationship between enzyme vibrational modes and (the temperature-dependence of) 
catalysis, incorporating a difference in enzyme heat capacity (and thus vibrational modes) 
along the reaction, Δ𝐶𝑃
‡
. Our data point to a model that links small changes in the 
vibrational modes of the substrate (or reacting species) to large changes in enzyme 
fluctuations in different states along the reaction. Δ𝐶𝑃
‡
 reflects the change in the 
distribution (and/or magnitude) of protein vibrational modes between the ground and 
transition state. Therefore, we expect that the apparent disconnect between the scale of 
substrate isotopic mass changes and the (thermodynamic) heat capacity changes might be 
resolved by a deeper understanding of the distribution of these protein vibrational modes 
and how these modes are affected by subtle changes in substrate vibrations. For example, 
based on our present understanding of the physical origin of Δ𝐶𝑃
‡
, we suggest a physical 
model where the isotopic changes in the substrate are translated to a shift in the 
conformational landscape (structural, energetic or both) of the enzyme, resulting in a 
difference in fluctuations between the reactant and transition state complexes.284 
 
Materials and methods  
 
ssGDH expression and purification. 
ssGDH was expressed with AmpR in a pET3a plasmid. It was transformed into BL21 
(DE3) Escherichia coli using heat shock and grown on LB agar with ampicillin (100 
µg/ml) at 37 °C. A 50 ml LB starter culture was used to inoculate 5 x 1L LB until an 
OD600 of 0.5-0.6 was reached. Cells were harvested by centrifugation (4 °C, 8000 rpm, 10 
min) before being lysed by sonication using a lysis buffer (pH 7) containing 100 mM 
HEPES, lysozyme, DNAase and a protease inhibitor cocktail tablet. Soluble and insoluble 
fractions were separated by centrifugation at 4 °C (25,000 rpm, 10 min). Due to the 




°C for 50 min. To remove precipitated protein, samples were centrifuged (4 °C 13,000 
rpm, 10 min) before being dialysed for 4 hours in 100 mM HEPES buffer (pH 7). Samples 
were further purified/concentrated through the use of Vivaspin centrifugal concentrators 
(MWCO = 30 kDa). The concentration of purified samples was measured by the 
absorbance at 280 nm (ε280 = 49,390 M-1 cm-1), obtained via the input of ssGDH amino 
acid sequence into the ExPASy ProtParam tool.313 Approximately 8 ml of 35 mg/ml 
purified sample was obtained. 
Substrates and coenzymes.  
D-glucose, D-xylose, D2O and NADP
+ were obtained from Sigma Aldrich. D-glucose (1-
D), D-glucose (1,2,3,4,5,6,6-D7) and D-xylose (1-D) were obtained from Cambridge 
Isotope Laboratories. In this manuscript the varying isotopes and D2O combinations will 
be described with the following nomenclature: D-glucose (1-D) – D1 , D-xylose (1-D) – 
D1, D-glucose + D2O – D5 , D-glucose (1,2,3,4,5,6,6-D7) – D7 , D-glucose (1,2,3,4,5,6,6-
D7) + D2O – D12. 
Enzyme assays. 
Steady-state ssGDH kinetic measurements were carried out using a lidded 1 ml quartz 
cuvette to prevent evaporation at high temperatures and a UV⁄ Vis spectro-photometer 
(Agilent Cary 60 UV-Vis spectrometer) in 100 mM HEPES (pH 8). Accurate 
concentrations of NADP+ were determined using NADP ε260 = 17,800 M
-1 cm-1. Enzyme 
activity was measured for each condition at 85 °C by following the formation of NADPH 
at 340 nm using ε340 = 6220 M
-1 cm-1 as a direct measurement of ssGDH steady-state rates 
; the data fitted well to Michaelis-Menten kinetics.   Temperature-dependences were 
carried out from 60 °C – 90 °C at 5 °C intervals using initial velocity measurements at 
substrate concentrations maintained above 10x Km to ensure saturation. The data were 
fitted to Eq 15 or Eq 16 as described in the manuscript using OriginPro 2016 (MicroCal). 
The measured pH for experiments performed in D2O was adjusted accordingly to match 
that of the pH in H2O.
314 
Molecular dynamics simulations.  
The ssGDH crystal structure 2CDB299 was prepared for simulation using scwrl4315 to 
revert the T41A mutation and modeller316 to model in the missing loop at positions 50-59 
(based on chain A). To obtain similar starting points for the glucose and xylose 
complexes, this loop was used for all four chains and coordinates from 2CDB were also 
used for the xylose complex (where xylose was placed based on alignment with 2CDC299). 
The Amber16 suite of programs was used for periodic boundary simulation and 
analysis222, with the ff14SB force-field for protein atoms60, GLYCAM-06j for 
glucose/xylose63, parameters from Ryde et al. for NADP+,317 TIP3P for water and 
ZAFF318 for the Zn2+ coordinated by Cys93, Cys96, Cys99 and Cys107. For the Zn2+ 
directly adjacent to the substrate binding site, restraints were used to maintain the 
crystallographically observed coordination with Cys39 and His66. After brief 
minimization of the complex and added water, the system was heated to 300 K and 





atoms). After gradual release of Cα positional restraints, 50 ns NPT production 
simulations were performed at 300 K and 1 atm. Histograms of the D-A distances were 
calculated over all four binding sites using 10-50 ns of four independent simulations for 
each substrate. (Further details of model setup, restraints and simulation procedures are 
included in the Supporting Information.)  
QM Cluster Model.  
The aforementioned X-ray crystal structure of ssGDH in complex with glucose and 
NADP+ (PDB ID 2CDB299) was used to create a 148 atom model of the active site (Figure 
S5). To preserve the overall structure of the active site, several atoms were fixed 
throughout the optimisation process and care was taken to ensure non-reacting groups 
stayed in the same local minima throughout the reaction. The T41A mutation was reversed 
in silico with the rotamer selected based on our MD simulations. All Calculations were 
performed using Gaussian16,319 employing the M06-2X functional.320 Geometry 
optimisations and frequency calculations were performed in vacuo with the 6-31G(d,p) 
basis set. All models were optimised on an ultrafine integration grid and under tight 
convergence criteria. Single point energies were obtained using the 6-311++G(2d,2p) 
basis set, with the surrounding protein environment accounted for using the SMD 
solvation model with a dielectric constant of 4.321 Thermal corrections to the obtained 
energies were taken from the aforementioned frequency calculations, employing a scale 
factor of 0.97.322  Contributions to tunnelling on the rate of reaction were estimated using 
Wigner’s correction.323 Further details about calculation methodology and the coordinates 
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Supporting Information Materials and Methods 
Molecular dynamics simulations: Model setup, restraints and simulation details  
The ssGDH crystal structure 2CDB299 was prepared for simulation using scwrl4315 to 
revert the T41A mutation and modeller324 to model in the missing loop at positions 50-
59, based on the coordinates of the surrounding residues in chain A. The same loop 
conformation was subsequently transferred to the other three chains. To avoid a clash with 
this loop in chain C, conformer B (assigned 50% occupancy) was chosen for His118. (If 
not mentioned, conformer A was chosen for other residues with multiple conformers 
defined, including for the glucose O6.) Asn/Gln flips and His tautomers and were selected 
based on optimal hydrogen bonding contacts through the AmberTools facility reduce, 
with His66 and His319 singly protonated on Nδ1, others on Nε2. The exception was 
His297, which was protonated on Nδ1: test simulations indicated that this tautomer better 
retained the crystallographically determined enzyme-ligand conformation structure. All 
ionizable residues (with exception of the Cys residues coordinating Zn2+, see below) were 
modelled in their standard protonation states (in agreement with pKa predictions by 
PropKa 3.1)158. To obtain similar starting points for the glucose and xylose complexes, 
the same protein starting model was used for the xylose complex  (where xylose was 
placed based on alignment with 2CDC 299).  
The Amber16 suite of programs was used for periodic boundary simulations and 
analysis,222 with the ff14SB force-field for protein atoms,60 GLYCAM-06j for 
glucose/xylose,63 parameters from Ryde et al. for NADP+,317 TIP3P for water and 
ZAFF318 for the Zn2+ coordinated by Cys93, Cys96, Cys99 and Cys107. These Cys 
residues were thus modelled as thiolates (CYM). For the Zn2+ directly adjacent to the 
substrate binding site, the default Amber ion parameters were used. To avoid coordination 
changes around the Zn2+ ion, the following one-sided harmonic restraints were applied if: 
1) the His66 NE2–Zn2+ distance was larger than 2 Å (force constant 70 kcal mol−1 Å−2); 
2) the Asp42 OD2–Cys39 N distance was larger than 1.95 Å (force constant 70 kcal mol−1 
Å−2); 3) the Asp42 OD2–Zn2+ distance was smaller than 4.2 Å (force constant 100 kcal 
mol−1 Å−2).  
In addition to the water molecules present in the crystal structure, a rectangular box of 
water was added using the AmberTools facility tleap such that all protein atoms were at 
least 11.5 Å away from the edge of the box (closeness parameter of 0.9). 20 water 
molecules (at least 5 Å away from the protein) were replaced with Na+ ions to neutralize 
the system. After minimization of solvent and hydrogens (100 steps steepest descent, 400 
steps conjugate gradient), the full system was briefly minimized (400 steps) with 
positional restraints of 5 kcal mol−1 Å−2 on all Cα atoms. Maintaining these positional 
restraints on C atoms, velocities were assigned at 25 K and the system was heated to 300 
K in 50 ps using Langevin temperature control in the NVT ensemble (with a 1 ps−1 
collision frequency). Subsequently, 100 ps of equilibration was performed in the NPT 
ensemble at 1 atm, using the Berendsen barostat (1 ps pressure relaxation time) and 





positional restraints on C atoms were gradually removed in four consecutive 10 ps 
simulations under the same conditions (4, 3, 2, and 1 kcal mol−1 Å−2 as force constants). 
Production MD (without positional restraints) was then performed in the NPT ensemble 
at 1 atm and 300 K for 50 ns, saving coordinates every 10 ps. All MD simulations were 
performed with the default direct-space cut-off for non-bonded interactions and particle-
mesh Ewald summation for long-range electrostatics, run with pmemd.cuda. Four 
independent simulations were run for each complex (GDH-glucose and GDH-xylose). 
 
QM Cluster Model Calculations: Model Construction, pKa and KIE Calculations  
The X-ray crystal structure of ssGDH in complex with glucose and NADP+ (2CDB)299 
was used to create a 148 atom model of the active site. Truncations of the enzyme active 
site were made across non-polar bonds. All titratable residues included in the model were 
in their standard protonation state. The T41A mutation used to crystallise ssGDH was 
reverted in silico, with the rotamer (side chain alcohol group acting as a hydrogen bond 
acceptor to the alcohol group of the glucose C1) chosen based on its prevalence in our 
MD simulations. To preserve the overall structure of the active site, several atoms were 
fixed throughout the optimisation process and care was taken to ensure non-reacting 
groups stayed in the same local minima throughout the reaction.  
All Calculations were performed using Gaussian16,319 employing the M06-2X 
functional.320 Geometry optimisations and frequency calculations were performed in 
vacuo with the 6-31G(d,p) basis set. All models were optimised on an ultrafine integration 
grid and under tight convergence criteria. Single point energies were obtained using the 
6-311++G(2d,2p) basis set, with the surrounding protein environment accounted for using 
the SMD solvation model with a dielectric constant of 4.321 Thermal corrections to the 
obtained energies were taken from the aforementioned frequency calculations, employing 
a scale factor of 0.97.322 Contributions to tunnelling on the rate of reaction were estimated 
using Wigner’s correction.323  
In order to simulate the deprotonation of the Zn coordinated water to a Zn coordinated 
hydroxide by the bulk milieu (reactant to reactive intermediate), a proton on the Zn 
coordinated water (reactant model) was removed and the structure re-optimised, giving 
the reactive intermediate. During optimisation, the Zn coordinated hydroxide abstracted 
the sugar C1 alcohol group’s proton, forming an alkoxide on the sugar. This therefore led 
us to propose the stepwise mechanism as seen in Scheme S1. To calculate the barrier for 
the transition from reactant to reactive intermediate, the experimentally determined 
barrier at 298 K (73.5 kJ mol-1) was subtracted from the computationally determined 
hydride transfer barrier (32.6 kJ mol-1), with the subsequent energy difference used to 




All polar hydrogen atoms in the cluster model were considered deuterated when 
modelling the SKIE (see Figure S5). Heat capacities of activation (Table S2) were 
calculated from the differences in constant volume heat capacity for the reactive 
intermediate and transitions state models.  
PLEASE NOTE: In the interest of saving paper/space, only the Supporting 
Information Methods are included and not the figures or tables. They can instead be 






Appendix Chapter 2: Probing the 
Importance of the Environment in 
Regulating Functionally Important 
Enzyme Dynamics  
 
In this second appendix chapter we applied a combination of computational and 
experimental approaches to study the biomedically relevant enzyme monoamine oxidase 
B (MAO-B). The primary aim of this study was to understand how the environment can 
perturb/tune the functionally important dynamics of this enzyme. This was first studied 
experimentally with enzyme temperature dependence studies, which showed how the use 
of different substrates and/or a different membrane environment were able to significantly 
modify the heat capacity of catalysis (∆𝐶𝑝
‡
), suggesting both the substrate and membrane 
are able to tune functionally important dynamics linked to catalysis. We complemented 
our experimental approach with molecular dynamics (MD) simulations of MAO-B in a 
lipid bilayer. Our MD simulations were able to identify and characterise a new entrance 
for substrate/ligand binding, which is of particular relevance considering the that MAO-
B can be inhibited for the treatment of both Parkinson’s disease and depression. 
Furthermore, our MD simulations with substrate bound suggested the possibility of half-
site reactivity. Finally, we used MD simulations in an attempt to understand how the 
previously described distal mutations removed activity from MAO-B. We demonstrated 
that that dynamics of the loop which control substrate/ligand entry were significantly 
altered in all of the variants as compared to the wild-type, suggesting substrate 
binding/product release was disrupted in the variants. My role in this project was to lead 
the setup, running and analysis of the MD simulations of MAO-B, with this aspect of the 
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Exposing the Interplay Between Enzyme Turnover, Protein Dynamics 
and the Membrane Environment in Monoamine Oxidase B 
Hannah B. L. Jones†∥, Rory M. Crean#†∥, Anna Mullen§, Emanuele G. Kendrick†, Steven 
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%School of Biochemistry, University of Bristol, Biomedical Sciences building, 
University Walk, Bristol BS8 1TD, United Kingdom. 
§School of Chemistry, University of East Anglia, Norwich Research Park, Norwich NR4 
7TJ, United Kingdom. 
Abstract: There is an increasing realization that structure-based drug design may show 
improved success rates by understanding the ensemble of conformations and sub-states 
accessible to an enzyme and how the environment affects this ensemble. Human 
monoamine oxidase B (MAO-B) catalyzes the oxidation of amines and is inhibited for 
the treatment of both Parkinson’s disease and depression. Despite its clinical importance, 
its catalytic mechanism remains unclear and routes to drugging this target would be 
valuable and relevant. Evidence of a radical in either the transition state or resting state of 
MAO-B is present throughout the literature, and is suggested to be a flavin semiquinone, 
a tyrosyl radical or both. Here we see evidence of a resting state flavin semiquinone, via 
absorption redox studies and electron paramagnetic resonance, suggesting that the anionic 
semiquinone is biologically relevant. Based on enzyme kinetic studies, enzyme variants 
and molecular dynamics simulations we find evidence for the crucial importance of the 
membrane environment in mediating the activity of MAO-B and that this mediation is 
related to effects on the protein dynamics of MAO-B. Further, our MD simulations 
identify a hitherto undescribed entrance for substrate binding, membrane modulated 
substrate access, and indications for half-site reactivity: only one active site is accessible 
to binding at a time. Our study combines both experimental and computational evidence 
to illustrate the subtle interplay between enzyme activity, protein dynamics and the 
immediate membrane environment. Understanding key biomedical enzymes to this level 
of detail will be crucial to inform strategies (and binding sites) for rational drug design 
for these drug targets.  
KEYWORDS EPR, Molecular Dynamics, Monoamine Oxidase B, semiquinone, 
enzyme, flavin, membrane 
Human monoamine Oxidase B (MAO-B) catalyzes the oxidative deamination of amines, 




is located in the outer mitochondrial membrane,326 as a dimer, with bipartite substrate 
binding and active site cavities.325 MAO-B is the target of treatment for both depression 
and Parkinson’s disease, with inhibitors of the enzyme first being approved as 
pharmaceuticals in the 1960’s.327,328 
Despite the important medical applications associated with MAO-B its chemical 
mechanism remains unclear and there is debate over the role of MAO-B conformational 
change and protein dynamics. Reduction of the FAD has been shown to proceed by a 
tunneling mechanism via primary (1°) and secondary (2°) kinetic isotope effect (KIE) 
studies.329 These studies have suggested that MAO-B catalysis is not linked to fast 
(pico/nanosecond) dynamics.329,330 MAO-B catalysis has been investigated via 
experimental and computational studies, with at least seven different proposed 
mechanisms, including polar nucleophilic,331 radical,332 direct hydride transfer333–335 and 
two step hydride transfer336 (Scheme S2).  
Although the direct single electron transfer (SET) radical mechanism (Scheme S2) has 
previously been discounted experimentally337 and by quantum mechanics/molecular 
mechanics (QM/MM),338 a separate radical mechanism has been proposed by Murray et 
al.339 This was established via a model small molecule reaction that mimics MAO-B to 
provide evidence for a neutral semiquinone flavin that can be formed aerobically. The 
authors suggest that a neutral semiquinone flavin is the reactive species for the oxidation 
of benzylamine (BZA).339  This led to the hypothesis of a radical mechanism whereby 
MAO-B forms a neutral semiquinone flavin via a proximal tyrosine radical (Y398). The 
presence of a stable anionic semiquinone flavin and tyrosyl radical intermediate are also 
reported in MAO-A and MAO-N.340,341 
In our hands, we find spectroscopic evidence for a stable semiquinone in resting state 
MAO-B (vida infra). Here, MAO-B was expressed and purified in Pichia pastoris as 
outlined by Newton-Vinson et al. 342  This protocol attributes observations of 
oxidized/semiquinone MAO-B FAD to reactive oxygen species (ROS) that form upon the 
disruption of the mitochondrial membrane, which they observe upon purification from 
bovine liver, but not from P. pastoris.342 
Previous observation of a stable anionic semiquinone FAD in MAO-B343,344 led to a 
hypothesis of half-site reactivity. This mechanism posits that one monomer of the MAO-
B dimer is inaccessible to oxygen and substrate, resulting in the formation of the stable 
semiquinone species, whilst the other contains oxidized FAD. Electrons are then shuttled 





to the semiquinone species, allowing for the oxidation of the reduced FAD upon 
turnover.344 The authors suggest this might arise from electron shuttling between specific 
amino acids. Potentially, such a mechanism might require significant conformational 
change associated with turnover in each monomer. Indeed, conformational changes have 
been found to be associated with MAO-B turnover, with a molecular dynamics (MD) 
study demonstrating the potential for the membrane to regulate access to the active site 
entrance via two gating loops (residues 85-119 and 155-165).345 Other MD studies have 
been carried out on MAO-B, both with and without a membrane environment, with the 
focus on identifying or improving inhibitors for MAO-B346–350, or ascertaining how 
MAO-B binds to the membrane.351 
Herein, we find evidence for a resting-state anionic semiquinone, and through kinetic and 
computational studies, evidence for conformationally controlled enzyme activity at each 
MAO-B monomer. Crucially, we find that the membrane environment exposes novel 
substrate/product channels that could be potential new drug targets. We thereby link the 
membrane environment, substrate binding and MAO-B conformational change to enzyme 
turnover. 
Results and Discussion 
Evidence for a resting-state semiquinone in MAO-B.  
The presence of purified MAO-B was established by SDS-PAGE (Figure S6; essentially 
a single band via size exclusion chromatography) and via electrospray ionization 
quadrupole time-of-flight (ESI-Q TOF) mass spectrometry in combination with the 
MASCOT server.352 The absorption spectrum of purified MAO-B is shown in Figure 
42A. The spectra share characteristics of an anionic semiquinone FAD (FAD‧-) with an 
absorption feature at ~415 nm.353 The preparation protocol of MAO-B was the same as 
that used by Newton-Vinson et al.,342 with small differences outlined in the Materials and 
Methods. Multiple preparations were completed, including the final polymer partition step 
outlined by Newton-Vinson et al. and without EDTA present, with the ~415 nm spectral 
feature consistently present. The effect of incubation with BZA, under anaerobic 
conditions, on the MAO-B absorption feature at ~415 nm was monitored over time 
(Figure 42A inset).   From Figure 42A inset, we find a decrease in absorption at 415nm 
with respect to time on incubation with BZA, suggesting the ~415 nm spectral feature is 
redox sensitive with a natural MAO-B substrate.  
We note that the absorption spectrum shown in Figure 42A lacks a defined feature around 
~450 nm where one would expect oxidized flavin as well as spectral features at ~475 nm 
that would also characterize a putative anionic semiquinone. We do not have a clear 
explanation for the lack of these features and the complexity of the absorption spectrum; 
the protein is purified to homogeneity, it is identified as MAO-B by mass spectrometry 
and is catalytically active with the natural substrates (Figure 44A, Figure S7 and as 
described below). The electronic environment around both flavins is highly complex, with 




from the alloxan moiety, respectively). Potentially, this gives rise to a complex absorption 
spectrum arising from different electronic environments for a sub-set of active site 
conformational states. This hypothesis requires MAO-B to be able to explore different 
conformational states and we consider this in more detail below. Given the complexity of 
the absorption spectrum, we turned to fluorescence and electron paramagnetic resonance 
(EPR) spectroscopy to provide more specific evidence for the oxidation state(s) of the 
MAO-B flavin.  
Previously, MAO-B steady-state fluorescence spectroscopy has demonstrated that there 
are two different chromophores present in resting state MAO-B.354 The authors concluded 
that these two different species were consistent with oxidized and semiquinone flavin. To 
establish if we similarly have both oxidized and seminquinoid flavin present (which is not 
obvious from the absorption spectrum), we have monitored the fluorescence excitation-
emission matrix (Figure 42B). Similar to the previous report, the spectra resolve at least 
two different emission peaks suggesting the presence of two different oxidation states of 
the flavin with λEx ~ 400-420 and 460 nm. Notably, the excitation/emission profile at λEx 
~ 460 and λEm ~ 540 nm (Figure 42B) indicates the presence of oxidized flavin. 
The ~415 nm absorption feature could be potentially attributed to a tyrosyl radical, which 
has a characteristic absorbance peak at 410 nm,355 or a mixture of both an FAD 
semiquinone and tyrosyl radical, as seen as intermediates in MAO-A.340,341 Murray et al. 
postulated that the reactive semiquinone FAD was formed by a proximal tyrosyl radical 
(Y398). However, the UV-vis absorption spectrum of Y398F MAO-B also shows the 
spectral feature at ~415 nm (Figure S8A), indicating that this feature is not attributable 
Figure 42: (A) The absorbance spectra of MAO-B after treatment with BZA over time. 
Inset, the effect on the 415 nm peak over time. (B) Fluorescence excitation/emission 
matrix resolves oxidized and semiquinone flavin states (highlighted in solid black 
boxes). Scale bar is relative intensity Conditions: 50 mM HEPES 0.5 % w/v Triton X-






to a Y398 tyrosyl radical. The Y398F variant also shows a slight increase in Km (Figure 
S9), similar in magnitude to previously reported changes in Km for Y398F.
356  
A stringent approach to identifying the nature of the flavin oxidation state is EPR. The 
EPR X-band spectrum of the wild type MAO-B (wtMAO-B) clearly indicates that the 
signal arises from a semiquinone radical (Figure 43), in agreement with the UV-Vis and 
fluorescence spectroscopy (Figure 42). The measured spectra lack the defining features 
which would identify the signal as arising from a tyrosyl radical:  the typical ‘wings’ or 
‘shoulders’ around the central signal at around g = 2 340,357 at X-band (Figure 43), and 
increased g-value anisotropy at higher frequency (and therefore resonant field), i.e. Q-
band (data not shown). Furthermore, the signal persists in the Y398F variant, confirming 
that it is not caused by the proximal tyrosine. Further, computational simulation and fitting 
of the experimental X-band data of the WT and Y398F MAO-B (Table 7) suggests that 
the semiquinone radical species is anionic; the hyperfine environment of a neutral 
semiquinone radical would contain a contribution from an additional hydrogen 
atom.344,358 This is not the case for the signals seen in the X-band spectra. 
Previous studies have illustrated the importance of the membrane environment in 
mediating the normal enzymatic activity of MAO-B.345 To probe if the putative 
semiquinoid species (inferred from spectroscopic studies above) was also stably present 
in the membrane environment, we have conducted spectroscopic studies in an artificial 
membrane environment using l-α-phosphatidylcholine styrene maleic acid co-polymer 
(SMA) nanodiscs, prepared as reported previously.359 We find that the absorption feature 
Figure 43: X-band cw-EPR spectra of WT (top, black) and Y398F (bottom, black) MAO-
B, with their respective fitted simulations (red). EPR microwave frequency = 9.3916 GHz 






at ~415 nm is present in both reduced Triton X-100 and nanodisc environments (Figure 
S8A), implying that the putative anionic semiquinone is not an artifact of the buffer 
system used, and that its presence is not affected by the specific membrane environment 
used. It is clear from these data (Figure 42 and Figure 43) that the FAD of resting state 
MAO-B is able to stably occupy oxidation states other than fully oxidized FAD. Evidence 
for this is recurring in the literature, demonstrated by Raman343, fluorescence354, and 
EPR342,344 spectroscopy. We suggest that these different observations could be 
rationalized by an equilibrium of energetically similar conformational states, which allow 
differently stable oxidation states. Indeed, below we provide evidence that shows MAO-
B is able to sample a range of conformational states.    
 
Table 7. Spectral Parameters of EPR Data Extracted by Simulation and Fitting. 
 
Influence of the membrane environment on MAO-B turnover. 
To assess how/if the membrane environment affects enzyme turnover, we measured 
MAO-B turnover with both BZA and kynuramine dihydrobromide (KYN) at a range of 
temperatures. We monitor enzyme turnover based on the absorption features of 
benzaldehyde product formation at 250 nm for BZA,337 and 4-hydroxyquinoline product 
formation at 316 nm for KYN.360 This assay notionally primarily reflects the rate of 
reduction of the flavin.337 Our temperature-dependence studies allow us to analyze not 
just the observed rate of enzyme turnover but also the thermodynamics of the system. The 
temperature-dependence of the observed rate is shown in Figure 44. 
There has been a recent move to fitting enzyme temperature-dependence data to physical 
models that allow for curvature in the associated plots. Such models often provide a more 
realistic fit to experimental data. We fit the MAO-B temperature-dependence data to a 
model that incorporates the heat capacity of catalysis (Δ𝐶𝑃
‡
) Eq 16 into the Eyring equation 
(Eq 15).290  
   WT MAO-B  Y398F MAO-B 
g-tensor gx 2.00444  2.00444 
 gy 2.00429  2.00429 
 gz 2.00191  2.00191 
 giso 2.00355  2.00355 
A(14N) (MHz) A∥ 39.3  38.4 
 A⟂ 0  0 
A(14N) (MHz) A∥ 34.1  40.1 
 A⟂ 0  0 
Linewidth (mT) 1.1  1.1 





 𝑘 = (𝑘B𝑇/ℎ)𝑒
∆𝑆‡/𝑅𝑒−∆𝐻
‡/𝑅𝑇 (15) 


















Where ΔH‡ is the change in enthalpy and ΔS‡ is the change in entropy between the ground 
and transition state of the reaction at an arbitrary reference temperature (T0). This model 
has recently gained traction in studying enzyme temperature-dependencies.287,288,297,361 In 
the absence of other confounding factors, Δ𝐶𝑃
‡
 quantifies the temperature-dependence of 
ΔH‡ and ΔS‡ and reflects the difference in the distribution and frequency of vibrational 
modes between the ground state and transition state.290,291 We have recently suggested 
that Δ𝐶𝑃
‡
 can be used as a proxy for the changes in these vibrational modes during enzyme 
turnover and thus relates to some aspect of the protein’s molecular dynamics.287 This is 
relevant in the present study where the membrane environment may not alter the tertiary 
structure of the enzyme, but potentially alters protein fluctuations, which have previously 
been proposed to affect small molecule binding to the active site.345 
From Figure 44 and Table S3, we find Δ𝐶𝑃
‡
 to be the same within error for both KYN 
and BZA substrates when in a reduced Triton X-100 environment. However, when in 
nanodiscs, the difference in Δ𝐶𝑃
‡
 for the different substrates is ΔΔ𝐶𝑃
‡
 = 2.4 ± 1.0 kJ mol−1. 
The Δ𝐶𝑃
‡
 increases in magnitude from reduced Triton to nanodiscs with KYN, and 
decreases with BZA (Figure 44). These data suggest that the difference in conformational 
fluctuations in the reactant and transition states is different in a more native membrane 
environment and for different substrates. Moreover, we find a significant difference in the 
observed rate of enzyme turnover in the nanodiscs (~5 times faster). These data therefore 
provide experimental evidence of the notion that the membrane environment has a role in 
‘tuning’ the molecular dynamics of MAO-B. However, given we observe a retention of 
the putative anionic flavin semiquinone, we would suggest the membrane does not affect 
the chemical mechanism of enzyme turnover per se.  
Computational evidence for a new entrance to the MAO-B active site mediated by 
the protein-membrane interaction.  
To obtain detailed insight into the role of the membrane environment on protein dynamics, 
we performed MD simulations of the MAO-B dimer embedded in a phospholipid 
membrane. We explore (i) the influence of the phospholipid membrane in modulating 
substrate/inhibitor binding, (ii) the accessibility of small molecules to the active site of 
MAO-B, and (iii) the potential for half-site reactivity, as discussed above. 
MD simulations of MAO-B in complex with FAD in a POPC/POPE lipid bilayer (similar 




for 150 ns in 3 different states: no BZA present (BZA0), one active site occupied with 
BZA (BZA1), and both active sites occupied with BZA (BZA2). Protein Cα RMSD and 
area per lipid head groups (Figure S10) indicated equilibration of both the protein and 
membrane after 50 ns of production MD. The analysis described below is therefore from 
50 to 150 ns.  
Prior simulations of BZA0-MAO-B in a bilayer established that MAO-B ligand binding 
site access is modulated by the membrane.345 We investigate this further using longer 
simulations (150 ns vs. 50 ns) and with substrate (BZA) bound. To measure possible 
access to the substrate cavity of MAO-B via the membrane, we quantify the occurrence 
and features of tunnels in our simulations using Caver 3.0.363 Tunnels identified are 
grouped into clusters, allowing for the quantification of various characteristics, such as 
the frequency of occurrence and smallest width (bottleneck radius), as used here.364 This 
tool has previously been used to identify tunnels for ligand-induced protein flexibility 
analysis,365 to rationalize change in mechanism and kinetics of an enzyme upon a point 
mutation,366 and to identify a tunnel to the FAD moiety in MAO-A.367  
Two main possible entrances for ligands into the MAO-B active site are found at either 
side of the gating loop residues 99 to 112 (Figure 45). Entrance A (Figure 45A) is 
accessed via the membrane and its opening has previously been observed.345 Briefly, a π-
π stacking interaction between Tyr97 and Trp107 is lost as Trp107 buries into the aliphatic 
lipid tails of the bilayer, establishing an additional interaction of MAO-B with the 
phospholipid bilayer.  
Entrance B (Figure 45B) is solvent accessible, and its opening is controlled by the 
conformation of three loop regions (81 to 88, 99 to 112 and 198 to 208). To the best of 
our knowledge, its opening has not yet been observed through protein crystallography or 
Figure 44: The temperature-dependence of MAO-B with BZA (A) and KYN (B) with 
reduced Triton and nanodisc environments, fit to the MMRT equation. Conditions, 50 
mM HEPES 0.5 % w/v reduced Triton X-100 pH 7.5. Reduced Triton X-100: 1.5 mM 





simulation. To provide a qualitative description of the open and closed conformations of 
this entrance, we have performed clustering analysis on the entrance loop residues (see 
Materials and Methods). Opening of Entrance B (Figure S11) can be described by: 1) 
loop 81-88 separates from loop 199-206, breaking a number of transiently formed 
electrostatic interactions and instead forming interactions with the solvent in the open 
conformation; 2) the central region of the gating loop (residues P102, F103, P104) rotates 
down and away from the hydrophobic core of the entrance cavity. The opening of both 
entrance A and B involves residues directly interacting with the bilayer.  This indicates 
that the membrane is important in modulating access to the substrate binding pocket of 
MAO-B. 
Evidence of asymmetry in MAO-B from MD simulation.  
Previous studies have suggested that the presence of an anionic semiquinone could be 
mechanistically significant as part of a half-site reactivity mechanism.344 To investigate 
the potential for half-site reactivity in MAO-B, tunnels from the N5 of the flavin to the 
solvent were first identified from all MD trajectories with BZA0, BZA1 and BZA2 (with 
three replicates). These data are useful to determine the size of species that could access 
the active site and to investigate whether access to the active site is half-site specific. To 
avoid identifying numerous tunnels that cannot accommodate substrate/product 
molecules, a minimum tunnel radius was set to 1.5 Å. (This avoids identifying water 
tunnels, as water has a Van der Waals radius of ~1.4 Å.368) With this criterion, no tunnels 
were found, which demonstrates a closed active-site on the timescales of our simulations. 
Whilst larger conformational changes may be occurring on longer time-scales (or in 
presence of substrate in the vicinity of a bottleneck) to enable substrate access to the active 
site, a generally closed off active site is in agreement with previous experimental 
findings.344  
Next, tunnels were identified from the substrate binding cavity towards the protein 
surface. The starting point was defined as the centre of mass between the alpha carbon 
(Cα) atoms of residues 168 and 316 (Figure S12). This starting point was chosen as it is 
located within the substrate binding cavity and is common to both previously described 
substrate entrance tunnels (Figure 45). Tunnel frequency and the average bottleneck 
radius of all tunnels identified in both monomers were obtained for BZA0 and BZA1 
(Figure 46A+B).  To aid discussion, we designate each monomer as monomer 1 or 






Notably, both the frequency and maximum bottleneck radius of tunnels to the substrate 
binding cavity of MAO-B is significantly different for each monomer. In the absence of 
BZA, monomer 1 presents a higher frequency of tunnels, with a larger average maximum 
bottleneck radius. When BZA is present in monomer 1 and not monomer 2, the frequency 
of tunnels and maximum bottleneck measurements are higher for monomer 2 (Figure 
46A+B and Table S4). In Figure 46C+D, the pathways are coloured according to the 
entrance pathway they use from the starting point to the solvent, with the majority of 
tunnels passing the aforementioned entrances A and B (Figure 45). 
The observed ‘closing’ of the active site entrance in the BZA1-bound monomer and 
‘opening’ in the BZA1-unbound monomer are particularly notable. This indicates that when 
BZA is bound to the active site cavity of one monomer, a subsequent BZA is more likely 
to enter the binding site of the opposite monomer. Such asymmetry may prevent binding 
of subsequent BZA into the same monomer, allowing for the release of products, whilst 
increasing the efficiency of binding in the opposite ‘free’ monomer. Previous 
experimental work indicated that binding of inhibitor to the intermediate binding site of 
MAO-B was increased where inhibitor was already bound into the active site (see Figure 
45 for binding/active site differentiation).369 Whilst it is not known whether this is within 
the same monomer, it could explain the asymmetry in binding site access seen here when 
BZA1 is present.  
BZA2 was not considered for half-site reactivity analysis. This was due to BZA leaving 
the active site altogether in one simulation trajectory (Figure S13), meaning that the 
identified tunnels would not be comparable to those where BZA does not leave. This BZA 
Figure 45: MAO-B in POPC/POPE membrane environment. The substrate binding area 
is shown in light green and light blue (residues 80-210, 286-390) for each monomer. The 
active site area is shown in dark green and dark blue (residues 4-79, 211-285, and 391-
452). The C-terminal tail and transmembrane helix are shown in red (residues 453-520). 
The binding site gating loop is shown in magenta (residues 99-112). Images A and B inset 
denote the two main entrances (or tunnels) to the binding site (denoted Entrance A and 
Entrance B throughout the manuscript), with a representative tunnel (navy spheres) shown 
for both entrances.  Key residues which describe the location of the entrance are shown 






movement may indicate that BZA2 is potentially an unstable configuration, providing 
further evidence towards asymmetry in MAO-B.  
 
 
Mutagenesis reveals long-range networks of motion are important in MAO-B.  
Our findings above suggest a model where MAO-B intramolecular dynamics are 
intimately linked to the environment. That is, we hypothesize, that functionally important 
MAO-B conformational changes are at least in part controlled by the membrane 
environment. We expect that those conformational changes (or protein dynamics) are 
influenced by the global protein scaffold. To explore this hypothesis, we have turned to 
computationally informed mutagenesis studies.  
We identify enzyme variants that are predicted to affect networks of flexible motion 
throughout MAO-B using the FIRST (floppy inclusion and rigid substructure topography) 
algorithm.370 FIRST uses a single conformation (e.g. a crystal structure) to define a 
constraint-network of movement for a protein. This constraint-network is composed of 
terms describing covalent and non-covalent contributions to the rigidity of the protein, 
allowing prediction of the relative rigidity/flexibility of each residue. These calculations 
can therefore be used to predict the relative rigidity (and therefore stability) of MAO-B 
variants, both on a local (per-residue) and global (sum of all residues) level.  
Figure 46: The summed tunnel frequency from the substrate binding site of MAO-B to 
solvent, identified by Caver.363 BZA0 – No BZA is bound in either monomer. BZA1 – 
BZA is bound only in monomer 1. All are from triplicate MD runs. B, The average 
maximum bottleneck (Å) from the substrate binding site of MAO-B to the solvent, as 
identified by Caver. C + D, All tunnels identified by Caver over all three MD simulation 
repeats for BZA0 (C) and BZA1 (D). FAD and BZA (when present) are shown as yellow 
sticks. Tunnels are colored according to entrance/exit pathway used, with magenta and 
green representing Entrances A and B respectively. Blue tunnels indicate pathways which 




FIRST was used to perform high-throughput screening to identify point variants that were 
predicted to significantly rigidify the network of flexible motion of wtMAO-B, without 
significantly perturbing the flexibility of residues considered 
In short, we perform computational alanine scanning, by applying FIRST with the 
contribution of each amino-acid side chain to the constraint network discounted in turn. 
This allows us to identify residues with side chains that make a negligible contribution to 
the overall rigidity of MAO-B. All residues identified with the above approach were then 
subjected to in silico mutagenesis to all other canonical amino acids and subsequent 
FIRST analysis.  
From these calculations, we selected three enzyme variants (W184F, F402V and E466Y) 
that, based on our calculations, were predicted to increase the rigidity of the protein 
scaffold, but are distal to the active site (between 13-21 Å from BZA) and do not 
significantly alter the rigidity of catalytically relevant residues (Figure S14A-C; see SI 
Materials and Methods). We find that these variants retain the absorption feature at ~415 
nm (Figure S8A) and their overall structure is not significantly perturbed, at least as 
assessed from their far-UV circular dichroism spectra (Figure S8B). However, despite 
the variants being located a significant distance from the active site, we find that enzyme 
activity is ablated. Given that these variants are expected to alter the network of flexible 
motion, we suggest these data reflect the importance of protein conformational changes 
in MAO-B turnover. Moreover, the importance of such changes may also provide a 
rationale for the differences of our temperature-dependence studies when MAO-B is in 
different environments (Figure 41). 
The FIRST calculations have the advantage that they are rapid and so enable very large 
in silico screening. However, they are thus necessarily approximate and do not reflect the 
realistic (and complex) protein molecular dynamics. An additional important caveat of 
our FIRST calculations is that they do not include the membrane environment. Therefore, 
in an attempt to rationalize the loss of activity for the variants, and explore our hypothesis 
above, we have performed 3 independent 100 ns MD simulations on each variant in the 
BZA1 state (as above, see SI Materials and Methods).  
Based on the flexibility in MD simulations (root-mean square fluctuations, RMSF), each 
variant is predicted to be slightly more rigid (Figure S14D-F) than wtMAO-B. 
Comparison of predictions of relative rigidity (by FIRST) and flexibility (by MD) for 
wtMAO-B show only moderate correlation (Figure S15). Poor correlation is particularly 
found for residues near the bilayer, which is not taken into account in our FIRST 
calculations; this demonstrates the importance of modelling the molecule in a native-like 
environment.  
Figure 47A-D, (additional measurements can be found in Figures S16 and S17) shows 
the fluctuation in the catalytic distance between BZA and FAD (BZA CH2 and FAD N5) 
for each variant and wtMAO-B. There is clearly some fluctuation in individual 





observed between the variants and wtMAO-B. That is, we do not find any evidence (at 
least on these timescales) that catalytically competent conformations are disadvantaged 
in the variants. Therefore, based on these data, we do not expect the immediate active site 
environment to be compromised in the enzyme variants, which correlates with the 
observation of the retention of the putative anionic semiquinone peak in the absorption 
spectrum of each variant (Figure S8). 
 
 
To explore the changes in global protein dynamics for the MAO-B variants in more detail, 
we performed principal component analysis (PCA) on the Cα carbon of residues 1-455 
for all BZA1 simulations (Figure 47 and S18). The vector which describes each PC can 
be projected onto a static structure (to create a porcupine plot; Figure 47G), with the 
magnitude of the vector describing the relative change in each residues position over the 
PC. Analysis of the porcupine plot of PC1 (Figure S18B) shows a global motion 
Figure 47: (A–D) Distance between the N5 (FAD) and CH2 group of BZA for wtMAO-
B and all three enzyme variant simulations. A black dotted line indicates the start of each 
new trajectory (all runs performed in triplicate). Additional measurements for all BZA 
containing simulations can be found in Figures S16 and S17. (E+F), Normalized 
histograms (bin width 0.25 Å) of principle principal component 2 (PC2) for all BZA1 
simulations of the bound (E) and unoccupied monomers (F). (G) ‘Porcupine’ plot of PC2, 
with arrows indicating the direction of the PC2 eigenvector and arrow size indicating the 
magnitude of the corresponding eigenvalue, for all Cα atoms with eigenvalues greater 
than 4 Å. The gating loop residues (99 – 112) are coloured in red, and the approximate 
location of the bilayer is indicated with a black dotted line. (A mobility plot of PC2 is 
provided in Figure S18A.). key for catalysis (see Supporting Information Materials and 




dependent on several flexible regions of MAO-B, whereas PC2 is dominated by the 
movement of the gating loop (residues 99–112) region and residues around it (Figure 
47G). This gating loop sits between Entrance A and B (Figure 45) and is key for substrate 
binding and product release. Histograms of PC2 (Figure 47E+F) show 
reduced/differential conformational sampling of PC2 for all variants compared to 
wtMAO-B. Our MD simulations therefore suggest that the variants have lost activity 
because the mutations have altered the normal dynamics of the gating loop, potentially 
affecting substrate entrance/exit to the active site. The fact that these variants (distal from 
the gating loop) have such a significant and specific effect on the gating loop sampling 
implies the presence of a long-range network of motions in MAO-B (Figure 47G) through 




MAO-B is an important biomedical target, and as with many such targets, is associated 
with a biological membrane. Such association places enzymes in specific physiological 
contexts, can promote interaction with other species and enable specific structural 
features. Less obvious is the role of the membrane environment in mediating the 
conformational dynamics of enzymes, and whether this is functionally important.  
Previous molecular dynamics studies have illustrated that the immediate membrane 
environment of MAO-B is involved in controlling substrate entrance to channels leading 
to the active site. Here, using enzyme kinetic and mutagenesis studies, we consider the 
role of the membrane environment in tuning the molecular dynamics of MAO-B more 
widely, including its influence on turnover and catalysis. We find that placement of MAO-
B in SMA nanodiscs instead of in reduced Triton X-100 has a significant effect on the 
heat capacity of catalysis (Δ𝐶𝑃
‡
). Differences in Δ𝐶𝑃
‡
 reflect differences in the distribution 
and frequency of vibrational modes between the ground (reactant) and transition states 
and implies that the membrane environment is affecting the global protein dynamics of 
MAO-B and that these dynamics influence the thermodynamics of enzyme turnover. 
Indeed, kcat is ~5 times faster in the nanodisc environment versus reduced Triton X-100. 
These data further hint at the role of the specific lipid composition and fine structure of 
the membrane to tune MAO-B turnover efficiency. These findings are corroborated by 
studying enzyme variants that are predicted to alter the network of flexible motion in the 
enzyme, but do not affect the overall structure. These variants, which are distal to the 
active site, all lead to inactive enzyme, indicating the critical role of ‘optimized’ global 
protein dynamics of MAO-B.  
Through atomistic molecular dynamics simulations with and without substrate bound, we 
find two substrate entrance/product exit channels that are mediated by membrane 
interaction, one of which was not previously described.  The simulations further indicate 





other monomer may allow substrate access at any one time, with active site occupation in 
one monomer preferentially allowing substrate access to the other. Moreover, the gating 
loop dynamics appear to be highly sensitive to the global enzyme dynamics, potentially 
reflecting long-range networks of enzyme motion. 
Taken together, our study suggests that the global protein dynamics of MAO-B are ‘tuned’ 
by the specific immediate membrane environment. These protein dynamics have a major 
effect on MAO-B function, through tuning fluctuations linked to enzyme turnover, 
including controlling the opening and closing of substrate/product channels. The finding 
that two different channels mediated by the membrane environment are present in MAO-
B illustrates the potential to exploit novel small molecule binding sites with rational drug 
design. Therefore, our study illustrates that when searching for novel small molecule 
binding sites, one should consider not just the static structure of the system in isolation, 
but time-dependent changes in the population of conformational sub-states and in the 
‘native’ environment.371,372 The finding that there may be long range networks of motions 
that can, in particular, affect the gating loop also indicates the potential for allosteric 
inhibitors. Further, as MAO-B resides in the outer mitochondrial membrane of cells, the 
finding of a solvent accessible entrance is important for rational drug design efforts. That 
is, inhibitors that target MAO-B may not need to enter the mitochondrial membrane in 
order to access the active site of MAO-B. 
 
Materials and Methods  
 
Unless otherwise stated, all reagents were obtained from Sigma-Aldrich.  
MAO-B expression and purification.  
MAO-B was expressed and purified following the purification protocol by Newton-
Vinson et al.342 Small variations from the protocol include shake flask fermentation 
instead of bioreactor fermentation, with BMMY (buffered methanol-complex medium) 
media instead of MM (minimal methanol) media for induction, storage of cell pellets in a 
buffer with protease inhibitor tablets instead of PMSF, suspension of pellet in 100 ml of 
breaking buffer instead of 1 L, and cell breakage of 30 s on 30 s off x 10 sonication in 
addition to bead beating.  The purification was completed after MAO-B was passed over 
a DEAE-sepharose FF column, achieving satisfactory purity. The additional polymer 
partition step detailed by Newton-Vinson et al.342 did not change the state of the 
semiquinone MAO-B species seen here, with additional purity achieved by size exclusion 
chromatography if necessary. MAO-B concentration was determined spectroscopically 





Nanodisc preparation.  
Nanodiscs were prepared following methods by McDowall et al.,359 suspended in 50 mM 
HEPES, pH 7.5. and incubated with MAO-B in a 10x molar excess, for 2 hours prior to 
experiments.  
Enzyme assays.  
MAO-B was transferred from Triton X-100 containing buffer to reduced Triton X-100 or 
nanodisc containing buffer using detergent removal spin columns (Thermo Scientific 
Pierce).  Steady-state MAO-B kinetic measurements were carried out using a 1 ml quartz 
cuvette and a UV⁄ Vis spectro-photometer (Agilent Cary 60 UV-Vis spectrometer) in 50 
mM HEPES (pH 7.5), containing 0.5 % (w/v) reduced Triton X-100 or SMA l-α-
Phosphatidylcholine nanodiscs. Enzyme activity was measured by following the 
formation of benzaldehyde using ε250 = 12,800 M
−1 cm−1 for BZA,337 and 4-
hydroxyquinoline using ε316 = 12,300 M
−1 cm−1  for KYN.360  For each condition substrate 
dependences were monitored at 40 °C ; the data fitted well to Michaelis-Menten kinetics 
(Figure S7).   Temperature-dependences were carried out from 20 °C - 45 °C at 5 °C 
intervals using initial velocity measurements at substrate concentrations maintained above 
10x Km to ensure saturation. The data were fitted to (Eq 16) as described in the manuscript 
using OriginPro 2017.  
Redox assays.  
These experiments were performed anaerobically, all buffer was purged with nitrogen and 
samples were prepared in an anaerobic box. Glucose and glucose oxidase were added to 
maintain anaerobic conditions.  
EPR.  
Measurements were performed using WT and Y398F variant MAO-B in 50 mM HEPES 
0.5% Triton, pH 7.5, flash-frozen in liquid nitrogen in suprasil quartz sample tubes. X-
band cw-EPR spectra were recorded on a Bruker eleXsys E500 spectrometer using a 
standard rectangular Bruker EPR cavity (ER4102T) equipped with an Oxford helium 
cryostat (ESR900). Experimental parameters: microwave power, 0.2 mW; field 
modulation amplitude, 5 G; field modulation frequency, 100 kHz; measuring time 10 s; 
temperature 16 K. Q-band cw-EPR spectra were performed on a Bruker eleXsys E-560 
spectrometer using a ER 5106QT-W1 resonator equipped with a home-built ARS 
cryogen-free cryostat (data not shown). Spectral simulations were performed using the 
Matlab-based Easyspin package.374 
Computational materials and methods.  
The X-ray crystal structure of MAO-B in complex with 6-hydroxy-N-propargyl-1(R)-
aminoindan (1S3E)375 was used as the starting point for all MD simulations. The missing 
C-terminal residues (502 – 520 Chain A and 497 – 520 Chain B) which form the remainder 
of the transmembrane helix were built using Avogadro376 (assuming the standard 
backbone dihedral angles of an α-helix). MAO-B was then inserted into a lipid bilayer 





palmitoyloleoyl-phosphatidylethanolamine (POPE) using CHARMM-GUI.377 This 
composition has been used in prior bilayer MD simulations of MAO-B, and was chosen 
to represent the composition of the outer mitochondrial membrane.345,351,362 BZA was 
placed in the active site by alignment with the crystal structure of MAO-B in complex 
with nitrobenzylamine (2C70,378 Cα RMSD 0.118 Å to 1S3E; the latter was used due to 
its higher resolution). All simulations of BZA were performed with the amino group in its 
neutral form, as this is widely believed to be the catalytically competent state of 
BZA.332,338,379 Titratable residues were simulated in their standard protonation states, 
based on calculations with PropKa 3.0158. MolProbity was used to determine the optimum 
tautomerisation states of every His residue, and any required Asn/Gln side chain flips, 
based on optimizing the hydrogen bonding network75. Histidines 91, 115 and 452 were 
singly protonated on their Nδ1, with all others singly protonated on their Nε2. The system 
was then solvated such that there was no protein or lipid atom within 20 Å of the edge of 
the periodic box along the z-coordinate (bilayer normal). The total number of atoms for 
each system simulated was approximately 90,000. 
Periodic boundary simulations were performed with Amber16, using the CHARMM36 
force field to describe protein380 and lipid381 atoms, and TIP3P for water. Parameters for 
FAD in its oxidized form and BZA in its neutral form were taken from Abad et al.338 
Following minimization, heating and equilibration (see SI Materials and Methods), 
production MD simulations were run in the NpT ensemble at 310 K, with semi-isotropic 
coupling to a Monte Carlo barostat. Temperature was regulated using Langevin dynamics 
with a collision frequency of 1 ps−1. A time step of 2 fs was applied with the covalent 
bonds to hydrogen constrained by the SHAKE algorithm. A 12 Å non-bonded cut-off was 
applied with a force switch smoothing function from 10 to 12 Å. Long range electrostatics 
were evaluated with the particle mesh Ewald method.72 For wtMAO-B simulations, a total 
of 9 simulations were performed for 150 ns each, with the first 50 ns of simulation used 
to equilibrate the protein and bilayer (see Figure S10). The BZA2 run in which a BZA 
escapes the active site cavity was extended for a further 50 ns. Enzyme variant simulations 
(W184F, F402V, E466Y) were performed for 3 x 100 ns each in the BZA1 state (see SI 
Materials and Methods for further details). Coordinates were saved every 10 ps for further 
analysis. Routine analysis of trajectories was performed using CPPTRAJ160, from the 
AmberTools suite. Area per lipid calculations were performed with GridMAT-MD,382 
using a grid resolution of 200 x 200 points for each measurement. Tunnel analysis was 
performed with Caver 3.0363. All settings were kept default apart from bottleneck radius 
(1.5 Å).  
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Supporting Materials and Methods 
 
FIRST calculations  
FIRST370 (floppy inclusion and rigid substructure topography) calculations, as mentioned 
in the main text, were carried out on a crystal structure of Monoamine oxidase B (MAO-
B) (PDB 1S3E)375. The aim of this procedure was to establish rigidified mutations of 
MAO-B, and to access their impact on catalysis. Scwrl4315 was used to optimize the side-
chain conformations of 1S3E MAO-B, and calculations were run on both the original and 
optimized structures. Structures that were optimized using Scwrl4 were constrained 
against their FAD cofactor (FAD atoms are treated as non-interacting particles that 
provide steric restraints). Of mutants carried forward for experimental testing, F402V and 
W184F arose from Scwrl4 optimized 1S3E, and E466Y arose from the original 1S3E 
crystal structure. Prior to running calculations, the X-ray structure was pre-processed by 
removing all hetero atoms (apart from FAD), and water molecules with PyMOL, and 
adding hydrogens to all residues (all residues were at their standard protonation state for 
pH 7) using Molprobity75.   
An initial FIRST run was used to generate the constraint files for wildtype (WT) MAO-
B, which describe the strength of the covalent bonds, hydrogen bonds, hydrophobic 
interactions and pi-pi stacking interactions throughout the protein. FIRST was then run 
over 20 energy cut offs (Ecuts), using rigid cluster decomposition (RCD) as previously 
described.383 Results are quantified as 'the fraction of residues in rigid clusters' for each 
Ecut. Ecuts ranged from 0-4 kcal mol−1 with a step size of 0.2 kcal mol−1. The fraction of 
residues in rigid clusters from all Ecuts were then averaged to give a single value to reflect 
the overall rigidity of the protein. This was used as the background value for comparison 
to all further calculations.  
To replicate the premise of alanine scanning, a protocol ‘Sidescan’ (available upon 
request) was developed to produce the constraint files calculated by FIRST with the 
constraint contribution of a specified amino acid side chain past the beta carbon (Cβ) 
missing from the files.  These altered constraint files were produced sequentially for each 
amino acid (not including alanine or glycine) of MAO-B, and the RCD analysis was 
carried out to determine the rigidity value of MAO-B without each amino acid. A random 
sample of residues whose side chains were identified as making no contribution to the 
rigidity of MAO-B, were taken forward for in silico mutagenesis and additional screening 
within FIRST. Scwrl4 was used to mutate these residues to each possible amino acid 
alternative, and the FIRST/RCD calculations were implemented, to predict the relative 
rigidity of each mutant compared to the WT.  
Mutations that improved the overall rigidity of MAO-B were then analyzed using the 
protocol ‘GetRCD’ (available upon request). GetRCD assigned each amino acid in MAO-
B an Ecut (kcal mol
−1) value, which reflects the amount of energy required to free that 
residue from its constraint network. This was carried out on the selected mutants to 





relevant residues of wtMAO-B (Table S5). If a mutation altered the flexibility/rigidity of 
a catalytically relevant residue by more than 1 kcal mol−1 it was disregarded.   
From these calculations we selected three single point mutations to experimentally test 
(W184F, F402V, E466Y). W184F is located in the FAD binding domain of MAO-B and 
is 13.3 Å away from BZA and 15.9 Å away from the flavin ring of FAD. F402V is located 
in the FAD binding domain of MAO-B and is 15.3 Å away from BZA and 15.3 Å away 
from the flavin ring of FAD. E466Y is located on the C-terminal tail of MAO-B and is 
21.4 Å away from BZA and 16.6 Å away from the flavin ring of FAD. All measurements 
are based on PDB 2C70 (chosen because it is co-crystallized with nitrobenzylamine) and 
based on the closest atom to atom distance of the amino acid backbone and FAD or BZA. 
Graphical representations of the location of each mutant, alongside their predicted change 
in rigidity from FIRST calculations can be found in Figure S14A-C.  
 
Molecular Dynamics (MD) Simulations 
Equilibration Procedure  
Following structure preparation (as described in the main text), all systems were subjected 
to the same equilibration procedure as detailed below. First, all water molecules and 
hydrogen atoms were minimized with 500 steps of steepest descent followed by 500 steps 
of conjugate gradient minimization. The system was then rapidly heated from 100 K to 
310 K in the NVT ensemble over 100 ps, with 10 kcal mol-1 positional restraints on all 
protein and lipid atoms. Whilst retaining the 10 kcal mol-1 restraints on protein atoms, 
lipid restraints were gradually reduced to 2.5 kcal mol-1 over the course of 200 ps. During 
NVT simulation, the timestep was set to 1 fs and a collision frequency of 1 ps-1 was used 
with Langevin temperature control.  Systems were then simulated in the NPT ensemble 
(1 atm, 310 K, semi-isotropic coupling to a Monte Carlo barostat, Langevin temperature 
control with a collision frequency of 1 ps-1, 2 fs time step), with lipid restraints reduced 
from 2.5 to 0 kcal mol-1 over the course of 200 ps. Finally, protein restraints were reduced 
from 10 kcal mol-1 to 0 kcal mol-1 over the course of 1 ns. At this point 50 ns of production 
MD simulations were performed to equilibrate the bilayer and protein (as described in the 
main text).  
Mutant Simulations  
The point mutants (W184F, F402V and E466Y) were each subjected to 3 x 100 ns of MD 
simulation in the BZA1 bound state. The structure of wtMAOB-BZA1 at 50 ns into each 
of the three independent simulations was used to generate three unique starting structures 
for the point mutant MD simulations. BZA was re-orientated to a catalytically competent 
state for Run 3 simulations based on the structure of nitrobenzylamine in complex with 
MAO-B (PDB 2C70). Mutations were made in silico using PyMOL384, and any 
overlapping water molecules with the newly introduced sidechains were removed. For the 




the system had an overall charge zero. Each system was then prepared as described above 
(see Equilibration Procedure). Trajectory analysis was performed without the first 10 ns 
of simulation time, which was used to equilibrate each mutant simulation.  
Trajectory Analysis 
Trajectory analysis was performed using CPPTRAJ160, (part of the AmberTools suite of 
programmes). Per residue Root Mean Square Fluctuations (RMSFs) were performed on 
snapshots at 10 ps intervals using average structures calculated from 1 ns time windows 
over the course of each trajectory. Performing RMSF calculations in this way reduces the 
influence of larger scale conformational changes on the calculation, providing a more 
realistic indication of backbone mobility.385 RMS fitting was performed on the Cα carbon 
of residues 1-455 of each monomer. Clustering analysis was performed using the 
DBSCAN algorithm386, using all backbone heavy atoms of the three loop regions (81–85, 
100–108 and 202–207) which describe the opening of Entrance B.  Principal Component 
Analysis was performed on all BZA1 simulations (WT, W184F, F402V and E466Y) 
simultaneously using the Cα carbon of residues 1-455 of each monomer (with monomers 
inputted separately).  
 
PLEASE NOTE: In the interest of saving paper/space, only the supporting 
information Methods are included and not the figures or tables. They can instead 
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